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1. INTRODUCTION 
 
1.1. Biological role of vitamin K 
Vitamin K is an essential group of fat-soluble vitamins needed for a unique 
posttranslational chemical modification of proteins with calcium-binding properties, 
collectively known as vitamin K-dependent proteins (VKDPs) or Gla-proteins. Vitamin 
K is mostly required for blood coagulation but is also involved in metabolic pathways 
in bone and other tissue. 
1.1.1 Discovery, structure 
Discovery 
Vitamin K was discovered in the early 1930s by the Danish biochemist Henrik Dam 
by investigating the role of cholesterol by feeding chickens a cholesterol-depleted 
diet. After several weeks, the animals developed haemorrhages and started bleeding 
which could not be restored by adding purified cholesterol to the diet. In 1935, Dam 
was able to describe the nature of this antihaemorrhagic factor whose absence was 
responsible for bleeding 1, and he proposed to name the new factor vitamin K (for 
Koagulation from the German and Scandinavian languages). Structure determination 
of vitamin K1 was performed by Doisy 2,3. Dam was awarded the Novel Prize in 
Physiology or Medicine in 1943 for the discovery of vitamin K; together with Doisy for 
the purification, characterization and synthesis of the molecule.  
 
Structure 
Compounds possessing the classical vitamin K cofactor activity for the conversion of 
specific peptide-bound glutamate (Glu) residues to γ-carboxyglutamate (Gla) share a 
common methylated naphthoquinone ring structure (2-methyl-1,4-naphthoquinone) 
called menadione or vitamin K3 (Fig.1; I) and vary in the aliphatic side chain attached 
at position C3 (e.g. Fig.1; II, IV, V). In nature, this 3-substituent has an isoprenoid 
structure with varying length and degrees of saturation. Plants and cyanobacteria 
synthesize only one chemical form called phylloquinone or vitamin K1 containing four 
isoprenoid residues, one of which is unsaturated and three are saturated (Fig.1; II). 
All other bacteria that possess the ability for vitamin K synthesis produce a variety of 
isoprenologues called menaquinones or vitamin K2 4. Menaquinones (MK) have side 
chains composed of a variable number of unsaturated isoprenoid residues; generally 
18 
 
these are designated as MK-n according to the number of prenyl units. Bacterially 
synthesized menaquinones (Fig.1; IV, V) that may contribute to human vitamin K 
requirements, either synthesized by the gut flora or present in foods, generally have 
side chains with 4-12 prenyl units 5-8. 
Naphthoquinone is generally considered as the functional group, so that the 
mechanism of action is similar for all K vitamins. Substantial differences may be 
expected, however, with respect to intestinal absorption, transport, tissue distribution 
and bio-availability, caused by the different lipophilicity of the various side chains and 
by the different food matrices in which they occur. 
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Figure 1 Chemical structure of vitamin K and metabolites 9 
(I) Menadione; K3 (2-methyl-1,4-naphthoquinone) 
(II) Phylloquinone; K1 (2-methyl-3-phythyl-1,4-naphthoquinone) 
(III) Phylloquinone epoxide; K1O (2-methyl-3-phythyl-1,4-naphthoquinone-2,3-epoxide) 
(IV) Menaquinone-4; MK4 (2-methyl-3-geranyl-geranyl-1,4-naphthoquinone) 
(V) Menaquinone-7; MK7 (2-methyl-3-farnesylgeranyl-geranyl-1,4-naphthoquinone) 
(VI) 2-methyl-3-(5`-carboxy-3`-methyl-2`-pentenyl)-1,4-naphthoquinone 
(VII) 2-methyl-3-(3`-carboxy-3`-methyl propyl)-1,4-naphthoquinone 
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1.1.2 Vitamin K dependent proteins 
Vitamin K was discovered in association with a bleeding defect, about half of the 
known human vitamin K-dependent (VKD) proteins are circulating haemostatic blood 
proteins (factors VII, IX, X, prothrombin, proteins C, S and Z). Factor II, VII, IX and X 
are VKD procoagulant serin proteases while Protein C and S play a regulatory role in 
the inhibition of coagulation. Protein Z is suspected to have a haemostatic role as 
well. Haemostatic VKD proteins are mainly synthesized in the liver, however, several 
of these proteins are also expressed in other tissues and some have been shown to 
have additional roles beside haemostasis, e.g. protein C and S in inflammation 10. 
Nonhaemostatic VKD proteins include: osteocalcin, an abundant bone matrix protein; 
Gas6, a ligand for tyrosine kinase receptors with multiple functions including growth 
control, chemotaxis and apoptosis 11-14. Another nonhaemostatic VKD protein is 
matrix Gla protein, which inhibits calcification. Mice bearing a deletion of matrix Gla 
protein gene develop severe arterial calcification leading ultimately to death 15.  
Humans lacking functional matrix Gla protein show calcification of cartilage without 
exhibiting the gross vascular calcification observed in mice 16. A group of four 
transmembrane Gla proteins, homologue to VKD proteins by their structure, are 
suggested to have a role in signal transduction 17,18. Moreover, the carboxylase itself 
is also carboxylated 19, which may regulate the carboxylation of other VKD proteins. 
Many of the VKD proteins show widespread tissue distribution, virtually every tissue 
expresses VKD carboxylase activity. Therefore, a broad biological impact of vitamin 
K is implicated by such a distribution and the various range of functions for VKD 
proteins. The VKD carboxylase is responsible for carboxylating all VKD proteins, and 
deletion of its gene leads to embryonic lethality in mice 20. 
 
1.1.3 Vitamin K cycle 
The biological role of vitamin K is to act as a cofactor for specific post-translational 
carboxylation that transforms selective glutamate (Glu) residues to γ-
carboxyglutamate (Gla) residues 21,22 and is required for the activity of VKD proteins. 
The conversion of peptide-bound Glu to Gla residues in VKD proteins is linked to an 
enzymatic cycle, denoted by vitamin K cycle (Fig.2), which carries out both γ-
glutamyl carboxylation and serves as a salvage pathway to recover vitamin K from its 
epoxide metabolite for reuse in carboxylation. The following enzymes are involved: γ-
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glutamyl carboxylase (GGCX), vitamin K epoxide reductase (VKOR) and NAD(P)H-
dependent quinone reductase (DT-diaphorase). The active form of vitamin K needed 
by the GGCX is the reduced form vitamin K hydroquinone. An obligatory metabolic 
consequence of γ- carboxylation is that hydroquinone is oxidased to epoxide which in 
turn undergoes reductive recycling, first to quinone and then to hydroquinone. 
The activity of the VKOR can be blocked by warfarin and other coumarin-based 
drugs 23 which are synthetic derivatives of dicoumarol, a 4-hydroxycoumarin-derived 
mycotoxin anticoagulant originally discovered in spoiled sweet clover-based animal 
feeds. Dicoumarol, in turn, is derived from coumarin, a coagulation-inactive chemical 
found in sweet clover and many other plants. Warfarin and related coumarin-based 
drugs decrease blood coagulation by inhibiting the VKOR. This results in decreased 
concentrations of vitamin K and vitamin K hydroquinone in the tissues, such that the 
carboxylation reaction catalyzed by the GGCX and the production of active VKD 
clotting factors is inefficient as well as inadequate. 
 
Figure 2 Vitamin K cycle 24 
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Several determinants of the vitamin K status in the human body are known, though 
biochemical markers are more conclusive than dietary assessment alone. 
○ Circulating concentrations of vitamin K 
Circulating phylloquinone concentrations in human plasma reflect dietary intake over 
the previous 24 h, and have high intra- and interindividual variation compared to 
other fat-soluble vitamins 25. Less is known about the diet-plasma associations for 
menaquinones. 
○ Coagulation times 
The prothrombin time (PT), also expressed as an International Normalized Ratio 
(INR), and activated partial thromboplastin time (APTT) are routine tests of 
coagulation that can reflect vitamin K deficiency. These tests are nonspecific - 
prolongation is also indicative of hepatic dysfunction, a haematologic disease 
unrelated to vitamin K deficiency, as well as other acute or chronic conditions. PT 
becomes prolonged only when the prothrombin concentration drops below 50% of 
normal and therefore has a low sensitivity for detecting vitamin K deficiency 26. 
○ Undercarboxylated VKD proteins 
Measurement of circulating undercarboxylated VKD proteins is currently considered 
to be a more sensitive indicator of vitamin K deficiency. Undercarboxylated 
prothrombin known as PIVKA-II (proteins induced in the vitamin K absence or 
antagonism-factor II) detects abnormalities in prothrombin before the prolongation of 
PT. Most infants with vitamin K deficiency have elevated PIVKA-II concentrations. 
PIVKA-II has also been reported to increase in response to low-dose (1mg) warfarin 
27 and vitamin K dietary restriction 28,29. Another marker used for assessment of 
vitamin K status, presents the proportion of serum osteocalcin that is not 
carboxylated expressed as either % ucOC (uncarboxylated osteocalcin) or ucOC/ 
tOC (total osteocalcin). The high proportion of ucOC is indicative of poor vitamin K 
status. 
○ Urinary measures 
Metabolites of vitamin K can be measured in urine and respond to dietary 
manipulation of vitamin K 30. Measurement of urinary Gla excretion is an overall 
measure of VKD proteins because Gla cannot be recycled and is excreted in urine 
during the turnover of individual VKD proteins 31. 
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1.2. Determinants of vitamin K serum levels 
To gain an insight into the multiple functions and impact of vitamin K in human 
health, it is important to identify determinants of the vitamin K status and its 
interindividual variation with regard to the current understanding of vitamin K 
physiology and metabolism. An inadequate diet is an important component in the 
multifactorial nature of numerous diseases. Infants are born deficient in vitamin K and 
when unsupplemented are at risk of haemorrhage due to vitamin K deficiency 
bleeding (VKDB) within the first few months of life. In contrast, dietary vitamin K 
deficiency in adults, without accompanying illness or predisposing factors, is rare. 
1.2.1. Nongenetic determinants 
1.2.1.1. Dietary intake of vitamin K 
In the human diet, phylloquinone is the predominant dietary form of vitamin K and is 
present in foods of plant origin. In general, green leafy and flower vegetables 
including broccoli, spinach and certain lettuces contain the highest known 
phylloquinone concentrations and contribute ~60% of total phylloquinone intake 32,33. 
Certain plant oils and margarine, spreads and salad dressings derived from these 
plant oils are also important dietary sources of phylloquinone 34. Menaquinones 
(vitamin K2) are primarily of bacterial origin. Vitamin K2 is found in chicken egg yolk, 
butter, cow liver and cheese. Menaquinone-4 (MK4) is not a major constituent of 
bacterial production; instead it is alkylated from menadione present in animal feeds 
or is the product of tissue-specific conversion directly from dietary phylloquinone 35,36. 
Menaquinone-7 (MK7) is primarily found in natto, a soybean product that is 
fermented using Bacillus natto.  
The recommended daily intake for vitamin K according to the “WHO expert 
consultation on human vitamins and mineral requirements” is 100 µg/ day for males 
and 90 µg/ day for females. 
Biomarkers of vitamin K status respond to phylloquinone restriction and 
supplementation. Interestingly, dietary restriction of phylloquinone to 35 µg/ day 
causes rapid decreases in plasma phylloquinone and urinary excretion of Gla 
residues and increases in the undercarboxylated forms of the VKD proteins, 
osteocalcin (% ucOC) and prothrombin (PIVKA-II), without affecting classic 
measurements of blood coagulation 29,37. 
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1.2.1.2. Absorption, transport and cellular uptake of vitamin K 
Most diseases influencing vitamin K status are related to malabsorption or other 
gastrointestinal disorders including biliary atresia, cystic fibrosis, celiac disease and 
short bowel syndrome 38. In common with other fat-soluble vitamins, phylloquinone is 
absorbed from the proximal intestine and the absorption is dependent on bile and 
pancreatic secretion 39. In healthy adults the efficiency of absorption of phylloquinone 
in its free form is about 80% 39. Vitamin K is not known to have a carrier protein; 
instead triglyceride-rich lipoproteins (TRL), primarily chylomicrons remnants and very 
low density lipoproteins (VLDL) are thought to be the main phylloquinone 
transporters 40-42. Absolute plasma phylloquinone concentrations are higher among 
individuals with elevated triglyceride concentrations. Fasting plasma phylloquinone 
and triglyceride (TG) concentrations are both higher in older adults compared to 
younger adults 43,44, however, when phylloquinone concentrations are adjusted for 
TG, these are lower in the older adults compared to the younger individuals 44. 
Most of the knowledge regarding intestinal absorption, cellular uptake and metabolic 
fate relates to phylloquinone with less known about menaquinones. Figure 3 shows a 
schematic illustration of the known metabolic processes that lead from the intestinal 
absorption of dietary vitamin K to its entry into cells 9 analogue to cholesterol 
transport. The following are key processes: 
○ Intestinal absorption and entry into circulation 
After digestion, dietary vitamin K in its quinone form and the products of triglycerides 
(TG) are emulsified by bile salts, mono – and diglycerides and lysolecithin to form 
mixed micelles. These are taken up by the enterocytes of the intestinal epithelium 
and incorporated into nascent chylomicrons (CM) containing apoA and apoB-48. CM 
are then secreted into the lymph lacteals within the intestinal villi. The lacteals drain 
into larger lymphatic vessels emptying into the blood circulation via the thoracic duct 
45. Once in the blood, CM acquire apoC and apoE from HDL. In the capillaries of 
muscle, adipose tissue etc., CM are stripped of their TG by lipoprotein lipase (LPL) 
which lines the capillaries. The resultant smaller CM remnants (CR) re-enter the 
circulation having lost much apoA and apoC (apolipoproteins) but retaining vitamin K 
in the lipophilic core. 
○ Uptake by liver 
In the liver CR enter hepatocytes by binding to LDLR and LRP followed by receptor 
mediated endocytosis. Their lipids are repackaged into VLDL containing apoB-100 
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and return to the circulation where they acquire apoC and apoE. Further TG is 
removed by LPL in the capillaries resulting in VLDL remnants called IDL. Subsequent 
metabolism and loss of apoC and apoE from IDL gives rise to smaller LDL particles 
containing almost exclusively apoB-100. Vitamin K is presumed to still be located in 
the lipophilic core. 
○ Uptake by bone 
Circulating lipoproteins such as CR and LDL can deliver lipids to osteoblasts which 
are attached to the surfaces of bone matrix. Osteoblasts express lipoprotein 
receptors such as LDL receptor (LDLR) and LDL receptor-related protein 1 (LRPI) 
which can interact with CR and LDL allowing receptor mediated endocytosis of the 
particles and their incorporated vitamin K. Evidence suggests that osteoblasts obtain 
most of their K1 via the CR pathway and most of their MK7 via the LDL pathway. 
       
 
 
Figure 3 Schematic representation of the absorption, transport and cellular 
uptake of dietary vitamin K (phylloquinone, MK7) (modified from 9) 
 
 
1.2.1.3. Tissue stores of vitamin K and distribution 
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Until the 1970s, the liver was the only known site of synthesis for VKD proteins and 
hence was presumed to be the only significant storage site for vitamin K. However, 
the discovery of VKD processes and proteins in a number of extra-hepatic tissues 
suggests that this may not be the case. 
Human liver stores normally comprise about 90% menaquinones and 10% 
phylloquinone 46,47. There is evidence that the phylloquinone liver stores are very 
labile: under conditions of severe dietary depletion liver concentrations were reduced 
to about 25% of initial levels after only 3 days 47. This high turnover of hepatic 
reserves of phylloquinone corresponds with the high losses of vitamin K through 
excretion 39. In contrast to the hepatic preference of long-chain menaquinones, the 
major circulatory form of vitamin K is invariably phylloquinone. The menaquinones 
MK7 and possibly MK8 are also present but the common hepatic forms MK 9-13 are 
not detectable in blood plasma 7,46. This might be a consequence of a different route 
of absorption (a portal route for long-chain MKs versus the established lymphatic 
route for phylloquinone). 
With the widespread occurrence of extrahepatic Gla proteins there is a need for 
knowledge of the extrahepatic distribution of K vitamins. In a study of human tissues 
obtained at autopsy, Thijssen et al. found that heart and pancreas contained 
phylloquinone at comparable or higher levels than found in the liver 48. An intriguing 
finding was that MK4 was ubiquitously present in extrahepatic tissues with 
particularly high levels, often exceeding that of phylloquinone, in the brain, kidney 
and pancreas. The origin of tissue MK4 has yet to be exclusively defined. It is 
postulated that phylloquinone is locally converted into MK4 with menadione as an 
intermediate and accumulates in extrahepatic tissues 49. 
1.2.1.4. Metabolism and excretion of vitamin K 
Vitamin K is extensively metabolized in the liver and excreted in the urine and bile. 
Following scheme (Fig.4) presents hepatic metabolism of vitamin K 9. Under usual 
physiological conditions vitamin K is mainly recycled by VKOR. However, in the 
presence of vitamin K antagonists such as warfarin the activity of the VKOR is 
blocked. This leads to a build-up of vitamin K epoxide (KO) in the cell. An alternative 
hepatic quinone reductase activity can bypass the warfarin inhibition of the VKOR to 
provide vitamin K hydroquinone (KH2) substrate for the GGCX. The liver is also the 
site of a catabolic pathway, where the side chains of phylloquinone and MKs undergo 
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ω-oxidation followed by β-oxidation resulting in two major aglycone metabolites with 
side chain lengths of five and seven carbon atoms respectively (5C and 7C 
metabolites). After conjugation, the glucoronides are excreted in the bile and urine. 
Phylloquinone, the major dietary form, is rapidly and extensively catabolised in 
humans with about 40% of a daily physiological dose being excreted via the bile and 
20% via the urine. 
 
 
Figure 4 Hepatic metabolism of vitamin K (modified from 9) 
Vitamin KH2 Vitamin K hydroquinone 
Vitamin KO Vitamin K epoxide 
VKOR  Vitamin K epoxide reductase 
GGCX  Gamma glutamyl carboxylase 
QR  Quinone reductase 
 
Further, in tracer experiments it was found that approximately 20 % of an injected 
dose of phylloquinone was recovered in the urine whereas 40 - 50 % was excreted in 
the faeces via the bile 39. It seems, therefore, likely that approximately 60 – 70 % of 
the phylloquinone amounts absorbed from the diet will ultimately be lost from the 
body by excretion and the body stores of phylloquinone are being constantly 
replenished. 
 
1.2.1.5. Age and gender 
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Infants are born deficient in vitamin K because of poor maternal-fetal transfer across 
the placenta 50. Breast milk contains very low phylloquinone concentrations, which 
does not appear to be related to the maternal diet and initially there is limited 
bacterial colonization of the gut, which could otherwise produce endogenous 
menaquinones. In addition, coagulation factor concentrations are low at the time of 
birth, which increases the risk of hemorrhagic bleeding (VKDB). Vitamin K 
prophylaxis in a form of a single oral dose of 2 mg Konakion® MM (phytomenadione, 
vitamin K1) is routinely administered as an effective intervention against VKDB. 
During adulthood, there may be subtle age-related changes in vitamin K status but 
these are inconsistent and may be primarily related to dietary intake and lifestyle 
differences among the age groups. In controlled dietary studies, older adults have 
been reported to be relatively more resistant to the development of subclinical 
vitamin K deficiency when fed a low-vitamin K diet 29. It has been proposed that there 
are age-related differences in absorption and catabolism of phylloquinone, and the 
turnover of VKD proteins is lower in older adults. Further, Booth et al. 51 reported 
differences in vitamin K status among women of different estrogen status from the 
Framingham Offspring Study and suggested that estrogen levels may be an 
important determinant of vitamin K status, independent of diet. 
1.2.1.6. Xenobiotics 
Warfarin and other coumarin-based drugs block the activity of the Vitamin K epoxide 
reductase. This results in decreased concentrations of vitamin K quinone and 
hydroquinone in the tissue and increased levels of vitamin K epoxide. An oral 
therapeutic dose of warfarin produces a profound change in the plasma kinetics of an 
intravenous dose of tritiated vitamin K1 and its urinary metabolites 39,52. It was found 
that warfarin produced an apparent delay in the clearance from the plasma of the 
injected radioactive substance due to the rapid accumulation of vitamin K epoxide in 
the plasma, but the rate of clearance of injected phylloquinone was not different 
compared to that in warfarin-untreated subjects. In addition, the urinal excretion of 
radioactive metabolites was increased about twofold. Furthermore, vitamin K 
deficiency is often attributed to broad-spectrum antibiotic use, presumably by a 
reduction in the endogenous menaquinone production by intestinal bacteria 53. 
Salicylates and anticonvulsants are also associated with vitamin K deficiency in some 
individuals with coexisting compromised nutritional status. 
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1.2.1.7. Life style 
Different observational studies examined intake and sources of vitamin K according 
to sociodemographic and lifestyle factors. A high phylloquinone intake may simply be 
a marker for an overall healthy diet that includes high vegetable consumption given 
that green leafy vegetables are consistently the primary form of vitamin K in the diet 
54. This study suggested that high phylloquinone intake may be a marker for low 
coronary heart disease risk. Thane et al. 33 showed positive correlation between 
plasma phylloquinone concentrations and vitamin K intake from the diet in free-living 
British people in comparison to hospitalized groups. Further, the participants living in 
private households showed a seasonal dependence of plasma phylloquinone levels 
which were significantly lower in the time period from October to March. In 
conclusion, a high phylloquinone intake may be a marker for an overall heart-healthy 
dietary pattern 55. Furthermore, results from the Rotterdam study showed that dietary 
intake of menaquinone is associated with a reduced risk of coronary heart disease 56. 
Intake of menaquinone was also inversely related to all-cause mortality and severe 
aortic calcification. 
 
1.2.2. Genetic Determinants 
There has been a recent interest in the role of genetics as a determinant of the 
interindividual variation in vitamin K status. The response to dietary vitamin K 
supplementation under controlled conditions has been shown to widely vary among 
healthy individuals 57. Nongenetic determinants account for ~20% of the 
interindividual variation in vitamin K status in Caucasian adults 58. Potential genetic 
determinants of vitamin K status include variation in the genes involved in the 
transport or uptake of vitamin K into the tissue and the genes involved in the tissue 
specific availability and recycling of vitamin K. 
1.2.2.1. VKOR, gamma glutamyl carboxylase 
Vitamin K epoxide reductase (VKOR) is involved in the vitamin K cycle. In 2004, the 
gene encoding vitamin K epoxide reductase complex subunit 1 (VKORC1), the key 
protein in the vitamin K cycle, was identified and characterized 59,60. Common 
polymorphisms and haplotypes within VKORC1 gene have been associated with 
interindividual variability in warfarin dose 61-63. Because warfarin acts as a vitamin K 
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anatagonist and works by directly inhibiting VKOR and thus the recycling of vitamin 
K, polymorphisms affecting vitamin K recycling in the liver may modulate vitamin K 
status. One study in a Chinese cohort has shown that single nucleotide 
polymorphisms and haplotypes within the VKORC1 gene were associated with ucOC 
and PIVKA-II concentrations 64. Paradoxically, the genotype that was associated with 
lower PIVKA-II concentrations, hence better vitamin K status, was also associated 
with greater risk of vascular disease. In another study, Watzka et al. showed that 
functional promoter polymorphism in the VKORC1 gene is no major genetic 
determinant for coronary heart disease (CHD) in Northern Germans 65. The 
discrepant association findings in Chinese and German populations may be 
explained by ethnic differences in genetic and perhaps environmental predisposition, 
modifying the polygenic CHD phenotype by interacting with VKORC1 variants and 
thus conferring disease susceptibility in some populations, but not in others. 
Gamma glutamyl carboxylase (GGCX) is necessary for the carboxylation of VKD 
proteins. Common variations within the GGCX locus have been analyzed for 
association with transcriptional activity and required warfarin dose 66. However, little 
is known about the effect of these polymorphisms on direct measures of vitamin K or 
γ-carboxylation of extrahepatic proteins such as osteocalcin. 
1.2.2.2. CYP4F2, ABCC6 
Anticoagulant drugs work by directly inhibiting VKOR and thus the recycling of 
vitamin K. Therefore, polymorphisms affecting vitamin K recycling may modulate 
vitamin K status. McDonald et al. screened various cytochrome P450 enzymes and 
showed that CYP4F2 was capable of metabolizing vitamin K1 to a single product 
acting as a vitamin K1 oxidase 67. The V433M polymorphism in CYP4F2 (haplotype 
CYP4F2*3) has been linked to altered vitamin K1 metabolism. The data demonstrate 
that CYP4F2 is a vitamin K1 oxidase and that carriers of the CYP4F2 V433M allele 
have a reduced capacity to metabolize vitamin K1 as well as decreased steady-state 
hepatic concentrations of the enzyme. Therefore, the presence of this polymorphism 
indicates elevated hepatic vitamin K1 levels, necessitating a higher warfarin dose to 
reach the same anticoagulant response. 
ABCC6 represents a transmembrane efflux transporter expressed primarily in the 
liver. Mutations in the ABCC6 gene cause an autosomal recessive disease, 
Pseudoxanthoma elasticum (PXE), characterized by a progressive mineralization of 
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connective tissue and resulting in skin, arterial and eye disease. Recent studies on 
Abcc6-I- mice show that the absence of ABCC6 in the liver is crucial for PXE and 
confirm the “metabolic disease hypothesis” that tissue calcification is caused by the 
absence of a plasma factor secreted from the basolateral hepatocyte membrane 68. It 
was proposed that this plasma factor is vitamin K precursor secreted by ABCC6 from 
the liver as a glutathione-(or glucoronide)-conjugate and that this supplements the 
vitamin K need of peripheral tissue receiving insufficient vitamin from the diet due to 
ineffective extraction of dietary vitamin K from blood by the liver. Peripheral tissue 
vitamin K is needed for the γ-carboxylation in proteins required for calcification of 
connective tissue throughout the body. Vanakker et al. found significantly decreased 
vitamin K serum concentrations in PXE patients compared with controls 69. The 
findings assumed that ectopic mineralization in the PXE-like syndrome and in PXE 
results from a deficient protein carboxylation of VKD inhibitors of calcification (e.g. 
MGP). In PXE-like patients this is caused by mutations in the GGXE gene, whereas a 
deficiency of the carboxylation cofactor vitamin K is crucial for the decreased activity 
of calcification inhibitors in PXE. 
1.2.2.3. Apolipoprotein E 
The gene encoding apolipoprotein E (ApoE) codes for a 34-kDa lipoprotein primarily 
found on the triglyceride rich lipoproteins (TRL;VLDL and chylomicrons) and HDL 70. 
ApoE is a ligand for the LDL receptor and other TRL receptors and therefore it is 
responsible for cellular uptake of TRL. Three common alleles (amino acid 
substitutions at positions 112 and 158) are of particular importance: E2, E3 and E4 
71. The various ApoE isoforms interact differently with the LDL receptors, altering 
circulating levels of cholesterol and triglycerides 71. The ability of ApoE to clear 
vitamin K-rich intestinal lipoproteins from circulation is greatest with E4 and least with 
E2 40,72. Lower concentrations of LDL cholesterol were found in patients with the E3/4 
or E4/4 genotypes compared to levels in patients carrying the E3/3 genotype. Those 
with the genotype E2/3 or E2/2 had the highest serum phylloquinone concentrations 
40. It is thought that carriers of the E4 allele may have increased hepatic vitamin K 
uptake and decreased vitamin K in circulation, hence decreased levels of vitamin K 
available for γ-carboxylation of osteocalcin in the bone 73. This is supported by the 
observation that E4 homozygotes require, on average, a higher dose of warfarin in 
comparison to non-E4 carriers 74; a higher warfarin dose in E4 homozygotes would 
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be necessary to compensate for the increased hepatic vitamin K uptake. In contrast, 
another study showed carriers of the E4 allele have higher plasma phylloquinone 
concentrations and lower % ucOC 75 which suggested that the E4 carriers had slower 
clearance of the TRL remnants from circulation and subsequently more 
phylloquinone available for uptake in the bone. Clearly, more research is required to 
determine the direction and magnitude of the ApoE genotype effect on vitamin K 
status. 
 
1.3. Pharmacokinetics 
Pharmacokinetics can be defined as the study of the fate of drugs in the body or as 
the study of the influence of the body on drugs. It includes the study of the 
mechanisms of absorption and distribution of an administered drug, the rate at which 
a drug action begins and the duration of the effect, the chemical changes of the 
substance in the body (e.g. by enzymes) and the effects and routes of excretion of 
the metabolites of the drug. The aim of pharmacokinetics is to provide the knowledge 
needed to understand how to adjust the dosage of a drug to obtain the plasma 
concentration including the optimum effect, i.e. the best efficacy with the minimum of 
adverse effects 76. Pharmacodynamics is the study of the various effects of drugs. 
Pharmacogenetics is generally regarded as the study or clinical testing of genetic 
variations in metabolic pathways which can affect individual responses to drugs, both 
in terms of therapeutic effect as well as adverse effects. 
In clinical pharmacology, the only directly accessible parameter is the concentration 
of drugs in plasma or serum. All pharmacokinetics is based on the variations of 
plasma concentrations. The pharmacokinetic features of a drug result primarily from 
their facility to cross biological membranes and from the rate of their inactivation. 
To construct a concentration-time profile, valid bioanalytical methods are needed to 
measure the concentration of drugs and substances in biological matrix, most often 
plasma or serum. Proper bioanalytical methods such as high performance liquid 
chromatography with fluorescence detection (HPLC-FL) or liquid chromatography 
using mass spectrometry (LC-MS) should be selective and highly sensitive due to the 
complex nature of the matrix. Standard curves and internal standards are used for 
quantification in the samples. The samples represent different time points as a drug 
is administered and then metabolized or eliminated from the body.  
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Pharmacokinetic analysis is performed by non-compartmental (model independent) 
or compartmental methods 76. Non-compartmental data analysis evaluates the 
exposure to a pharmaceutical compound by estimating the area under the curve 
(AUC) of a concentration-time graph and subsequent calculation of various 
pharmacokinetic parameters. Compartmental pharmacokinetic analysis uses kinetic 
models to describe and predict the concentration-time curve. Pharmacokinetic 
models are relatively simple mathematical schemes representing complex 
physiological spaces or processes. 
Non-compartmental pharmacokinetic analysis is highly dependent on estimation of 
total drug exposure most often expressed by AUC methods as well as on the blood/ 
plasma sampling schedule. A large number of data points are necessary to reflect 
the actual shape of the concentration-time curve more precisely. 
Population pharmacokinetics studies the various sources and correlations of 
variability in drug concentration among individuals who represent the target patient 
population 77.  
 
1.4. Objectives 
The main objective of the present work by means of a phase I clinical study was to 
determine inter-individual variance in pharmacokinetics of intravenous and oral 
phylloquinone (vitamin K1) mixed micelles formulation as well as to explore a 
possible effect of the VKORC1 promoter polymorphism c.-1639 G>A on the 
metabolism of phylloquinone and its pharmacokinetics in humans. Examining the 
phenotype-genotype relationship in the clinical study facilitates to gain a deeper 
insight into potential determinants of inter-individual variation in vitamin K status. In 
this regard, the phenotype refers to physiological processes like absorption, 
distribution, metabolism and elimination of the vitamin K. Pharmacokinetic 
parameters including maximum serum concentration (Cmax), time of the maximum 
serum concentration (tmax), area under the curve (AUC), bioavailabilty (Fp.o.), 
clearance (CL), volume of distribution at steady state (Vss) and terminal half-life (t1/2) 
based on serum concentration-time data of vitamin K1 were considered as primary 
variables. 
To ensure accurate, precise and reliable measurements of plasma phylloquinone 
concentrations, our aim was also to obtain a simple and fast method, suitable for the 
routine analysis of plasma or serum vitamin K as well as to improve the sensitivity of 
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the determination assay. Validation evidence and quality assurance performance 
were required in order to prove and warrant the practical applicability of vitamin K 
serum determination. As first application of the HPLC method served examining of 
the vitamin K1 pharmacokinetics in several human volunteers. 
Further aspect of the present work was to gain an insight into the enzymatic 
characteristics of VKORC1 by studying its enzyme kinetics. The enzyme activity was 
characterized after chromatographic separation and quantification of the substrates 
and the correspondent products. After calculation of the enzymatic kinetic constants 
Km and Vmax, the reaction velocity as well as the affinity of the substrate (vitamin K1 
and vitamin K2) for the VKORC1 enzyme could be assessed to a certain extent. 
These experiments helped to explain how the enzyme works and to predict its 
behaviour in vivo.  
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2. MATERIALS AND METHODS 
2.1. Materials 
The described experiments were carried out in molecular biological laboratories of 
the security level S1 using common routine equipment. Basic equipment chemicals 
and devices are not separately listed. Chemicals of daily use were gained in highly 
purity degree, aqueous solutions were prepared using deionized water (Millipore). 
 
2.1.1. Equipment 
Name Purpose Manufacturer 
ABI Prism 3130xl DNA 
Sequencer 
DNA Sequencing Applied Biosystems 
ANTAES 48/72 Laminar airflow Biohit 
Axiovert 25 Microscope Zeiss 
ChemiDoc UV gel documentation Biorad 
Cooling/Freezing Unit  Liebherr 
CO2 Incubator Incubator Nunc 
Dispensette Organic  VWR 
Elite LaChrom 
- Autosampler L-2200 
- Column oven L-2300 
- Fluorescence detector 
L-2485 
- Pump L-2130 
HPLC system Hitachi/ VWR 
Eppendorf Pipettes  Eppendorf 
Gas Chromatograph-FID: 
6890 GC 
-Injector : 7683 
Autosampler 
GC-FID system Hewlett Packard/ 
Agilent Technologies 
Gas Chromatograph-MS: 
5890 Series II Plus 
- Injector: 7673 
Autosampler 
- Detector: MSD 5972, 
5973 
GC-MS system Hewlett Packard/ 
Agilent Technologies 
Heating Block incl. N2 
Evaporation System 
 Labomedic 
Heraeus Multifuge 4 KR  Heraeus 
NanoDrop ND-1000 Spectrophotometer Peqlab 
Savant Vacuum Dryer Thermo Scientific 
Speedvac  Savant 
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Thermomixer comfort Thermomixer Eppendorf 
Vacuum Chamber Chromabond Macherey-Nagel 
Vacuum Pump  Vacuubrand 
Vortex Mixer  Heidolph 
 
2.1.2. Reagents, disposables and standards 
2.1.2.1. List of chemicals 
Name/ Acronym Chemical/ Solution Manufacturer 
Acetic acid,  
water-free 
CH3COOH>99 %, glacial acetic acid, 
ethanoic acid, ethylic acid, ice-vinegar 
VWR/ Merck 
Acetonitrile CH3CN, methyl cyanide 
LiChrosolv Acetonitrile gradient grade 
for liquid chromatography 
VWR/ Merck 
Agar  BD Biosiences 
Agarose Agarose polymer Biozym 
Amp Ampicillin (beta-lactam antibiotic) Sigma-Aldrich 
AmphoB Amphotericin B (polyene antifungal drug) PAA 
Aqua destillata Distilled water VWR/ Merck 
Bacto-Yeast Extract  Becton 
Dickinson 
BHT 3,5-di-tert.-Butyl-4-hydroxy-toluene VWR/ Merck 
BSA Bovine serum albumin Sigma-Aldrich 
Calcium chloride CaCl2 Sigma-Aldrich 
CHAPS 3-[(3-
Cholamidopropyl)dimethylammonio]-
1-propanesulfonate 
Sigma-Aldrich 
Chenodeoxycholic 
acid 
Bile acid Sigma-Aldrich 
Cholic acid  Bile acid Serva 
Chloroform CHCl3 VWR/ Merck 
5-Cholestane  Sigma-Aldrich 
Cholesterol   Sigma-Aldrich 
Cupric sulfate CuSO4 Sigma-Aldrich 
Cyclohexane  VWR/ Merck 
n-Decane HPLC-grade VWR/ Merck 
Deoxycholic acid Bile acid Sigma-Aldrich 
dH2O  Deionized water VWR/Merck 
Diethyl ether (C2H5)2O, ethoxyethane VWR/ Merck 
Dimethoxypropan  VWR/ Merck 
DMEM 
High Glc 4,5 g/ L 
Dulbecco/ Vogt modified Eagle´s 
minimal essential medium without 
PAA 
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with L-Gln phenol red 
DMSO (CH3)2SO, dimethyl sulfoxide Sigma-Aldrich 
dNTPs  Fermentas 
DTT Dithiothreitol, Cleland´s reagent Sigma-Aldrich 
Dulbecco´s PBS 
with Ca & Mg 
Phosphate buffer PAA 
Dulbecco´s PBS 
without Ca & Mg 
Phosphate buffer PAA 
EDTA Ethylenediaminetetraacetic acid Sigma-Aldrich 
Epicoprostanol  ISTD Sigma-Aldrich 
Ethanol C2H5OH, EtOH, ethyl alcohol 
LiChrosolv gradient grade for liquid 
chromatography 
VWR/ Merck 
Ethidium bromide  Sigma-Aldrich 
Ethyl acetate  VWR/ Merck 
FBS Fetal bovine serum PAA 
Folin-Ciocalteau-
Reagent 
Folin´s phenol reagent 
(mixture of phosphomolybdate and phosphotungstate) 
Sigma-Aldrich 
Gases: 
Helium  
Hydrogen  
Nitrogen 
for GC and evaporation Linde AG 
 
 
GeneRuler DNA Mix Length standard 100 – 10,000 bp Fermentas 
Hexamethyldisilazane  VWR/ Merck 
n-Hexane C6H14, hexane 
LiChrosolv n-Hexane for liquid 
chromatography 
VWR/ Merck 
HiDi Formamide Carbamaldehyde Applied 
Biosystems 
Hydrochloric acid HCl Sigma-Aldrich 
7-
Hydroxycholesterol 
Bile acid precursor 
Oxysterol 
Sigma-Aldrich 
Hydrogen peroxide H2O2, 30 % (w/ w) Sigma-Aldrich 
Hyodeoxycholic acid Bile acid Sigma-Aldrich 
Imidazole C3H4N2, 1,3-diazole Sigma-Aldrich 
Isopropanol (CH3)2CHOH, isopropyl alcohol, 2-
propanol, IPA 
LiChrosolv 2-Propanol gradient grade 
for liquid chromatography  
VWR/Merck 
Kana Kanamycin (aminoglycoside antibiotic) Sigma-Aldrich 
Lathosterol  Cholesterol precursor Sigma-Aldrich 
Lithocholic acid Bile acid Sigma-Aldrich 
Magnesium chloride MgCl2 Sigma-Aldrich 
MEM with Earls Salts Minimal Essential Medium PAA 
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Methanol CH3OH, MeOH, methyl alcohol 
LiChrosolv Methanol gradient grade 
for liquid chromatography 
VWR/ Merck 
NEAA Non-essential amino acid PAA 
PBS Phosphate buffered saline PAA 
PenStrep Penicillin/ Streptomycin 100 x 
Concentrate 
PAA 
Peptone  Becton 
Dickinson 
PFA Paraformaldehyde, polyoxymethylene Sigma-Aldrich 
Potassium chloride KCl Sigma-Aldrich 
Pyridine  VWR/ Merck 
Sodium acetate CH3COONa Sigma-Aldrich 
Sodium carbonate Na2CO3 Sigma-Aldrich 
Sodium chloride NaCl Sigma-Aldrich 
Sodium citrate  Sigma-Aldrich 
Sodium hydroxide NaOH Sigma-Aldrich 
Trimethylchlorosilane  VWR/ Merck 
Tris (HOCH2)3CNH2 
Tris(hydroxymethyl)aminomethane 
Sigma-Aldrich 
Tryptone  Becton 
Dickinson 
Ursodeoxycholic acid Bile acid Sigma-Aldrich 
Vitamin K1 Phylloquinone Sigma-Aldrich 
Vitamin K2 Menaquinone-4 Sigma-Aldrich 
Warfarin Vitamin K antagonist Roche 
Water for the 
chromatography 
LiChrosolv VWR/ Merck 
Zinc Acetate 99.99 % metalics basis 
Acetic acid zinc salt 
Sigma-Aldrich 
Zinc Dust < 10 µ, 98+ % Sigma-Aldrich 
Zinc Powder < 150 µ, 99.995 % Sigma-Aldrich 
 
2.1.2.2. List of consumable material 
Material Manufacturer 
Adjustable pipettes: 100 µL, 1000 µL Eppendorf 
Analytical balance Sartorius MC-5, Sartorius AG 
Cartridges Chromabond 
SiOH 3 mL/ 500 mg 
Macherey-Nagel 
Cell scraper, 23 cm Nunc 
Cellstar 1 mL Pipette Greiner Bio One 
Cellstar 12 Well Cell Culture Plate Greiner Bio One 
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Cellstar 6 Well Cell Culture Plate Greiner Bio One 
Cryo tubes Nalgene Nunc 
Culture Test Tubes VWR/ Duran 
Glass Pasteur pipettes Labomedic 
Glass vials for auto-sampler, 2 mL VWR 
Inserts for glass vials 300 µL VWR 
Optical-8 Tube Strip + Cap Strip Applied Biosystems 
pH- indicator strips 0 – 6  
Pipette Tips Eppendorf 
Reaction glass tubes with Teflon® lined 
septa and screw caps 
Macherey-Nagel 
Reaction tubes 1.5 mL/ 2 mL Eppendorf 
Reaction tubes 15 mL/ 50 mL Greiner Bio One 
Spatula Macherey-Nagel 
Stripette 10 mL Costar 
Test Tube Racks Roth 
Tissue Culture Dish 100 mm Sarstedt 
Tissue Culture Dish 60 mm Sarstedt 
Tweezers Roth 
Vial Inserts Macherey-Nagel 
Vials With Slotted Cap Macherey-Nagel 
 
2.1.2.3. HPLC columns, lamps, GC columns 
Column / Lamp Purpose of use Manufacturer 
BDS Hypersil C18, 
3 µ, 100 x 3 mm, 
reversed phase 
Vitamin K serum 
determination assay by 
HPLC 
ThermoScientific 
D2 long Life Lamp VKOR enzyme activity 
assay by HPLC 
VWR/ Hitachi 
DB-XLB 122-1232 30 m x 
0.25 mm x 0.25 µm 
Vitamin K, bile acids, 7-
hydroxycholesterol 
determination by GC-MS 
and cholesterol by GC-FID 
J&W Scientific 
Nucleodur C18 Gravity, 
3 µ, 100 x 3 mm, 
reversed phase 
Vitamin K serum 
determination assay by 
HPLC 
Macherey-Nagel 
Supelcosil TM LC-18-S 
15 cm x 4,6 mm, 5 µm 
HPLC enzyme activity 
assay 
Sigma-Aldrich 
Xenon Lamp Ushio 
Uxl 157 
HPLC vitamin K serum 
determination assay 
VWR/ Hitachi 
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2.1.2.4. Commercial kits 
Name Purpose of use Manufacturer 
BigDye Terminator v3.1 
Cycle Sequencing Kit 
Sequencing Applied Biosystems 
Fugene HD Reagent Transfection Roche 
QIAprep Maxiprep Kit Plasmid preparation QIAGEN 
QIAprep Midiprep Kit Plasmid preparation QIAGEN 
QIAprep Spin Miniprep 
Kit 
Plasmid preparation QIAGEN 
QIAquick Gel Extraction 
Kit 
DNA gel extraction QIAGEN 
 
2.1.2.5. Plasmids 
Name Purpose of use Manufacturer 
peGFP-N2 eGFP plasmid expression 
in mammalian cells 
Invitrogen 
pcep4-VKORC1 VKORC1 expression in 
mammalian cells 
Invitrogen 
self-production 
pcep4-VKORC1L1 VKORC1L1 expression in 
mammalian cells 
Invitrogen 
self-production 
 
2.1.2.6. Buffers 
10x PCR Buffer 0.5 M KCL 
0.2 M Tris HCl (pH 8.4) 
1x PCR Buffer 100 µL 10 x PCR Buffer 
0.22 mM dNTPs 
1.67 mM MgCl2  
Aqua dest. 
10x TE-Puffer 0.1 M Tris HCl 
10 mM EDTA (pH 8.0) 
Aqua dest. 
50x TAE 0.5 M EDTA pH 8.0 
2 M Tris Base 
1 M Glacial acetic acid 
LB Medium (Lysogeny Broth Medium) Tryptone/ Peptone  10 g/ L 
Bacto Yeast Extract   5 g/ L 
NaCl      5 g/ L 
Agar (optional)  15 g/ L 
antibiotics (50 µg/ mL) 
4x Loading Buffer for agarose gels 40 % w/ v Saccharose  
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0.1 % w /v Xylene cyanol 
0.1 % w/ v Bromphenol blue 
TAE Buffer 
EtOH Acetate Solution 0.1 M NaAc pH 4.6 
75 % v/ v EtOH 
Buffer for VKOR Enzyme Activity Assay 
 
 
DTT Stock Solution 
CHAPS Stock Solution 
CaCl2 Stock Solution 
25 mM Imidazole 
pH 7.6 
0.5 % w/ w CHAPS 
125 mM 
2 % w/ w 
400 mM 
 
2.1.2.7. Primer sequences 
Name Sequence (5´- 3´) Use 
M13-F 
M13-R 
GTA AAA CGA CGG CCA G 
CAG GAA ACA GCT ATG AC 
Plasmid 
Sequencing 
VKORC1-
Promoter F 
CAA GTT CCA GGG ATT CAT GC 
 
PCR 
VKORC1 
VKORC1-
Promoter R 
CCA AGA CGC TAG ACC CAA TG PCR 
VKORC1 
Cyp4F2 Ex11-F TGA GGG AGG TGA TGT TGG AT 
 
PCR 
CYP4F2 
Cyp4F2 Ex11-R GTC TCC TGG GTA GGA AGA GG 
 
PCR 
CYP4F2 
SQ_Cyp4F2 
Ex11-R 
TGA AGG AGG CCT TCT CCT GAC Seq 
CYP4F2 
 
2.1.2.8. Biological material and enzymes 
Name Use Firm 
HEK 293T 
(human embryonic kidney cells) 
Cell culture experiments DMSZ 
E. coli DH5α (competent) Cloning, plasmid transformation Invitrogen 
BamHI, NotI Restriction digestion Fermentas 
Taq Polymerase PCR Roche 
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2.1.2.9. Animals 
Tissue from mice of the laboratory bred CD1 at the age of 7 weeks was used for 
determination of tissue vitamin K. 
Following tissues were dissected and prepared for analysis: 
lung, bone, pancreas, kidney, tongue, uterus, muscle, heart, brain, liver, ovary, testis 
 
2.1.3. Standards and vitamin K-spiked serum preparation 
2.1.3.1. Vitamin K epoxides 
Vitamin K epoxides were performed  as described by Fieser et al. 78.  
100 mg vitamin K was dissolved in 10 mL of ethanol (100 %) and after addition of 
100 mg sodium carbonate and 1.2 mL hydrogen peroxide 30 %, the mixture was 
warmed for 2.5 h at 70 °C with occasional agitation. Complete decolouration of the 
yellow mixture occurred after about 50 minutes. After thoroughly cooling, 10 mL 
water and 20 mL diethyl ether were added. The mixture was vortexed for 5 min 
followed by a brief centrifugation step (5 min at 3000 rpm). The upper diethyl ether 
phase was collected containing vitamin K epoxide (colourless). To remove traces of 
water from the organic phase, anhydrous sodium sulfate was added until the crystals 
no longer clumped together. Afterwards the ether extract was evaporated to dryness 
under a gentle stream of nitrogen at 50°C. The residue was being weighed and 
redissolved in a known volume of methanol. The epoxide solutions can be kept for a 
long period of time at 4 °C in the dark.  
Vitamin K1 epoxide has a molar mass of 466 g mol-1, menaquinone-4 epoxide of 460 
g mol-1. 
2.1.3.2. Solutions and dilutions 
All solutions and dilutions including K vitamins were prepared using 100 % HPLC 
grade solvents and were shielded from UV light. 
 
Standards for VKOR Enzyme Activity Assay 
Stock solutions of vitamin K1 and vitamin K2 (menaquinone-4) epoxide, with the 
molar mass of 466 g mol-1 and 460 g mol-1 respectively, were prepared in µM 
concentrations. For this adequate amounts (calculated by using molecular weight of 
each compound) of the epoxides were dissolved in ethanol. Initially, 8500 µM 
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solution of each epoxide was prepared. To create accurately diluted solutions, a 
constant one-fold serial dilution at each step was carried out nine times. Finally an 
appropriate amount of the epoxide stock solution was used while performing the 
enzyme assay to gain the designated end concentration of the substance - 0.5, 1, 2, 
4, 8, 16, 32, 64, 128, 256 µM. In addition, 400 µM vitamin K1 and K2 epoxide stock 
solutions were prepared for use as extraction standards. 
 
Standards for vitamin K determination assay from serum 
All standards – vitamin K1, vitamin K2 (MK-4), vitamin K1(25) ISTD - were dissolved 
in 100% HPLC-grade isopropanol. 
Solvents: MK-4 → weigh 10 mg of MK-4 and dissolve in 1 mL of isopropanol 
  K1 → weigh 10 mg of K1 and dissolve in 1 mL isopropanol 
  ISTD → weigh 10 mg of K1(25) and dissolve in 1 mL isopropanol 
 
 
Stock Solution MK-4: Dilute the solution 10 mg/ mL MK-4 at the ratio 1:1000 
= 10 µg/ mL of MK-4 
= Primary Stock Solution MK-4  
  
Stock Solution K1:  Dilute the solution 10 mg/ mL K1 at the ratio 1:1000 
= 10 µg/ mL of K1  
= Primary Stock Solution K1 
 
Stock Solution ISTD: Dilute the solution 10 mg/ mL K1(25) at the ratio 1:1000 
= 10 µg/ mL of ISTD 
Dilute the solution 10 µg/ mL K1(25) at the ratio 1:10 
= 1000 ng/ mL of ISTD 
= Primary Stock Solution ISTD 
 
  
Preparation of K1 and MK-4 calibration curves using K1(25) as internal standard 
 
For the calibration curves, working solutions of K1 and MK4 were prepared at 
concentrations ranging from 0.0625 to 20 ng per absolute injection. The primary 
stock solution of the concentration 10 µg/ mL was diluted at the ratio 1:20 to gain the 
calibration point 10 (0.5 µg/ mL equating to 20 ng per 40 µL absolute injection) which 
was further used to prepare the remaining calibration points by dilution as described 
below: 
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Calibration 
point 
Vitamin K 
per absolute injection 
[ ng ] 
 
Diluted calibration 
point 
 
Dilution ratio 
1 0.0625 2 1:1 
2 0.125 3 1:1 
3 0.25 4 1:1 
4 0.5 5 1:1 
5 1 6 1:1 
6 2 8 1:4 
7 5 8 1:1 
8 10 10 1:1 
9 15 10 2:1 
10 20   
 
The internal standard K1(25) was kindly provided by Dr. Schurgers (University of 
Maastricht, the Netherlands). The primary stock solutions (1000 ng/ mL) of the 
internal standard were prepared in isopropanol. Dilutions of the primary stock were 
prepared at concentrations ranging between 25 and 100 ng/ mL. An appropriate 
amount of the defined secondary solution was added to the calibration solutions of 
vitamin K1 and MK4 to gain a final concentration of 0.5, 1 or 2 ng internal standard 
per absolute injection depending on the expected vitamin K concentration. 
2.1.3.3. Vitamin K-spiked human serum 
A serum pool was obtained from healthy volunteers. For validation studies and as 
qualifiers for performing the vitamin K serum determination assay, pool samples were 
enriched to increase the basal concentration of phylloquinone and MK4 by 0.1, 1, 10 
and 100 ng per absolute injection. 
 
Sample name Concentration of K1, MK4 
QM1 basal serum concentration 
QM2 basal serum concentration + 0.1 ng/ inj. 
QM3 basal serum concentration + 1 ng/ inj. 
QM4 basal serum concentration + 10 ng/ inj. 
QM5 basal serum concentration + 100 ng/ inj. 
 
Prior to performing the vitamin K determination assay, an adequate amount of 
internal standard was added to each serum sample. 
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2.1.3.4. Bile acid calibration curves 
Different concentrations of the bile acids were dissolved in 10 mL ethylacetate (stock 
solution). 100 µL of this solution was taken for quantification via GC-FID  by adding 1 
µg hyodeoxycholic acid as an internal standard. The ethylacetate was evaporated 
under nitrogen at 65 °C. The carboxylic group was methylated by addition of 2 mL 
MeOH, 1.5 mL 2.2-dimethoxypropane and 20 µL HClconc. at room temperature over 
night. After solvent evaporation, hydroxy-groups of the bile acids were derivatisized 
to trimethylsilyl (TMSi)- ethers by adding 0.6 mL TMSi-reagent 
(pyridine:hexamethyldisilazane-trimethylcholorsilane; [9:3:1, v/v/v])   to the residue 
and incubation for 1 h at 65 °C. After evaporation under nitrogen at 65 °C, the 
residue was dissolved in 50 µL n-decane + 20 µL TMSi-reagent and transferred into 
micro-vials for GC-FID analysis. 
The stock solution was diluted 5 times with ethylacetate at the ratio of 1:3. For the 
calibration curve 100 µL of each dilution were used. As internal standards for the 
preparation of standard curves 0.1 µg hyodeoxycholic acid and 0.1 µg [2,2,4,4-d4] 
ursodeoxycholic acid were added. After methylation and silylation at 65 °C for 1 h 
and evaporation, the residue was dissolved in 50 µL n-decane + 20 µL TMSi-reagent 
and transferred into micro-vials for GC-MS analysis. 
2.1.3.5. Cholesterol and 7α-hydroxycholesterol calibration curves 
80 mg of cholesterol was dissolved in 100 mL cyclohexane, 5 mg of 7-
hydroxycholesterol was dissolved in 100 mL methanol. 100 µL of each solution was 
taken to quantify sterol content by adding 50 µg of 5-cholestane and 1 µg of 
epicoprostanol as internal standards via GC-FID. Six samples were prepared and 
cyclohexane was evaporated under nitrogen by 65 °C. The residual sterols were 
trimethylsilylated by addition of 200 µL of a mixture of pyridine-hexamethyldisilazane-
trimethylcholorsilane; (9:3:1, v/v/v) and incubated at 65 °C for 1 h. After evaporation, 
the residual TMSi-ethers were dissolved in 100 µL n-decane for GC-FID analysis.  
Sterols were identified via retention time defined via individual measurement of 
prepared stock solutions. Peak integration was performed manually. The ratios of the 
sterols areas to the area of internal standard were calculated and multiplied by the 
added amount of the internal standard 5-cholestane to reveal absolute 
concentrations of cholesterol and multiplied by the added amount of the second 
internal standard epicoprostanol to reveal absolute concentrations of 7-
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hydroxycholesterol in the stock solution. The stock solution was diluted seven times 
with cyclohexane at a ratio of 1:3 to gain eight calibration points. The sterol amount 
was calculated by dividing per three for each of the seven dilutions. 
 
2.2. Molecular biological methods 
 
2.2.1. PCR performance 
2.2.1.1. Creation of oligo-nucleotides for the PCR 
Oligo-nucleotides for the amplification of particular DNA fragments were ascertained 
by means of web-based program Primer3 (http://frodo.wi.mit.edu/primer3/). Synthesis 
and purification were carried out by Eurofins/ MWG (Cologne, Germany). Primer 
selection was guided by GC-content within 40-60 %, annealing temperature 
exceeding 55 °C and minimum length of 20 bases. 
2.2.1.2. Polymerase chain reaction 
The polymerase chain reaction (PCR) is a technique in molecular biology to amplify 
copies of appointed base sequences, generating thousands to millions of copies of a 
particular DNA sequence. Developed in 1983 by Kary B. Mullis, PCR was first 
described by Saiki et al. 79. 
PCR initialization and DNA denaturation occur by heating the reaction to a 
temperature of 95°C which causes melting of the DNA template by disrupting the 
hydrogen bonds between complementary bases, yielding single-stranded DNA. To 
enable annealing of the primers to the single-stranded DNA, the reaction temperature 
is lowered to 50-62°C depending on the primer sequence. The polymerase binds to 
the primer-template hybrid and begins DNA synthesis. At this extension/ elongation 
step at 72 °C the DNA polymerase synthesizes a new DNA strand complementary to 
the DNA template strand by adding dNTPs in 5` to 3` direction. Under optimum 
conditions at each extension step the amount of DNA target is doubled, leading to 
exponential amplification of the specific DNA fragment. 
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PCR Master-Mix:     Temperature profile (35 cycles): 
25 µL 1x PCR Buffer    95 °C   5 min 
0.5 µL Primer (5´-3´; 3´-5´)   95 °C   30 s 
0.3 µL Taq Polymerase    50-62 °C  30 s  35x 
20-100 ng DNA     72 °C   30 s  
       72 °C   5 min  
       4 °C   ∞ 
2.2.1.3. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments by length and size 
with the help of defined length standard (DNA ladder). In the context of this work, 
DNA was separated electrophoretically using 1 % (w/ v) agarose gel in 1x TAE 
buffer. To produce the gel, the agarose was solved in 1x TAE buffer and boilt up. 
Ethidium bromide was added in the end concentration of 10 µg/ mL to allow later 
DNA detection. The DNA solution was injected into the gel slots; the particular DNA 
fragments were separated electrophoretically at 150 V for 20-30 min whereas the 
DNA ladder of defined length was injected into a separate gel slot. The following 
DNA detection was carried out in a ChemiDoc system (Biorad, Germany). 
2.2.1.4. DNA isolation from agarose gels 
DNA molecules were isolated from the agarose gel after electrophoretic separation 
using Qiaquick Gel Extraction Kits (Qiagen). The required gel band was cut out while 
illuminating with an ultraviolet lamp followed by a DNA purification on Qiaquick 
membrane columns and dissolving in 30 µL elution buffer. 
2.2.1.5. Preparative plasmid isolation 
The plasmid preparation from bacteria occurred by using Qiagen Plasmid Mini, Midi 
or Maxi Kits. Therefore, a predetermined volume of LB medium was inoculated with a 
particular bacterial strain (in glycerine) and incubated over night at 37 °C in a shaker. 
The bacterial lysis and subsequent plasmid purification was carried out regarding the 
kit protocol. Separated plasmids were held in dH2O. Both concentration and grade of 
purification were determined photometrically. 
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2.2.1.6. DNA digestion by endonuclease restriction enzymes 
Restriction assays of plasmids and DNA molecules were conducted in an end 
volume of 20 µL which contained the recommended enzyme concentration in an 
appropriate buffer depending on the used DNA amount as per manufacturer. All 
reactions were incubated at 4 °C over night and verified using an electrophoretic 
separation (see section 3.2.1.3.). If required, specific DNA bands were extracted from 
the gel for further use. 
2.2.1.7. Plasmid transformation in E.coli DH5α 
For transformation, 50 µL competent E.coli DH5α (Invitrogen) bacteria were carefully 
mixed with 2 µL ligation mix, incubated for 30 min on ice followed by heat shock at 42 
°C for 45 sec in water bath. 250 µL LB medium (room temperature) were added and 
the reaction was agitated at 37 °C for 1.5 h in heating block. After incubation, 50-150 
µL transformation mix was placed on antibiotic-rich LB agar plates and selected over 
night at 37 °C in an incubator. Transformed plasmids of grown colonies were verified 
via colony PCR and sequencing. 
2.2.1.8. DNA sequencing and ethanol-acetate-precipitation 
DNA sequencing is the process of determining the accurate nucleotide order of a 
given DNA fragment. DNA sequencing has been performed using the chain 
termination method with dideoxynucleotides developed by Sanger 80. DNA 
sequencing was carried out by using ABI Prism big-Dye Terminator Cycle 
Sequencing Ready Reaction Kit and ABI Prism 3130xl DNA Sequencer. Sequencing 
reactions contain DNA or purified PCR products regarding schema and temperature 
profile as follows: 
Mix       Temperature profile (45 cycles) 
2 µL DNA      1.) 96 °C    1 min  
0.5 µL Ready Mix     2.)  96 °C  10 s  
1.5 µL 5 x Sequencing buffer   3.)  50 °C    5 s  45x 
0.5 µL For or Rev Primer 3.2 pmol/ µL  4.)  60 °C    4 min 
6.5 µL Aqua dest.         5.)    4 °C    ∞ 
10 µL Total volume 
 
After the sequencing reaction, DNA fragments were purified by ethanol-acetate-
precipitation. 10 µL dH2O, 2 µL 3M sodium acetate (pH 4.6) and 50 µL ethanol 95 % 
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were added to the sequencing product and centrifuged at 4°C and 4000 rpm for 45 
min. After discarding the supernatant, the samples were centrifuged again with 200 
µL of ethanol 70% (4 °C, 4000 rpm, 10 min). The supernatant was discarded again, 
the dried samples were dissolved in 15 µL HiDi formamide and sequenced. 
 
2.3. Cell biological and enzymological methods 
Cell culture experiments were performed under sterile laminar flow conditions using 
autoclaved or aseptic packed disposable material. All mediums and buffers, unless 
otherwise stated, were warmed to 37°C before use. 
 
2.3.1. Cultivation of mammalian cell lines 
Adherent (sticky) growing mammalian cells HEK 293T (human embryonic kidney 
293T cells) were cultivated under controlled conditions at 37 °C, 5 % CO2 in a cell 
incubator. MEM (minimal essential medium) containing 10 % FBS (fetal bovine 
serum) was used as growth medium. Penicillin-streptomycin solution and non-
essential amino acid mixture were used to supplement the medium. Medium was 
changed every 3-4 days. 
 
2.3.2. Subcultivation of cell cultures 
Passaging also known as subculture or splitting cells involves transferring a small 
number of cells into a new vessel and occurred with 90 % confluent cell culture 
plates. After the medium was removed, cells were washed with PBS (phosphate 
buffered saline) and detached from the bottom of the plate with a mixture of trypsin-
EDTA for 3 min at 37 °C. Care was taken not to overexpose cells to trypsin, as it can 
damage important cell surface proteins, channels and receptors. Growth medium 
was added (proteins present in growth medium essentially absorb the action of 
trypsin) and the cells and medium were mixed with. Then, the cell suspension was 
transferred to new plates, fresh medium was added to each plate. 
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2.3.3. Long-term storage of cells 
After detaching from the plate with trypsin, the cells were resuspended in 1.7 mL 
medium containing 5 % DMSO (dimethyl sulfoxide) and 20 % FBS. Then the stocks 
were stored on ice for 30 min and at -20 °C for 24 h. After further storage at -80 °C 
for three days, the stocks were preserved at -196 °C in liquid nitrogen. 
 
2.3.4. Cell transfection 
Transient transfection for gene expressions in mammalian cell cultures was 
conducted with Fugene HD Reagent (Roche). The transfection suspension contained 
500 µL FBS-free medium, 10 µg DNA and 30 mL Fugene HD transfection reagent 
and was incubated at room temperature for 15 min. For transfection, 80 % confluent 
cell plates were used. During the incubation of the transfection suspension, cell 
medium was replaced by FBS-free medium. DNA-Fugene suspension was 
distributed equally on the plate. After a period of 24 h, the cells could be further 
cultivated with FBS-containing medium. 
 
2.3.5. Harvesting of full-cell homogenate 
The preparation of cell extracts was required for enzymatic analysis of VKOR activity 
in HEK cells. Cells were washed with 4 °C cooled PBS followed by scraping these 
from the plate surface and transferring to 6 mL PBS. After centrifugation at 1000 g, 4 
°C for 5 min, the supernatant was discarded. The cells were resuspended in 100 µL 2 
% CHAPS (w/w) and incubated on ice for 10 minutes. Then 40 µL 250 mM imidazole 
was added to the suspension and incubated on ice for further 10 min. 230 µL 
glycerine (87 %, v/v) and 20 µL dH2O were added prior to using the cell extracts for 
VKOR activity determination. The homogenates were stored at -80 °C. 
 
2.3.6. Lowry protein assay 
The Lowry protein assay was used for determining the total level of protein 
colorimetrically as described by Lowry et al. 81. The method combines the reactions 
of cupric ions with the peptide bonds under alkaline conditions with the oxidation of 
aromatic protein residues. Cell extracts were diluted with dH2O in the ratio 1: 100 in 
order to reach a protein concentration in the determination range of BSA (bovine 
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serum albumin) standard curve. Protein standards were generated with defined BSA 
concentrations in the range between 0 and 1 µg/ mL using 2 % BSA stock solution in 
dH2O. Following reagents were used: 
Reagent “A”: 2 % Na2CO3 in 0.1 N NaOH 
Reagent “B”: 0.5 % CuSO4 in 1% sodium citrate 
Reagent “C”: 1 mL “B” to 50 mL “A”  
Folin-Ciocalteu reagent: a mixture of phosphotungistic acid and phosphomolybdic 
acid in the Folin-Ciocalteu reaction 
Protein determination was carried out in microtiter plates with sample volume of 10 
µL. After addition of 100 µL reagent “C” and incubation for 10 min in the dark at room 
temperature, 10 µL Folin-Ciocalteu reagent was added. The plates were incubated 
for 30 min at room temperature in the dark. The absorption was photometrically 
measured at 690 nm. On the basis of the standard curve, the protein concentrations 
of the samples were determined. 
 
2.3.7. VKORC1 enzymatic activity assay 
The VKOR is featured to reduce vitamin K epoxide to quinone which is used to 
determine VKOR enzymatic activity and further for estimation of enzymatic constants 
as Km and Vmax for both epoxides. VKOR enzymatic activity was measured in whole-
cell extracts according to published procedures 82. Unless otherwise stated, all steps 
of the reaction were performed on ice. For each reaction, 30 µL HEK cell 
homogenate (VKORC1 transfected cells) was suspended in 470 µL on ice cooled 
reaction buffer. After addition of 20 µL dithiothreitol providing reducing equivalents 
(end concentration in the mixture 5 mM), the suspension was incubated for 1 min at 
room temperature and 5 µL CaCl2 (end concentration 5 mM) was then added. An 
appropriate amount of vitamin K epoxide solution in ethanol was used to gain the 
designated substrate end concentration in the range 0.5 to 256 µM. After incubation 
at 30 °C for 1 h, the reaction was stopped with 1 mL isopropanol/ hexane (3:2, v/v). 
As an extraction in-process control step, the other epoxide was added in the end 
concentration of 8 µM. The remaining substrate (epoxide) and the product 
(corresponding quinone) contained in the hexane phase were extracted, dried under 
vacuum and redissolved in 50 µL methanol, 40 µL of which were used for injection in 
the HPLC. Subsequently, vitamin K epoxides and quinones were separated by 
isocratic HPLC on a reverse phase C18 column (oven temperature 45 °C) using 
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methanol as a mobile phase (flow rate 1 mL/ min). The detection was carried out by 
DAD at 254 nm 83. The quantification of the generated quinone was adjusted 
according to the extraction standard and the total protein concentration in the 
sample. Some parameters were varied in the different trials while performing the 
VKOR enzymatic activity assay. The concentration of vitamin K epoxide as substrate 
was in the range between 0.5 and 256 µM. Moreover, the enzyme reaction was 
incubated for different time intervals: 5, 10, 30 or 60 min. Besides the regular 
experiments with vitamin K1 or K2 as substrate, some experiments were conducted 
in addition using both epoxides as substrate in varying ratios with the total 
concentration of 8 µM. More than 400 reactions were performed in triplicate. 
 
2.3.8. Determination of kinetic constants 
The most common kind of enzyme kinetic experiment is to vary the concentration of 
substrate and measure enzyme velocity. The main goal is to determine the enzyme´s 
kinetic constants Km and Vmax 
84. Km is the Michaelis-Menten constant and describes 
the substrate concentration needed to achieve a half-maximum enzyme velocity. 
Vmax is the maximum velocity that can be reached and it is the velocity of the enzyme 
at very high concentrations of substrate. In our experiments, the Y-axis of the typical 
Michaelis-Menten saturation curve presents the formation rate of vitamin K quinone 
in nmol per mg protein (reaction rate), the X-axis shows the substrate concentration 
in the range between 0.5 and 256 µM. 
To calculate the apparent kinetic constants Km and Vmax, Lineweaver-Burk plot was 
used which is a common way of illustrating kinetic data. This model plots the 
reciprocal of substrate concentration versus the reciprocal of enzyme velocity 
(double-reciprocal plot), thereby curve data are transformed into straight lines. In this 
way, the slope and intercept of a linear regression line are used to determine values 
for Km and Vmax. 
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2.4. Bioanalytical methods 
 
2.4.1. High-Performance Liquid Chromatography 
Vitamin K1 (phylloquinone), vitamin K2 (menaquinone-4) and their epoxides were 
quantified via HPLC 85 with fluorescence detection according to their 
chromatographic features and the resultant specific retention times. A modified HPLC 
method, based on Davidson and Sadowski 86, with fluorescence detection after zinc 
post-column reduction was developed and validated for the analysis of K vitamins in 
plasma and serum samples. All solvents and chemicals were of the highest purity 
commercially available. 
2.4.1.1. HPLC instrumentation 
The isocratic HPLC system (VWR, Hitachi) consisted of separation modules with in-
line vacuum degasser, L-2130 Pump, L-2200 Autosampler, L-2300 Column Oven 
and L-2485 Fluorescence Detector, all controlled by Elite LaChrom software 
(V.3.1.7.). A BDS Hypersil C18 (3x 100 mm) or Nucleodur C18 Gravity (3x 100 mm), 
both of 3 µm particle size, were used. During analysis the column temperature was 
maintained at 22 °C, the autosampler temperature at 15 °C. A 10 cm long, post-
column peek tubing was dry-packed with zinc powder (<150 µ) and connected 
between the analytical column and fluorescence detector. 
2.4.1.2. Sample preparation and hexane extraction of vitamin K 
from serum 
Blood samples were obtained by venipuncture from German volunteers. Blood was 
collected into serum tubes and serum was separated by centrifugation, transferred to 
plastic cryotubes and stored at -80 °C for around 1 year with no further freeze-thaw 
cycles prior to analysis. Samples were protected from light immediately after blood 
withdrawal. 
Vitamin K compounds were purified from serum by liquid-liquid extraction. Aliquots of 
0.5 mL serum samples were transferred to a disposable glass centrifuge tube (16x 
100 mm) containing 0.5 mL dH2O. Two mL ethanol 100 % was added to precipitate 
the proteins with brief agitation. Then internal standard (0.5, 1 or 2 ng per absolute 
injection) was added and the mixture was vortexed for 30 sec. After this 4 mL n-
hexane were added and the contents were mixed vigorously. Then the mixture was 
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vortexed again for 1 min and centrifuged at 1500 g for 10 min at room temperature to 
separate an upper hexane layer from a lower aqueous-ethanolic layer and 
precipitated proteins. The upper hexane layer was quantitatively transferred to a 
disposable glass tube. The lower layer was additionally re-extracted with 4 mL 
hexane as described above and the upper organic layer was pooled with the first 
hexane extract. The hexane pool was evaporated to dryness under a stream of 
nitrogen at 50 °C. 
2.4.1.3. Isolation of vitamin K fraction from lipid extracts using 
Sep-Pak silica cartridges 
The isolation of the vitamin K fraction from lipid extracts was carried out by using 
solid phase extraction (SPE) system. SPE Sep-PakTM silica cartridges (Chromabond® 
SiOH 3 mL/ 500 mg, Macherey-Nagel) were placed in a SPE manifold and 
preconditioned with 9 mL of hexane (3 x 3 mL). The prewashing step with hexane 
removes materials from the cartridge which may otherwise interfere with the vitamin 
K assay. The dried lipid extract was dissolved in 2 mL of n-hexane, agitated briefly 
and introduced into the cartridge using Pasteur pipette. The hexane solution was 
pushed through the cartridge to load the extract at the head of the Sep-Pak. The tube 
that contained the lipid extract was rinsed with 2 mL hexane and loaded onto the 
cartridge in the same way. Nine mL of hexane (3 x 3 mL) were drawn through each 
cartridge under vacuum to separate the hydrocarbon lipid fraction and the eluate was 
discarded. Furthermore, the retained vitamin K compounds were eluted with 9 mL of 
3 % (v/v) diethylether in hexane and collected in disposable glass tubes (16x 100 
mm). Eluates were evaporated to dryness under a stream of nitrogen at 50 °C. 
2.4.1.4. Final analytical stage of the vitamin K determination 
assay 
The dried vitamin K fraction was dissolved in 50 µL isopropanol and transferred to 
200-µL glass vials for HPLC analysis. A volume of 40 µL was injected onto the 
column via a valve injector.  
The separation of the vitamin K compounds was carried out under the following 
HPLC conditions: 
 
Column:  Nucleodur C18 Gravity MN 3 µ, 100x 3.0 mm (RP, MN) 
   or 
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BDS Hypersil C18 3 µ, 100x 3.0 mm (RP, TS) 
Mobile phase: 100 mL Acetonitrile 
1.1 g Zinc acetate 
10 mL dH2O 
10 mL Acetic acid 
in Methanol, final volume 1L 
Flow-rate:  0.8 mL/ min 
Detector:  Fluorescence detector 
Excitation wavelength: 246 nm  
Emission wavelength: 430 nm    
Zinc-reduction: 100x 2 mm peek tubing filled with zinc powder (<150 µ) 
2.4.1.4.1. Separation on RP-18 column 
The isocratic separation of vitamin K compounds occurred on Reversed Phase-C18 
column. 
Reversed phase HPLC has a non-polar stationary phase and a moderately polar 
mobile phase. With this stationary phase, retention time is longer for molecules which 
are more non-polar, while polar molecules elute more readily. According to this, 
vitamin K epoxides elute faster than corresponding quinones. Furthermore, vitamin 
K2 (menaquinone-4) containing four isoprenoid residues in the side chain is 
considered as more polar than phyloquinone and elutes faster while vitamin K1 
undergoes stronger interactions with the non-polar stationary phase and elutes at a 
slower rate from the column. 
2.4.1.4.2. Post-column zinc reduction 
The HPLC assays used for the determination of endogenous phylloquinone (vitamin 
K1), menaquinones (vitamin K2) and their epoxides, have evolved from the 
postcolumn reduction and fluorimetric detection methodology originally described by 
Haroon et al. 87-89. The analytical system utilized to reduce nonfluorescent vitamin K 
compounds to their fluorescent hydroquinone forms consists of a postcolumn dry-
packed with zinc powder (<150 µ). Hydroquinones are produced by chemical 
reduction over zinc in the presence of zinc ions, which are provided by the mobile 
phase. This on-line reduction process forms the core of the chromatographic systems 
used for the determination of vitamin K. 
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Vitamin K and the internal standard, all in the quinone or epoxide forms, were 
separated on the HPLC column and were then reduced to their hydroquinones in the 
post-column zinc reduction step.  
2.4.1.4.3. Fluorescence detection 
The chromatographic peaks of vitamin K hydroquinones and the appropriate internal 
standard (vitamin K1(25) eluting after phylloquinone) were detected and measured 
via fluorescence detector. The fluorescence detector is one of the most sensitive 
liquid chromatography detectors and senses only those substances that fluoresce i.e. 
compounds with conjugated double bonds (delocalised π-system).                                     
An excitation light of 246 nm was used for vitamin K detection. The emission 
wavelength was 430 nm. 
 
2.4.1.5. Calibration and calibration curve of vitamin K  
Calibration solutions (calibration point 1 – 10) of phylloquinone and menaquinone-4 
were prepared as described above (3.1.3.2.). Calibration curves were constructed by 
plotting the weight ratio of vitamin K to internal standard on the Y-axis against the 
peak area ratios of vitamin K to internal standard on the X-axis. Tables 1 shows the 
calculated weight ratios used for construction of the calibration curves. 
 
Table 1 Calibration points of K1 or MK4 using K1(25) as internal standard 
(1 or 2 ng/ absolute injection) and corresponding weight ratios 
 
 
Calibration point 
K1 or MK4 
per absolute injection 
[ng] 
Internal Standard 
per absolute injection 
[ng] 
Weight ratio 
MK4 / ISTD 
1 0.0625 1 2 0.0625 0.03125 
2 0.125 1 2 0.125 0.0625 
3 0.25 1 2 0.25 0.125 
4 0.5 1 2 0.5 0.25 
5 1 1 2 1 0.5 
6 2 1 2 2 1 
7 5 1 2 5 2.5 
8 10 1 2 10 5 
9 15 1 2 15 7.5 
10 20 1 2 20 10 
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After construction of the calibration curve, the linear fit (y=ax+b) and the goodness of 
fit (R2) were determined. The linear equation was further used to calculate the vitamin 
K concentration in samples of interest with unknown substance concentration. 
Theoretically, the peak area ratio (vitamin K/ ISTD) was calculated. Then, the 
corresponding weight ratio in the calibration curve was read and the amount of the 
unknown vitamin K in the sample calculated. 
Practically, the linear equation was used to calculate the unknown vitamin K amount 
in the sample: 
y = ax + b 
a =  slope 
b = axis intercept 
 
   
                   
               
 
 
  
                
            
 
 
                       
                  
              
                   
 
 
2.4.2. Gas-Chromatography Mass-Spectrometry 
2.4.2.1. Gas-Chromatography 
Gas chromatography identifies the individual substances that make up an unknown 
sample by separating those substances utilizing the basic chromatographic principles 
of mobile and stationary phases 85,90. 
2.4.2.2. Mass-Spectrometry 
MS is an analytical technique used to measure the mass to charge ratio of ions. It is 
most generally used to find the composition of a physical sample by generating a 
mass spectrum representing the masses of sample components. A typical mass 
spectrometer comprises three modules: an ion source (convert gas phase sample 
molecules into ions), a mass analyzer (sorts the ions by their masses by applying 
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electromagnetic fields), and a detector (measures the value of an indicator quantity 
and thus provides data for calculating the abundances of each ion present) 91.  
2.4.2.3. GC-MS and GC-FID analyses 
Authenticity of vitamin K1, MK4 and the corresponding epoxides was proven by 
comparison of the spectra with the literature using GC-MS analytics in Scan mode 
(m/z 50-600). Cholesterol was measured by gas-liquid chromatography-flame 
ionization detection (GLC-FID). Bile acids and the bile acid precursor 7-
hydroxycholesterol were analysed using gas-chromatography mass-spectrometry-
selected ion monitoring (GLC-MS-SIM) in the splitless mode using helium (1mL/ min) 
as carrier gas. 
2.4.2.3.1. Determination of vitamin K in human serum by GC-MS 
Vitamin K was extracted from human serum and subsequently subjected to GC-MS 
analysis. A HP 5890 Series II Model gas chromatograph coupled to HP 5972 mass 
spectrometer was used. The gas chromatograph was equipped with a cross-linked 
methyl silicone DB-XLB 122-1232 fused silica capillary column (J&W Scientific), 30 m 
x 0.25 mm i.d. x 0.25 µm film thickness. Helium was used as the carrier gas. The 
initial column temperature was 70 °C for 1 min, followed by an increase of 30 °C min-
1 to 150 °C, an isothermal hold for 3 min, followed by another increase of 30 °C min-1 
to 180 °C and a final isothermal hold of 45 min. One mL serum sample, diluted with 1 
mL of water, was mixed thoroughly, and kept in the dark for 10 min at room 
temperature. A 2 mL volume of methanol was added and the mixture left another 10 
min in the dark. After the addition of 4 mL of hexane, the mixture was extracted for 15 
min. After centrifugation, the supernatant was decanted into glass vials and the 
solvent was evaporated under a stream of nitrogen. After evaporation of the solvent, 
the sample was dissolved in hexane, transferred to autosampler vials and an aliquot 
of 2 µL was subjected to GC-MS analysis. 
2.4.2.3.2. GC-MS bile acid analysis 
0.1 µg of hyodeoxycholic acid and 0.1 µg of [2.2,4.4-d4] ursodeoxycholic acid, as 
internal standards, were added to 500 µL of human serum (at room temperature). 
Alkaline hydrolysis was performed at 90 °C for 1 h after addition of 1 mL 10 M 
sodium hydroxide solution. After cooling to room temperature and addition of 500 µL 
distilled water and 500 µL ethanol the unsaponified lipids were extracted twice with 3 
59 
 
mL cyclohexane and discharged. After adjusting the pH to 1-2 by adding 1mL conc. 
HCl, the bile acids were extracted twice with 3 mL diethylether and transferred into a 
new scew-capped 10 mL glass-tube. The combined organic phases were evaporated 
at 30 °C under nitrogen. The carboxylic group was methylated by addition of 2 mL 
methanol, 1.5 mL 2.2-dimethoxypropane and 20 µL HClconc. at room temperature 
over night. The samples were incubated for 30 min at 30 °C. The solvent was 
evaporated at 65 °C under nitrogen. The hydroxyl-groups of the bile acids were 
derivatisized to trimethylsilyl (TMSi)-ethers by adding 0.6 mL TMSi- reagent (pyridine-
hexamethyldisilazan-trimethylchlorsilane 9:3:1, v/v/v) to the residue and incubated for 
1 h at 65 °C followed by evaporation under nitrogen at 65 °C. The residue was 
dissolved in 50 µL n-decane + 20 µL TMS and transferred to micro- vials for GC-MS-
analysis. Bile acids from the samples were analyzed by GC-MS on HP gas 
chromatograph 6890 combined with an HP 5973 quadrupole mass selective detector 
(MSD). Splitless injection was performed with an HP 7673 automatic sample injector 
plus tray. The GC-MSD instrument is controlled by a computer with the HP 
ChemStation Software G1701DA revision D.03.00. The chromatographic separation 
of bile acids was performed on a 30 m DB-XLB capillary column (J&W, Folsom, USA) 
with a 250 µm film of crosslinked methyl silicone with helium as carrier gas. Initial 
pressure was set to 0.765 bar, the pulse pressure to 2 bar. The measurement took 
place in constant flow mode at an initial flow of 0.8 mL/ min. The temperature 
program started at 150 °C and raised after 3 min to 290 °C with a rate of 30 °C/ min. 
The final temperature was maintained for 23 min. The injector and MSD transfer line 
heater temperature were set to 280 °C. The MS source was set to 230 °C. Multiplier 
voltage was set to ~ 1400 V. Electron impact ionisation was employed at 70 eV 
ionisation energy. Selected ion monitoring (SIM) was performed by cycling the 
quadrupole mass filter between the chosen m/z values at a rate of 2.0 cycles/ s. 
Autotune was performed before a sequence in order to check the condition of the 
mass selective detector. SIM mode was started after a solvent delay of 12 min. Table 
2 lists the retention times and specific masses (m/z values) of each measured 
compounds. 
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Table 2 Chromatographic and mass selective detection parameters for 
trimethylsilyl-ethers of bile acids in human serum or plasma 
 
No. Derivatives of Category Retention Time  
[min] 
m/z-value(s) 
1 Deoxycholic acid Bile acid 17.25 255/370 
2 Cholic acid Bile acid 17.56 458/368 
3 Lithocholic acid Bile acid 17.61 372 
4 Chenodeoxycholic 
acid 
Bile acid 18.03 370 
5 Hyodeoxycholic acid Internal 
standard 
18.27 370 
6 d4-Ursodeoxycholic 
acid 
Internal 
standard 
18.85 464/374 
7 Ursodeoxycholic acid Bile acid 18.94 460/370 
 
2.4.2.3.3. GC-FID analysis of cholesterol and GC-MS analysis of 
7α-hydroxycholesterol 
Ten mg tertiary butylated hydroxytoluene (BHT) as antioxidant, 50 µg 5-cholestane  
and 100 ng d6-7-OH-Chol as internal standards were added to 100 µL serum 
sample. After alkaline hydrolysis with 1 mL 1N sodium hydroxide in 90 % ethanol for 
1 h at 68 °C and addition of 500 µL of distilled water the unsaponified lipids were 
extracted twice into 3 mL of cyclohexane. The combined organic phases were dried 
under nitrogen at 65 °C. The hydroxyl groups of the sterols and oxysterols were 
derivatisized to trimethylsilyl (TMSi)-ethers by adding 1 mL TMSi-reagent (pyridine-
hexamethyldisilazan-trimethylchlorosilane 9:3:1, v/v/v) to the residue and incubation 
for 1 h at 65 °C. After evaporation under nitrogen at 65 °C, the residue was dissolved 
in 160 µL n-decane. 80 µL were transferred to micro-vials for GC-MS-analysis. The 
residual 80 µL were diluted by addition of 500 µL n-decane for GC-analysis. 
Cholesterol was measured after separation on a 30 m DB-XLB capillary column 
(J&W, Folsom, USA) with a 0.250 µm film of crosslinked methyl silicone in an Agilent 
Technologies 6890 GC using flame ionization detection. Splitless injection was 
performed with an HP 7683 automatic sample injector plus tray.  Initial pressure was 
set to 3.0 psi. and column head pressure was set to 13.4 psi. Carrier gas flow was 1 
mL/ min. and velocity is 37.8 cm/ s. The temperature program started at 150 °C and 
raised after 1 min to 290 °C with a rate of 30 °C/ min. The final temperature was 
maintained for 30 min. The injector and detector temperature were set to 280 °C.  
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The oxysterol 7α-hydroxycholesterol from the same sample for GC analysis was 
analyzed by GC-MS on HP gas chromatograph 6890 serie N combined with HP 5973 
quadrupole mass selective detector (MSD). Splitless injection was performed with HP 
7683 automatic sample injector plus tray. The GC-MSD instrument was controlled by 
HP ChemStation Software G1701DA revision D.03.00. The chromatographic 
separation of sterols and oxysterols was performed on a 30 m DB-XLB capillary 
column (J&W, Folsom, USA) with a 0.250 µm film of crosslinked methyl silicone with 
helium as carrier gas. Initial pressure was set to 3.0 psi. and column head pressure 
was set to 13.4 psi. Carrier gas flow was 1 mL/ min and velocity is 37.8 cm/ s. The 
temperature program started at 150 °C and raised after 1 min to 290 °C with a rate of 
30 °C/ min. The final temperature was maintained for 30 min. The injector and 
detector temperature were set to 280 °C. Multiplier voltage was set to 2700 V. The 
emission current was 220 µA. Electron impact ionisation was employed at 70 eV 
ionisation energy. SIM was performed by cycling the quadrupole mass filter between 
the chosen m/z values at a rate of 2.0 cycles/ s. SIM mode was started after a 
solvent delay of 14 min with the ion m/z 370 for epicoprostanol. Table 3 lists the 
retention times and specific masses (m/z values) of the measured compounds. 
 
Table 3 Chromatographic and mass selective detection parameters for 
trimethylsilyl-ethers of sterols (except cholesterol) and stanols in 
human serum or plasma 
 
No. TMSi-Ether of Category Retention Time  
[min] 
m/z-
value(s) 
1 D6-7α-OH-
Cholesterol 
Oxysterol 16.80 462 
2 7α-OH-Cholesterol Internal 
standard 
16.88 456 
 
2.5. Bioanalytical Method Validation 
The modified HPLC method for vitamin K analysis in serum samples with 
fluorescence detection after post-column zinc reduction was validated according to 
the guidances for Bioanalytical Method Validation 92,93. The fundamental parameters 
to ensure the acceptability in performance are accuracy, precision, selectivity, 
sensitivity, reproducibility and stability. Whenever possible, the same biological 
matrix as that in the intended samples should be used for validation purposes. 
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Measurements for each analyte in the biological matrix should be validated. In 
addition, the stability of the analyte in spiked samples should be determined. 
 
2.5.1. Selectivity 
Selectivity is the ability of an analytical method to measure unequivocally and 
differentiate and quantify the analyte in the presence of other components in the 
sample. For selectivity, analyses of blank samples without vitamin K and pool serum 
samples containing only the endogenous vitamin K basal concentration were 
conducted.  
 
2.5.2. Range of determination; Limit of detection (LOD); Limit of 
quantification (LOQ) 
The concentration range over which the analyte will be determined must be defined 
in the bioanalytical method, based on the evaluation of actual standard samples over 
the range, including their statistical variation (range of determination). This range of 
concentration should be reliably and reproducibly quantifiable with acceptable 
accuracy and precision through the use of a concentration response relationship. The 
limit of detection (LOD, the detection limit or lower limit of detection) is the lowest 
quantity at which a substance can be distinguished from the absence of that 
substance (a blank value) within a stated confidence limit. The limit of 
quantification (LOQ) is the analyte amount in a sample that can be quantitatively 
determined with suitable precision and accuracy. 
 
2.5.3. Calibration/ standard curve 
A calibration curve should be generated for each analyte in the sample. A sufficient 
number of standards should be used to adequately define the relationship between 
concentration and response. The number of standards used in constructing a 
calibration curve will be a function of the anticipated range of analytical values and 
the nature of the analyte/ response relationship. Concentrations of standards should 
be chosen on the basis of the concentration range expected in a particular study. A 
calibration curve should consist of a blank sample (matrix sample processed without 
63 
 
internal standard), a zero sample (matrix sample processed with internal standard), 
and six to eight non-zero samples covering the expected range, including LLOQ. 
2.5.3.1. Lower limit of quantification (LLOQ) 
The lowest standard on the calibration curve should be accepted as the limit of 
quantification if the following conditions are met: 
- The analyte response at the LLOQ should be at least 5 times the response 
compared to blank response. 
- Analyte peak (response) should be identifiable, discrete and reproducible with 
a precision of 20 % and accuracy of 80-120 %. 
2.5.3.2. Concentration-response 
The simplest model that adequately describes the concentration-response 
relationship should be used. The following conditions should be met in developing a 
calibration curve: 
- 20  % deviation of the LLOQ from nominal concentration 
- 15 % deviation of standards other than LLOQ from nominal concentration 
At least four out of six non-zero standards should meet the above criteria, including 
the LLOQ and the calibration standard at the highest concentration. Excluding the 
standards should not change the model used. 
 
2.5.4. Accuracy, precision 
The accuracy of an analytical method describes the closeness of mean test results 
obtained by the method to the true value (concentration) of the analyte. Accuracy is 
determined by replicate analysis of samples containing known amounts of the 
analyte and should be measured using a minimum of five determinations per 
concentration. A minimum of three concentrations in the range of expected 
concentrations is recommended. The mean value should be within 15 % of the actual 
value except at LLOQ, where it should not deviate by more than 20 %. The deviation 
of the mean from the true value serves as the measure of accuracy. 
The precision of an analytical method describes the closeness of individual 
measures of an analyte when the procedure is applied repeatedly to multiple aliquots 
of a single homogeneous volume of biological matrix. Precision should be measured 
using a minimum of five determinations per concentration. A minimum of three 
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concentrations in the range of expected concentrations is recommended.  The 
precision determined at each concentration level should not exceed 15 % of the 
coefficient of variation (CV) except for the LLOQ, where it should not exceed 20 % of 
the CV.  
 
2.5.5. Recovery 
The recovery of an analyte in an assay is the detector response obtained from an 
amount of the analyte added to and extracted from the biological matrix, compared to 
the detector response obtained for the true concentration of the pure authentic 
standard. Recovery pertains to the extraction efficiency of an analytical method within 
the limits of variability. Recovery of the analyte need not be 100 %, but the extent of 
recovery of an analyte and of the internal standard should be consistent, precise, and 
reproducible. Recovery experiments should be performed by comparing the 
analytical results for extracted samples at three concentrations (low, medium, and 
high) with unextracted standards that represent 100 % recovery. 
 
2.5.6. Quality Assurance 
Quality assurance or quality control is warranted by using a sample, most 
commonly used a spiked sample, to monitor the performance of a bioanalytical 
method and to assess the integrity and validity of the results of the unknown samples 
analyzed in an individual batch. 
 
2.5.7. Stability 
Substance stability in a biological fluid is a function of the storage conditions, the 
chemical properties of the substance, the matrix and the container system. The 
stability of an analyte in a particular matrix and container system is relevant only to 
that matrix and container system. Stability procedures should evaluate the stability of 
the analytes during sample collection and handling, after long-term (frozen at the 
intended storage temperature) and short-term (bench top, room temperature) storage 
and after going through freeze and thaw cycles and the analytical process. 
Conditions used in stability experiments should reflect situations likely to be 
encountered during actual sample handling and analysis. The procedure should also 
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include an evaluation of analyte stability in stock solution. All stability determinations 
should use a set of samples prepared from a freshly made stock solution of the 
analyte in the appropriate analyte-free, interference-free matrix. Stock solutions of 
the analyte for stability evaluation should be prepared in an appropriate solvent at 
known concentrations. 
2.5.7.1. Freeze and thaw stability 
Analyte stability should be determined after three freeze and thaw cycles. At least 
three aliquots at each of the low and high concentrations should be stored at the 
intended storage temperature for 24 h and thawed at room temperature. When 
completely thawed, the samples should be refrozen for 12 to 24 h under the same 
conditions. The freeze-thaw cycle should be repeated two more times, then analyzed 
on the third cycle. If an analyte is unstable at the intended temperature, the stability 
sample should be frozen at -70 °C during the three freeze and thaw cycles. 
2.5.7.2. Short-term stability 
Three aliquots of each of the low and high concentrations should be thawed at room 
temperature and kept at this temperature from 4 to 24 h (based on the expected 
duration that samples will be maintained at room temperature in the intended study) 
and analyzed. 
2.5.7.3. Long-term stability 
The storage time in a long-term stability evaluation should exceed the time between 
the date of first sample collection and the date of last sample analysis. Long-term 
stability should be determined by storing at least three aliquots of each of the low and 
high concentrations under the same conditions as the study samples. The volume of 
samples should be sufficient for analysis on three separate occasions. The 
concentrations of all the stability samples should be compared by means of back-
calculated values to the standards at the appropriate concentrations from the first day 
of long-term stability testing. 
2.5.7.4. Stock solution stability 
The stability of the relevant stock solutions should be evaluated at room temperature 
for at least 6 h. Whether the stock solutions are refrigerated or frozen for a relevant 
period, the stability should be documented. After completion of the desired storage 
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time, the stability should be tested by comparing the instrument response with that of 
freshly prepared solutions. 
2.5.7.5. Post-preparative stability 
The stability of processed samples including the resident time in the autosampler 
should be determined. The stability of the substance of interest and the internal 
standard should be assessed over the anticipated run time for the batch size in 
validation samples by determining concentrations on the basis of original calibration 
standards. 
 
2.6. Vitamin K in mouse tissue 
Organ phylloquinone and MK4 and the respective epoxides were quantified using 
vitamin K determination assay. Briefly, organs were dried in vaccum dryer for 24 h. 
After visual controlling if the drying process was satisfactory, organs were weighed. 
The organs were transferred to disposable glass tubes (16 x 100 mm) and 
chloroform-methanol mixture (2:1 v/v) was added to gain an end concentration of 5 
mg/ mL. After storing the tubes at 4 °C for 24 h, 100 to 500 µL of the mixture was 
transferred to new glass tubes and internal standard K1(25) was added (1 to 5 ng per 
absolute injection). The mixture was evaporated to dryness under stream of nitrogen 
at 50 °C and redissolved in 2 mL ethanol 100 % and 1 mL dH2O. The components of 
interest were extracted twice with 4 mL of n-hexane. The organic phase was pooled 
and evaporated to dryness followed by isolation of the vitamin K fraction from lipid 
extracts using Sep-Pak silica cartridges as described in 3.4.1.3. The vitamin K 
compounds were quantified by fluorometric detection upon HPLC separation on RP-
18 column and post-column zinc reduction under the same conditions as noted 
above (3.4.). 
 
2.7. “Influence of VKORC1 promoter polymorphism c.-1639 G>A 
on the vitamin K1 pharmacokinetics”- phase I clinical study 
This chapter outlines briefly the main components of developing and preparing of a 
phase I clinical study that regards the “Influence of VKORC1 promoter 
polymorphism c.-1639 G>A on the vitamin K1 pharmacokinetics”. 
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The study protocol and trial design were worked out according to the current 
requirements of EMEA (European Medicines Agency) 94 to enable getting the 
required permissions from the different authorities. The EudraCT number (2008-
003643-36) of the proposed clinical investigation was issued from EMEA. The 
responsible local ethic committee of the Medical Faculty of the Friedrich-Wilhelm 
University Bonn gave its affirmative assessment. Moreover, the clinical trial was 
approved by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für 
Arzneimittel und Medizinprodukte, BfArM), the Regulatory Agency for medicines in 
Germany. Each volunteer participating in this study was informed by the clinical 
investigator on the modality and the possible risks of the trial and gave written 
consent. Prior to and after the trial, volunteers underwent safety clinical and 
laboratory screening. Excluded from the study were: women of child bearing potential 
without reliable contraception, pregnant or lactating women, persons with any 
disease likely to disturb the vitamin K metabolism such as bleeding or 
thromboembolic history (acute or persistent) or dysfunctions of intestinal lipid 
absorption (Morbus Crohn, cholestatic liver diseases). 
 
2.7.1. Study period and subject definition 
The intended study period covered 18 days per test person. Furthermore, 18 months 
were scheduled for planning, trial design, analysis of the samples and 
pharmacokinetic and statistical evaluation. 
Thirty subjects of Caucasian race, aged 22-46 years, participated in this study. 
Fifteen were males (28 ± 6 years, BMI 24 ± 2 kg/ m2) and 15 were females (29 ± 7 
years, BMI 21 ± 2 kg/ m2). Thereof, 5 females and 5 males belong to each genotype 
specific group of interest regarding VKORC1 promoter polymorphism c.-1639 G>A 62. 
Confirmatory genotyping was performed to ensure that the study subjects are equally 
distributed in the three genotype groups of interest regarding VKORC1:c.-1639 G>A 
promoter polymorphism: group GG (carriers of GG wild-type genotype), group AG 
(heterozygous individuals), group AA (homozygous AA carriers). Furthermore, 
confirmatory genotyping was performed retrospectively with regard to SNPs in the 
CYP4F2 (V433M polymorphism; haplotype CYP4F2*3 67) and ABCC6 (promoter 
polymorphism c.-127 C>T 68,69,95) genes involved in vitamin K metabolism. All 
subjects were healthy according to medical history, physical examination and 
standard laboratory procedures.  
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2.7.2. Trial design 
The clinical study is classified as a phase I trial by reason of testing the 
pharmacokinetics of a drug in human subjects. Furthermore, it is considered as open 
(each test person obtains the same drug in the same application-way), “single center” 
(conducted in one trial centre - the Institute of Experimental Haematology and 
Transfusion Medicine) and genotype specific (exact genotype specificity of the 
subjects is required).  
 
2.7.3. Investigational product 
Vitamin K1 acts as an investigational product in its synthesized form 
phytomenadione. 
KONAKION is the trade name of the medicine and contains phytomenadione as the 
active ingredient. Phytomenadione is a clear, yellow, very viscous, odourless oil. 
Konakion® MM 2 mg is available in ampoules as an oral liquid. The ampoule contains 
the active ingredient phytomenadione 2 mg/ 200 µL in a mixed micelles (MM) 
solution (the micelles are composed of glycocholic acid and lecithin in an aqueous 
solution). The MM ampoule also contains sodium hydroxide, hydrochloric acid and 
water for injection 96. Konakion® MM 2 mg is approved for prophylaxis and therapy of 
vitamin K deficiency bleeding in newborns. In this clinical trial vitamin K 
pharmacokinetics are investigated in healthy volunteers. 
 
2.7.4. Indication 
The indication for the accomplishment of the clinical investigation is to examine a 
possible effect of the VKORC1 promoter polymorphism c.-1639 G>A on the 
metabolism of vitamin K1 and its pharmacokinetics in humans. 
 
2.7.5. Trial procedure 
The trial procedure started with a single oral intake of 2 mg Konakion® MM followed 
by a wash-out period of seven days and continued with a single intravenous 
administration of the same dosage. The i.v. injection was carried out into a vein of 
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one forearm, opposite to the one from which blood samples were taken. Systemic 
and local tolerance of the test medication were carefully checked by the clinical 
investigator. Blood samples (à 7.5 mL) were collected into serum gel tubes to 24 h 
upon p.o. and i.v. vitamin K1 administration: at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 
7, 7.5, 8, 9, 10, 24 h after p.o. intake (Flow chart I), and at 2, 5, 10, 20, 30, 40, 50 min 
and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, 24 h after i.v. injection (Flow 
chart II). During the first ten hours blood was collected through a peripherous vein 
catheter. Serum was separated immediately by centrifugation at 2250 g for 10 min at 
18 °C and stored protected from light at -20 °C prior to analysis.  
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Flow charts – blood withdrawals after Konakion® MM 2 mg 
administration 
 
Flow chart I:   p.o. (oral administration) 
 
Blood withdrawal à 7.5 ml (serum tube) 
 
   
Date Time 
Set                     Actual 
Point Comments 
 
Day  -7  
   
Safety laboratory 
 
1 serum, 1 EDTA and 1 
citrate tube 
 
Day  1  
7.45  - 15 min  
8.00   0 min p.o. administration of 
Konakion
®
 MM 2 mg 
9.00  1 h  
10.00  2 h  
10.30  2 h 30 min  
11.00  3 h  
11.30  3 h 30 min  
12.00  4 h  
12.30  4 h 30 min  
13.00  5 h  
13.30  5 h 30 min  
14.00  6 h  
14.30  6 h 30 min  
15.00  7 h  
15.30  7 h 30 min  
16.00  8 h  
17.00  9 h  
18.00  10 h  
 
Day  2  
 
8.00 
  
24 h 
 
24 h value 
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Flow chart II:   i.v. (intravenous administration) 
 
Blood withdrawal à 7.5 ml (serum tube) 
 
   
Date Time 
Set                     Actual 
Point Comments 
 
Day  8 
  
7.45  - 15 min  
8.00  0 min i.v. administration of 
Konakion
® 
MM 2 mg 
8.02  2 min  
8.05  5 min  
8.10  10 min  
8.20  20 min  
8.30  30 min  
8.40  40 min  
8.50  50 min  
9.00  1 h  
9.20  1 h 20 min  
9.40  1 h 40 min  
10.00  2 h  
10.20  2 h 20 min  
10.40  2 h 40 min  
11.00  3 h  
11.30  3 h 30 min  
12.00  4 h  
12.30  4 h 30 min  
13.00  5 h  
13.30  5 h 30 min  
14.00  6 h  
15.00  7 h  
16.00  8 h  
17.00  9 h  
18.00  10 h  
 
Day  10            
 
8.00 
  
24 h 
 
24 h value 
    
Safety laboratory 
 
1 serum and 1 citrate tube 
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2.7.6. Trial schedule 
Visit Day  
I -7 Screening; Safety laboratory; Medical checkup  
 0 VKORC1 specific genotype assignment  
II 1 Investigation Part I → blood collection after oral 
administration of KonakionMM 2 mg  
III 2 Controlling; Adverse events  
 3-9 Wash-out period  
IV 10 Investigation Part II → blood collection after intravenous 
administration of KonakionMM 2 mg  
V 11 Controlling; Adverse events; Medical checkup 
 
The clinical trial was completed when 30 patients (assigned to the genotype specific 
groups) finished all visits (18 days per test person). 
Due to the fact that this trial was an explorative clinical trial with healthy volunteers 
and no patients were included, there was no treatment planned after the end of the 
clinical trial. The family doctor was informed about pathological blood values. 
 
2.7.7. Primary aim, primary endpoint 
The primary aim consisted in exploring the vitamin K1 pharmacokinetics depending 
on VKORC1 genotype, the so-called phenotype-genotype relationship. In this regard, 
the phenotype refers to physiological processes such as absorption, distribution, 
metabolism, elimination of the drug of interest. 
Serum concentration of vitamin K1 was considered as a primary endpoint as well 
as the evaluation of some pharmacokinetic parameters including Area under the 
curve (AUC), half-life time (t1/2), maximal serum concentration (Cmax), time of the 
maximal serum concentration (Tmax), bioequivalence (F), clearance (CL), distribution 
volume (Vd). 
 
2.7.8. Secondary aims 
Following secondary aims were defined: 
- serum concentration of vitamin K2 (MK4), vitamin K1 and K2 epoxide 
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- dimension of the phenotype variability 
- serum level of precursors and metabolites of cholesterol and bile acid 
metabolism 
 
2.7.9. Inclusion and exclusion criteria, criteria for stopping trial 
Certain requirements had to be fulfilled in order to participate in clinical trials. Defined 
inclusion and exclusion criteria should be met to enable enrolling of test persons. 
2.7.9.1. Inclusion criteria 
- Healthy volunteers, male and female 
- Age: 18 to 60 years 
- Full written Informed Consent to participating 
- VKORC1 genotype specific assignment (group A, B or C) 
- No blood clotting disorder 
- Normal values of safety laboratory parameters: 
Quick   70-130 %    
INR   0.9-1.1    
PTT    22-36 s    
 ALAT   <34 U/ L       
ASAT   <31 U /L 
γ-GT    <38 U/ L 
AP    34-131 U/ L 
LDL-C   <150 mg/ dL  
 HDL-C   m 27-65 mg/ dL 
    f 33-77 mg/ dL  
 Triglycerides  <200 mg/ dL  
 Creatinine  0.5-1.4 mg/ dL  
2.7.9.2. Exclusion criteria 
- Participation in another clinical trial 
- Bleeding or thromboembolic history (acute or persistent) 
- Dysfunctions of intestinal lipid resorption (M.Crohn, cholestatic liver diseases) 
- Pregnancy or lactation 
- Intake of following medication 10 days before starting the trial: 
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Acetylsalicylic acid and other salicylates  
Anticoagulants  
Cephalosporines  
Sulfonamides 
Anticonvulsants (Phenobarbital, Diphenylhydantoin) 
Antituberculotic drugs (Isoniazid, Rifampicin) 
Lipid lowering drugs 
2.7.9.3. Criteria for stopping trial 
- Proband absence 
- Insufficient compliance 
- Acute hazard of the test person during the trial (investigator´s decision) 
- Withdrawal of consent (proband´s decision) 
 
2.8. First approaches in human volunteers 
Some preliminary experiments to the phase I clinical study served as first relevant 
application of the vitamin K serum determination assay. Four human volunteers were 
investigated as described in section 3.4. With two of them the experiment was 
repeated a year later to gain insight into possible intra-individual differences in 
vitamin K1 pharmacokinetics. Collected blood samples were used for vitamin K 
determination from serum directly after the experiment was performed and a year 
later. In this way, possible differences in vitamin K serum level depending on the 
storage time were distinguished. 
 
2.9. Statistical and pharmacokinetic analysis 
Linear regression, mean, median, standard deviation (S.D.), standard error of the 
mean (S.E.M.) etc. were calculated by using Microsoft Excel and SPSS. Statistical 
evaluation was performed using SPSS (IBM SPSS Statistics 19.0). Various 
univariate analyses of variance (uANOVA) were performed which generally included 
gender as a factor and Tukey post-hoc testing.  
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The precision of the assay was defined as the coefficient of variation (CV) of at least 
six repeats. The limit of detection (LOD) and limit of quantification (LOQ) was based 
on signal-to-noise ratio. A signal-to-noise ratio of 3:1 was considered acceptable for 
estimating the LOD wheares the LOQ was based on signal-to-noise ratio of at least 
10:1. 
Pharmacokinetic evaluation was carried out on the basis of the data from the 
experiments on vitamin K1 pharmacokinetics using WinNonlin (version 5.2.1, 
Pharsight Corp.) as a standard program. Non-compartmental analysis of the serum 
concentration vs time profiles after oral and intravenous administration of 2 mg 
Konakion® MM was done for all volunteers and all experiments. Serum 
concentration-time data of vitamin K1 was considered as the primary variable as well 
as the evaluation of pharmacokinetic parameters including maximum serum 
concentration (Cmax), time of the maximum serum concentration (tmax), area under the 
curve (AUC), bioavailabilty (Fp.o.), clearance (CL), volume of distribution at steady 
state (Vss), terminal half-life (t1/2). Some of the main pharmacokinetic parameters 
could be directly taken from the data such as Cmax and tmax. The area under the 
plasma concentration vs time curve from time zero extrapolated to infinity was 
calculated by:  
AUC = AUC0-t + Clast / λz 
AUC0-t is the area under the plasma concentration versus time curve from time zero 
to the last sampling time at which the plasma concentration is at, or above, the limit 
of quantification (LOQ). The calculation was performed by using the lin-log 
trapezoidal method. Clast is the observed plasma concentration at the last sampling 
time at which plasma concentrations are at, or above, the LOQ.  
The terminal (first-order) elimination rate constant (λz) was calculated from the slope 
of the terminal linear portion of the log concentration vs time curve by linear 
regression analysis.  
The volume of distribution at steady-state was calculated as: 
Vss =  MRT x CL 
where MRT is the mean residence time calculated by AUMCi.v./ AUCi.v., and AUMCi.v. 
is the area under the first moment curve from zero extrapolated to infinity following 
intravenous administration. AUMC was calculated as:  
AUMC = AUMC0-t + Clast x tlast / λz + Clast / λz
2. 
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The absolute bioavailability upon oral administration of Konakion® MM was calculated 
as: 
Fp.o. = AUCp.o./ AUCi.v. x Dosei.v./ Dosep.o. x 100 %  
The systemic clearance was calculated according to the equation: 
CL = Dose i.v./ AUCi.v. 
The terminal half-lives (t1/2) were calculated using the terminal elimination rate 
constant as: 
t1/2 = 0.693/ λz. 
The plasma concentration values were corrected for endogenous vitamin K levels in 
each subject by subtraction of individual pre-dose value from all post-dose values. 
The plasma concentration was set to zero on some instances were such correction 
resulted in small negative values. 
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3. RESULTS 
 
3.1. Enzymological characterization of the VKORC1 
3.1.1. Separation and quantification of K vitamins 
Separation of the substances of interest was performed by reversed-phase 
chromatography. Phylloquinone (K1), menaquinone-4 (MK4) and their epoxides were 
quantified via HPLC with DAD detection according to their specific chromatographic 
features and the resultant retention times (RT). 
Figure 5 represents an authentic chromatogram of the vitamin K1 kinetics. MK4 
epoxide (RT 3.3 min) was used as an extraction standard. K1 epoxide (RT 4.7 min) 
served as a substrate for the VKORC1 which catalyzed its conversion to the product 
K1 quinone (RT 6.6 min). 

                     
 
Figure 5 Chromatogram of vitamin K1 kinetics 
 
Figure 6 shows an authentic chromatogram of the vitamin K2 (MK4) kinetics. K1 
epoxide (RT 4.7 min) was used as an extraction standard. MK4 epoxide (RT 3.3 min) 
acts as a substrate for the VKORC1 which catalyzed its conversion to the product 
MK4 quinone (RT 4.2 min). 
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Figure 6 Chromatogram of MK4 kinetics 
 
3.1.2. VKORC1 enzyme kinetics: determination of kinetic constants 
To gain an insight into the enzymatic characteristics of VKORC1, a number of in vitro 
experiments (described in 3.3.7.) were performed. These reproduced the step of 
quinone formation by the VKORC1 using the corresponding epoxide as substrate. 
 
3.1.2.1. Michaelis-Menten curves 
The Michaelis-Menten curves represent saturation curves for the VKORC1 displaying 
the relation between substrate concentration and the rate of product formation. The 
concentration of vitamin K epoxide as substrate was in the range between 0.5 and 
125 µM. Figures 7-10 show that VKORC1 velocity followed the Michaelis-Menten 
equation and display Michaelis-Menten curves of the enzyme reaction when 
incubated for different time intervals 5, 10, 30 or 60 min, respectively. Each figure 
shows the typical curves for both vitamin K1 and K2 kinetics of the VKORC1. 
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Fig.7  VKORC1 kinetics: 5 min incubation time              Fig.8  VKORC1 kinetics: 10 min incubation time 
     
Fig.9  VKORC1 kinetics: 30 min incubation time             Fig.10  VKORC1 kinetics: 60 min incubation time 
 
The same course of the curves was found for each incubation time. The quinone 
formation rate was lowest at 5 min and highest at 60 min incubation for both vitamin 
K1 and K2. Furthermore, the generation of K2 quinone was faster than the formation 
of K1 quinone. This difference is most obvious for incubation time of 30 and 60 min. 
Vitamin K1 time kinetics for each incubation time of 5, 10, 30 and 60 min is presented 
separately in figure 11. The appropriate vitamin K2 time kinetic curves are given in 
figure 12. Indeed, the formation of vitamin K2 quinone occurred significantly faster at 
30 and 60 min comparing to the generation of vitamin K1 quinone. 
   
Figure 11  K1 time kinetics            Figure 12   K2 time kinetics 
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3.1.2.2. Lineweaver-Burk graphs 
Lineweaver-Burk plot as a common model of illustrating kinetic data was used to 
calculate the apparent kinetic constants Km and Vmax. 
Figure 13 shows the Lineweaver-Burk graphs for vitamin K1 and vitamin K2 for 
incubation time of 60 min produced by taking the reciprocal of both sides of the 
Michaelis-Menten equation and transforming the curve data into straight lines. 
       
 
Figure 13 Lineweaver-Burk Graph 
 
3.1.2.3. Km and Vmax determination 
Based on the Lineweaver-Burk graphs for K1 and K2, the following Km and Vmax 
values were obtained shown in figure 14 and figure 15, respectively. 
 
       
     Figure 14   Km values           Figure 15   Vmax values 
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Differences were observed comparing Km and Vmax values for both substrates, K1 
and K2. 60 min Km values of 2.34 and 1.56 µM were calculated for K1 and K2, 
respectively. The Km for K1 was 1.5-fold higher than for K2. Therefore, the binding 
affinity of vitamin K2 epoxide to VKORC1 appears to be higher while vitamin K1 
epoxide seems to bind in a weaker manner to the enzyme. 
Differences were also identified when comparing the Vmax values 1.20 nmol mg
-1 h-1 
for K1 and 1.69 nmol mg-1 h-1 for at the incubation time of 60 min. The 1.4 fold higher 
Vmax value for K2 indicates faster generation of the K2 quinone by VKORC1 
compared with the formation of vitamin K1. 
 
3.1.2.4. Quinone generation during K1O and K2O substrate 
competition 
In addition, differences in quinone generation were also observed when K1 and K2 
epoxide was added as substrate in a varying ratio to the reaction. Single and 
concurrent K1 and K2 quinone production rate was distinguished. Starting with 100 
% K1 epoxide, K2 epoxide was added in the different trials to K1 epoxide at 
increasing ratios up to 100 % K2 epoxide as substrate. 
Using single epoxide as substrate, the VKORC1 showed a 1.5-fold higher preference 
for the reduction of K2 epoxide to the corresponding quinone compared to K1. The 
K2 quinone formation rate was found to be continuously 2.5 to 3.7-fold higher when 
K1 and K2 epoxides were added as substrate in various ratios to explore the 
competititve conversion to the corresponding epoxides by VKORC1. Figures 16 and 
17 below show the results for quinone production rate during substrate competititon 
(K1 and K2 epoxide). The quinone generation is expressed as percent of vitamin K 
epoxide converted into the appropriate quinone (Fig.16) and as µM quionone 
(Fig.17). 
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   Figure 16    % Quinone generation          Figure 17   µM Quinone generation 
 
When K1 and K2 epoxide were added as substrate in the ratio 1:1, simultaneously 12 
% of K1 epoxide and 40 % of K2 epoxide was converted into quinone. The 
corresponding absolute values were 0.5 µM K1 and 1.5 µM K2. These results 
support what the VKORC1 kinetic constants indicate: higher binding affinity of 
VKORC1 to K2 epoxide and faster production of K2, as well as confirming the 
VKORC1 ability to reduce K2 epoxide significantly more efficiently than K1 epoxide in 
vitro. 
 
3.2. Validation of the quantitative analysis of vitamin K1 
(phylloquinone) and vitamin K2 (menaquinone-4) in human 
serum by HPLC with fluorescence detection after solid-phase 
extraction 
The modified HPLC method for vitamin K determination in human serum or plasma 
was validated according to the guidances for Bioanalytical Method Validation of the 
International Conference of Harmonization. Main parameters were proved to ensure 
the acceptability of the performance of the method. 
 
3.2.1. Specificity, selectivity 
Selectivity and specificity express the ability of an analytical method to differentiate 
and quantify unequivocally the analyte in presence of other components in the 
biological sample. For instance, the retention time under particular conditions is 
considered to be reasonably unique to identify a given analyte.  
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Figure 18 shows an exemplary authentic chromatogram of the separation of vitamin 
K compounds MK4 (RT 2.6 min) and phylloquinone (RT 4.9 min) from the 
appropriate internal standard K1(25) (RT 10.5 min). 
 
 
 
 
Figure 18 HPLC chromatogram of K1, MK4, and K1(25) 
         (ISTD = Internal Standard) 
 
 
The authenticity of K vitamins was proved by GC-MS by using scan mode. Figure 19, 
20, 21, 22 and 23 present the characteristic spectra specific for K1, MK4, K1O, 
MK4O and K1(25) respectively. 
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Figure 19 Mass spectrum of phylloquinone (vitamin K1) 
 
 
 
 
 
 
 
Figure 20 Mass spectrum of vitamin K1 epoxide   
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Figure 21 Mass spectrum of menaquinone-4 (MK4; vitamin K2) 
 
 
 
 
 
 
Figure 22 Mass spectrum of menaquinone-4 epoxide (MK4O) 
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Figure 23 Mass spectrum of vitamin K1(25) – ISTD = Internal Standard 
(2-Methyl-3-(3,7,11,15,19-pentamethyl-2-eicosenyl)-1,4-naphtalenedione) 
 
Specificity 
The specificity of the method for the substances of interest, vitamin K1 
(phylloquinone) and vitamin K2 (menaquionone-4), was proved by testing several 
human serum samples from different healthy subjects for the absence of interfering 
compounds. 
The retention times of the substances under the conditions of the assay are given in  
Table 4. 
 
Table 4 Retention times of K vitamins 
No. Substance Category Retention Time  
[min] 
HPLC column* 
1 MK4 Vitamin K2; Menaquinone-4 2.6 BDS Hypersil C18 
2 K1 Vitamin K1; Phylloquinone 4.9 BDS Hypersil C18 
3 K1(25) Internal Standard 10.5 BDS Hypersil C18 
1 MK4O Vitamin K2 Epoxide 3.1 Nucleodur C18 
2 MK4 Vitamin K2 4.3 Nucleodur C18 
3 K1O Vitamin K1 Epoxide 5.3 Nucleodur C18 
4 K1 Vitamin K1 8.9 Nucleodur C18 
5 K1(25) Internal Standard 21.6 Nucleodur C18 
*  described in detail in 3.1.2.3. 
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Two concentration ranges were used for quantification during validation analyses: 
Concentration range I  → 0.0625 – 2 ng per absolute injection 
(calibration points 1-6, described in 3.4.1.5.) 
Concentration range II  → 1 – 20 ng per absolute injection 
(calibration points 5-10, described in 3.4.1.5.) 
Samples containing vitamin K concentration higher than 20 ng per absolute injection 
were further diluted to gain substance concentration in the range described above.  
 
Selectivity 
To prove the selectivity of the modified method for vitamin K determination, 
analyses of blank samples without vitamin K and of pool serum samples containing 
only the endogenous vitamin K basal concentration were conducted (n= 6). 
Concentration range I was used for precise quantification of low vitamin K 
concentrations. The peak areas of vitamin K1 and MK4 in spiked serum differed 
clearly and precisely from the peak areas of the lowest calibration point at the same 
retention times and were at least 5-fold greater than those of the blank values in pure 
isopropanol samples. 
 
3.2.2. Range of determination 
The limit of detection (LOD, the detection limit or lower limit of detection) as well as 
the limit of quantification (LOQ) could be determined. 
3.2.2.1. Limit of detection (LOD) 
The detection limit was based on signal-to-noise ratio. Determination of the signal-to-
noise ratio was performed by comparing measured signals (abundance) from 
samples with the lowest concentration of an analyte with the abundance of the 
baseline surrounding of vitamin K peak. A signal-to-noise ratio of 3:1 was considered 
acceptable for estimating the detection limit according to the following guidelines. 
 
detection limit = [ (3 x ∆baseline) / ∆analyte ] x c analyte 
 
∆baseline = difference in the abundance for the baseline 
∆analyt  = difference in the abundance for the analyte 
c analyte = absolute concentration of the analyte 
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The LOD that could be distinguished from the absence of the substances was 0.006 
ng K1 and MK4 per absolute injection. An exemplary chromatogram for the LOD 
estimation of phylloquinone is shown in Fig.24. 
 
 
Figure 24 LOD of K1, signal-to-noise ratio 3:1 
3.2.2.2. Limit of quantification (LOQ), lower limit of quantification 
(LLOQ) 
The LOQ averaged 0.0625 ng K1 and MK4 per absolute injection (10-fold higher than 
LOD). The LOQ was based on signal-to-noise ratio of at least 10:1 as shown in 
Fig.25 for phylloquinone where signal-to-noise ratio of 12:1 was accepted. 
 
Figure 25 LOQ of K1, signal-to-noise ratio 12:1 
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Lower limit of quantification (LLOQ) also met the required conditions since the 
analyte response at the LLOQ was at least 5 times the response compared to blank 
response and the analyte peak was identifiable, discrete and reproducible with  20% 
precision and 80-120% accuracy. 
The lowest standard on the calibration curve equal to 0.0625 ng K1 and MK4 per 
absolute injection was accepted as the LLOQ.  
Concentration range I was used for precise quantification of vitamin K concentration. 
The signals of blank isopropanol samples were compared to the signals of calibration 
point 1 and 2 containing 0.0625 and 0.125 ng K1 and MK4 per absolute injection, 
respectively, and the amount of vitamin K was evaluated. Additionally, a solution of 
0.1 ng/ absolute injection of both substances (solution LQ) was analyzed 
quantitatively in the same way. The analysis of K1 and MK4 of all three solutions was 
carried out both with and without solid-phase extraction in order to get insight into 
possible substance during the extraction procedure. 
Beside serum pool without any supplemental K1 or MK4 (QM1 with basal serum 
concentration of K1 and without any detectable MK4), pool samples enriched by 0.1 
ng K1 and MK4 per absolute injection (QM2 containing basal serum concentration of 
K1 plus 0.1 ng/ absolute injection and MK4 of 0.1 ng/ absolute injection) were 
analyzed. Table 5 lists relevant parameters of the quantitative K1 and MK4 analysis 
regarding LOQ. 
 
 Table 5 Limit of quantification of the method for MK4 and K1 
Sample Solide-
phase 
extraction 
Nominal 
value 
[ng/ abs.inj.] 
Actual value 
Mean 
[ng/ abs.inj.] 
Standard 
deviation 
SD 
Variation 
coefficient 
CV % 
Recovery 
% 
  MK4 K1 MK4 K1 MK4 K1 MK4 K1 MK4 K1 
Isopropanol + 0 0 n.d. n.d.       
Cal.point 1 + 0.0625 0.0625 0.0611 0.0602 0.014 0.009 22.5 14.4 97.7 96.2 
Cal.point 2 + 0.125 0.125 0.133 0.121 0.036 0.008 27.3 6.4 106.4 96.9 
Solution LQ + 0.100 0.100 0.096 0.115 0.010 0.001 10.7 0.7 96.2 114.9 
Isopropanol - 0 0 n.d. n.d.       
Cal.point 1 - 0.0625 0.0625 0.0716 0.0720 0.002 0.004 3.3 5.0 114.6 115.2 
Cal.point 2 - 0.125 0.125 0.136 0.128 0.009 0.017 6.4 13.2 108.8 102.3 
Solution LQ - 0.100 0.100 0.098 0.108 0.004 0.003 4.4 3.1 97.5 108.4 
QM1 + n.d * n.d. 0.268  0.004  1.6   
QM2 + 0.100 ** 0.138 0.332 0.003 0.134 1.8 40.4 138.2 112.3 
n= 6 for each sample 
n.d.= non-detectable 
* basal serum concentration 
** basal serum concentration + 0.1 ng/ absolute injection 
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3.2.3. Calibration/ standard curve 
Two concentration ranges of vitamin K1 and MK4 were used for quantification during 
validation analyses: 
Concentration range I  → 0.0625 – 2 ng per absolute injection 
(calibration points 1-6, described in 3.4.1.5.) 
Concentration range II  → 1 – 20 ng per absolute injection 
(calibration points 5-10, described in 3.4.1.5.) 
Samples containing vitamin K concentration higher than 20 ng per absolute injection 
were further diluted to gain substance concentration in the range described above. 
To evaluate linearity of the calibration curves, several calibration curves were 
prepared and analyzed. The curves were judged linear if the correlation coefficient r2 
was > 0.99 as calculated by weighted linear regression. The concentrations of the 
calibration standards were back-calculated in order to confirm the suitability of the 
used calibration model of linear regression. 
In developing a calibration curve, following conditions were met for every 
concentration range: 
- 20 % deviation of the LLOQ from nominal concentration 
- 15 % deviation of standards other than LLOQ from nominal concentration 
- correlation coefficient of the regression line ≥ 0.99 
At least four out of six non-zero standards met the above criteria, including the LLOQ 
and the calibration standard at the highest concentration. 
The standard curves for K1 and MK4 over range I (0.0625-2 ng/ abs.inj.) and range II 
(1-20 ng/ abs.inj.) exhibited good linearity with average correlation coefficient (r2) 
equal to 0.9996 and 0.9965 for MK4 and range I and II, respectively and equal to 
0.9992 and 0.9968 for K1 and range I and II, respectively. The deviation of the 
interpolated concentrations of standards in the daily calibration curves of K1 and 
MK4 were within the acceptable range of 85 - 115 % (80 - 120 % for LLOQ). 
Table 6 and 7 give an overview of the results. 
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Table 6 Concentration range I – calibration/ standard curve 
Calibration 
point 
Cal.curve 
r
2
 
Nominal 
conc. 
Mean 
[ng/ abs.inj.] 
SD CV 
% 
Recovery 
% 
 MK4 r
2
:0.9996 
K1 r
2
:0.9995 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
1 1a-6a 0.0625 0.0625 0.058 0.059 0.001 0.001 0.1 2.4 92.3 94.3 
2 1a-6a 0.125 0.125 0.115 0.123 0.001 0.006 0.6 5.3 91.7 98.4 
3 1a-6a 0.25 0.25 0.240 0.257 0.011 0.011 4.5 4.4 96.0 102.8 
4 1a-6a 0.5 0.5 0.475 0.491 0.012 0.016 2.5 3.2 95.0 98.2 
5 1a-6a 1 1 0.888 0.942 0.009 0.017 1.0 1.8 88.6 94.2 
6 1a-6a 2 2 1.786 1.957 0.056 0.104 3.2 5.3 89.3 97.9 
 MK4 r
2
:0.9996 
K1 r
2
:0.9993 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
1 1b-6b 0.0625 0.0625 0.051 0.051 0.003 0.001 5.8 2.7 82.2 81.8 
2 1b-6b 0.125 0.125 0.108 0.116 0.006 0.015 6.0 12.9 86.5 92.7 
3 1b-6b 0.25 0.25 0.259 0.256 0.011 0.024 4.4 9.4 103.4 102.5 
4 1b-6b 0.5 0.5 0.528 0.512 0.013 0.014 2.4 2.7 105.6 102.5 
5 1b-6b 1 1 1.080 1.055 0.100 0.065 9.2 6.2 108.0 105.5 
6 1b-6b 2 2 2.096 2.008 0.016 0.008 0.1 0.1 104.8 100.4 
 MK4 r
2
:0.9997 
K1 r
2
: 0.9988 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
1 1c-6c 0.0625 0.0625 0.060 0.068 0.004 0.003 6.5 4.0 95.8 108.2 
2 1c-6c 0.125 0.125 0.116 0.122 0.007 0.007 6.0 6.1 92.4 97.8 
3 1c-6c 0.25 0.25 0.249 0.248 0.003 0.010 1.0 4.0 99.8 99.2 
4 1c-6c 0.5 0.5 0.526 0.505 0.001 0.003 0.2 0.5 105.2 101.1 
5 1c-6c 1 1 1.039 0.985 0.105 0.077 10.1 7.8 103.9 98.5 
6 1c-6c 2 2 1.974 1.875 0.077 0.001 3.9 0.1 98.7 93.8 
n= 3 for each calibration point 
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Table 7 Concentration range II – calibration/ standard curve 
Calibration 
point 
Cal.curve 
r
2
 
Nominal 
conc. 
Mean 
[ng/ abs.inj.] 
SD CV 
% 
Recovery 
% 
 MK4 r
2
:0.9974 
K1 r
2
:0.9976 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
5 5a-10a 1 1 0.807 0.880 0.004 0.007 0.5 0.8 80.7 88.0 
6 5a-10a 2 2 1.732 1.915 0.088 0.067 5.1 3.5 86.6 95.8 
7 5a-10a 5 5 5.150 5.374 0.108 0.096 2.1 1.8 103.0 107.5 
8 5a-10a 10 10 10.342 10.633 0.098 0.313 1.0 2.9 103.4 106.3 
9 5a-10a 15 15 13.914 14.501 0.278 0.359 2.1 2.5 92.8 96.7 
10 5a-10a 20 20 19.548 20.439 0.422 0.502 2.2 2.5 97.7 102.2 
 MK4 r
2
:0.9957 
K1 r
2
:0.9961 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
5 5b-10b 1 1 0.868 0.844 0.004 0.071 0.4 8.4 86.8 84.8 
6 5b-10b 2 2 1.838 1.888 0.127 0.122 6.9 6.5 91.9 94.4 
7 5b-10b 5 5 5.429 5.394 0.087 0.092 1.6 1.7 108.6 107.9 
8 5b-10b 10 10 10.455 10.387 0.593 0.700 5.7 6.7 104.6 103.9 
9 5b-10b 15 15 14.429 14.415 0.406 0.528 2.8 3.7 96.2 96.1 
10 5b-10b 20 20 20.203 20.295 0.661 0.768 3.3 3.8 101.0 101.5 
 MK4 r
2
:0.9965 
K1 r
2
:0.9968 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
MK4  
K1 
5 5c-10c 1 1 0.816 0.880 0.054 0.010 6.6 1.2 81.6 88.0 
6 5c-10c 2 2 1.735 1.798 0.034 0.053 2.0 3.0 86.7 89.9 
7 5c-10c 5 5 5.212 5.166 0.025 0.003 0.5 0.1 104.2 103.3 
8 5c-10c 10 10 10.105 9.928 0.477 0.497 4.7 5.0 101.0 99.3 
9 5c-10c 15 15 13.833 13.694 0.104 0.153 0.8 1.1 92.2 91.3 
10 5c-10c 20 20 19.351 19.283 0.216 0.256 1.1 1.3 96.8 96.4 
n= 3 for each calibration point 
* basal serum concentration 
** basal serum concentration + 0.1 ng/ absolute injection 
 
 
3.2.4. Accuracy – robin round tests, KEQAS participation 
The accuracy describes the closeness of mean test results obtained by the method 
to the true value (concentration) of the analyte. To assess the accuracy of the 
method by examining vitamin K presented in human serum at basal level, our lab 
participated in the vitamin K quality assurance scheme (KEQAS), the so-called robin-
round tests. The performance of such tests aims to assist in the development and 
harmonisation of vitamin K analysis in order to improve the comparability of clinical 
and nutritional studies 97 as well as to improve the quality of vitamin K analysis. 
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Aliquots from a serum pool including spiked samples (vitamin K spiked within an 
endogenous range) as well as vitamin K ethanolic standard solutions were distributed 
for multiple replicate analyses within a period of one year by a number of participants 
including our lab (specified as group 44). All samples had to be analyzed according 
to the scheme schedule. 
Three batches per year (batch 43, 44 and 45 in 2010 and batch 46, 47 and 48 in 
2011) were sent out to be measured in February, June and October respectively. 
Thereby each batch contained two plasma samples (serum A and serum B) and one 
ethanolic standard (EtOH std.). The target for results was ±20 % deviation from the 
ALTM (all laboratory trimmed mean representing the target concentration) which was 
based on previous performance and designed to be attainable and yet indicative of 
poor performance according to participants´ manuals. 
A guide to performance was shown using a Z score system where: 
   
     
 
 
Z : Z score 
Xi : Result 
X : Mean result from all labs 
Σ : Target standard deviation 
 
The target standard deviation was 20% from the mean: 
   
          
 
 
Z scores were divided into the following categories: 
Z < 1  Good - GOLD 
1 < Z < 2 Satisfactory - SILVER 
2 < Z < 3 Questionable - BRONZE 
Z > 3  Unsatisfactory - RED 
 
Table 8 and 9 summarized the results achieved from our laboratory from the robin 
round tests in 2010 and 2011, respectively. The international requirements for 
harmonisation and quality assurance of vitamin K analysis were herewith certified 
successfully. 
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Table 8 KEQAS results 2010 
 Serum 
A 
Serum 
B 
EtOH 
std. 
Serum 
A 
Serum 
B 
EtOH 
std. 
Serum 
A 
Serum 
B 
EtOH 
std. 
Batch 43 
K1 [µg/ L] 
Batch 44 
K1 [µg/ L] 
Batch 45 
K1 [µg/ L] 
Result 0.25 2.06 1.41 0.26 0.16 1.69 2.06 0.16 4.06 
ALTM 0.32 2.91 2.16 0.31 0.19 2.49 2.85 0.16 5.38 
Z score 1.1 1.5 1.7 0.7 0.8 1.6 1.4 0.1 1.2 
Category SILVER SILVER SILVER GOLD GOLD SILVER SILVER GOLD SILVER 
Outlier? no no no no no no no no no 
 
Table 9 KEQAS results 2011 
 Serum 
A 
Serum 
B 
EtOH 
std. 
Serum 
A 
Serum 
B 
EtOH 
std. 
Serum 
A 
Serum 
B 
EtOH 
std. 
Batch 46 
K1 [µg/ L] 
Batch 47 
K1 [µg/ L] 
Batch 48 
K1 [µg/ L] 
Result 0.53 0.97 1.40 0.74 3.47 2.07 3.11 - 2.24 
ALTM 0.53 0.86 1.26 0.86 3.92 1.52 3.64 - 2.51 
Z score 0.0 0.6 0.6 0.7 0.6 1.8 0.7 - 0.5 
Category GOLD GOLD GOLD GOLD GOLD SILVER GOLD - GOLD 
Outlier? no no no no no no no  no 
 
 
3.2.5. Precision 
To assess the precision of the method, six replicates per concentration for QMs 
(described in 3.1.3.3.) were analyzed three times on the same day and once a day 
during three days within a week in order to determine the intra- and interday-
reproducibility, respectively. 
The precision of the method at each concentration was calculated as the coefficient 
of variation (CV). A CV of less than 15 % was accepted, except for the LLOQ, where 
it should not be more than 20 % as required in the guidelines (s. 3.5.4.). The 
precision determined at each concentration level did not exceed 15 % of the CV 
except for the LLOQ, where it did not exceed 20 % of the CV.  
The data for the validation of intra- and inter-day accuracy and precision are 
presented in table 10 and 12 for K1 and table 11 and 13 for MK4. The results showed 
CVs within the acceptable range. 
Table 10 Intra-day reproducibility for K1 
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Sample Nominal 
value 
[ng/ inj.] 
Actual value 
Mean 
[ng/ inj.] 
Standard 
deviation 
SD 
Variation 
coefficient 
CV % 
Recovery 
% 
Run  I II  III I II  III I II  III I II  III 
Cal.point 3 0.25 0.27 0.28 0.26 0.01 0.01 0.01 3.9 2.9 2.0 106 107 105 
Cal.point 5 1 0.99 0.92 1.00 0.02 0.01 0.04 2.4 1.5 4.1 99 92 86 
Cal.point 8 10 10.0 10.2 10.8 0.25 1.2 1.31 2.5 11.7 9.5 100 102 108 
QM1 * 0.24 0.14 0.16 0.22 0.01 0.02 9.0 6.6 8.8    
QM3 *** 1.08 1.12 1.09 0.05 0.06 0.06 4.4 5.0 5.8 95 98 95 
QM4 **** 10.2 10.7 10.9 0.56 0.46 1.11 5.5 4.2 7.9 101 106 108 
QM5 ***** 107 105 110 9.01 3.97 5.99 8.4 3.8 5.5 107 105 109 
n= 6 for each sample   
* basal serum concentration 
** basal serum concentration + 0.1 ng/ absolute injection 
*** basal serum concentration + 1 ng / absolute injection 
**** basal serum concentration + 10 ng/ absolute injection 
***** basal serum concentration + 100 ng/ absolute injection 
 
 
 
Table 11 Intra-day reproducibility for MK4 
Sample Nominal 
value 
[ng/ inj.] 
Actual value 
Mean 
[ng/ inj.] 
Standard 
deviation 
SD 
Variation 
coefficient 
CV % 
Recovery 
% 
Run  I II  III I II  III I II  III I II  III 
Cal.point 3 0.25 0.22 0.22 0.21 0.02 0.03 0.02 6.7 7.2 9.4 89 90 105 
Cal.point 5 1 0.90 0.98 0.90 0.06 0.03 0.06 7.1 2.6 6.9 90 98 90 
Cal.point 8 10 9.9 9.6 11.0 0.30 1.11 2.04 3.0 11.6 13.6 99 96 110 
QM1 n.d. n.d. n.d. n.d.          
QM3 1 1.00 0.97 0.98 0.05 0.04 0.06 4.6 3.6 5.9 100 97 98 
QM4 10 11.2 11.4 11.3 0.98 0.53 1.41 8.8 4.6 9.2 112 114 113 
QM5 100 110 110 112 15.9 2.92 6.57 14.4 2.7 5.9 111 110 112 
n= 6 for each sample  n.d.= non-detectable 
 
 
 
 
 
 
 
 
Table 12 Inter-day reproducibility for K1  
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Sample Nominal 
value 
[ng/ inj.] 
Actual value 
Mean 
[ng/ inj.] 
Standard 
deviation 
SD 
Variation 
coefficient 
CV % 
Recovery 
% 
Day  I II  III I II  III I II  III I II  III 
Cal.point 3 0.25 0.27 0.24 0.26 0.03 0.01 0.02 10.1 4.8 4.9 109 97 105 
Cal.point 4 0.5 0.49 0.48 0.49 0.03 0.01 0.02 5.2 2.7 4.2 99 96 98 
Cal.point 5 1 0.96 1.05 1.01 0.03 0.05 0.06 2.9 4.2 5.2 96 105 100 
Cal.point 8 10 10.4 10.1 9.9 0.56 0.32 0.76 4.4 3.2 7.6 104 100 100 
QM1 * 0.24 0.22 0.23 0.01 0.01 0.03 5.6 2.6 12.6    
QM2 ** 0.32 0.30 0.31 0.02 0.01 0.02 6.5 3.2 6.0 99 91 100 
QM3 *** 1.31 1.29 1.36 0.07 0.08 0.06 5.4 5.9 4.6 107 106 114 
QM4 **** 11.5 11.4 10.7 0.42 0.32 0.62 3.6 2.8 5.8 113 112 105 
QM5 ***** 105 107 103 4.4 1.51 1.36 4.2 1.4 1.3 105 108 103 
n= 6 for each sample   
* basal serum concentration 
** basal serum concentration + 0.1 ng/ absolute injection 
*** basal serum concentration + 1 ng/ absolute injection 
**** basal serum concentration + 10 ng/ absolute injection  
***** basal serum concentration + 100 ng/ absolute injection 
 
 
 
Table 13 Inter-day reproducibility for MK4 
Sample Nominal 
value 
[ng/ inj.] 
Actual value 
Mean 
[ng/ inj.] 
Standard 
deviation 
SD 
Variation 
coefficient 
CV % 
Recovery 
% 
Day  I II  III I II  III I II  III I II  III 
Cal.point 3 0.25 0.23 0.24 0.22 0.02 0.02 0.01 4.9 7.7 3.4 92 95 89 
Cal.point 5 1 0.86 0.89 0.88 0.02 0.07 0.10 2.7 6.8 11.6 86 89 88 
Cal.point 8 10 9.53 9.39 10.9 0.94 0.19 1.50 9.9 2.8 13.6 95 94 109 
QM1 n.d. n.d. n.d. n.d.          
QM3 1 1.09 1.02 1.09 0.11 0.07 0.04 9.7 7.3 3.8 109 102 109 
QM4 10 10.9 11.3 11.2 1.21 0.38 0.20 11.2 2.0 1.8 109 113 112 
QM5 100 105 99.1 114 4.71 1.86 4.29 4.2 2.4 3.8 105 99 114 
n= 6 for each sample  n.d.= non-detectable 
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3.2.6. Recovery 
Recovery experiments were performed by comparing analytical results for extracted 
samples at different concentrations (low, medium, high) with unextracted samples 
that represent 100 % recovery. 
Recovery rate 
MK4 → MK4 amount quantified from a spiked serum samples compared 
to MK4 solutions in isopropanol of the same concentration 
  MK4 in QM2 vs MK4 in solution LQ (0.1 ng/ inj.) 
  MK4 in QM3 vs MK4 in Cal.5  (1 ng/ inj.) 
  MK4 in QM4 vs MK4 in Cal.8  (10 ng/ inj.) 
K1 → K1 amount quantified from a spiked serum samples minus  
measured K1 amount in QM1 (K1 mean from minimum 3 QM1 
samples) compared to K1 solutions in isopropanol of the same 
concentration 
  K1 in QM2 minus K1 in QM1 vs K1 in solution LQ  (0.1 ng/ inj.) 
  K1 in QM3 minus K1 in QM1 vs K1 in Cal.5   (1 ng/ inj.) 
  K1 in QM4 minus K1 in QM1 vs K1 in Cal.8  (10 ng/ inj.) 
The ratio of the estimated concentration from matrix-containing samples (Cmatrix,SPE) 
to that from the solutions in isopropanol (Cisopropanol) yielded the recovery rate. 
 
Recovery rate              
           
             
      
 
These experiments allowed an insight into the influence of the matrix (serum) and the 
extraction procedure on the signal areas to be gained. 
In addition, the influence of the matrix and the extraction procedure respectively were 
investigated separately.  
  
Recovery rate             
           
                 
      
 
Recovery rate             
                 
             
      
 
Calculated recovery rates (Rec 1, Rec 2, Rec 3) are summarized in table 14. 
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Table 14 Recovery rates of MK4 and K1 
Sample SPE 
Solide-phase 
extraction 
Nominal 
value 
[ng/ abs.inj.] 
Actual value 
Mean 
[ng/ abs.inj.] 
Rec 1 
% 
Rec 2 
% 
Rec 3 
% 
  MK4 K1 MK4 K1 MK4 K1 MK4 K1 MK4 K1 
Isopropanol + 0 0 n.d. n.d.       
Isopropanol - 0 0 n.d. n.d.       
Solution LQ + 0.1 0.1 0.07 0.12     70 109 
Solution LQ - 0.1 0.1 0.10 0.11       
Cal.point 5 + 1 1 0.90 0.99     89 95 
Cal.point 5 - 1 1 1.01 1.04       
Cal.point 8 + 10 10 9.92 10.2     100 101 
Cal.point 8 - 10 10 9.88 10.1       
QM1 + n.d * n.d. 0.27       
QM2 + 0.1 ** 0.09
(1)
 0.40
(1)
 90 118 129 108   
QM3 + 1 *** 0.98 1.12 97 82 109 86   
QM4 + 10 **** 11.2 10.7 113 103 113 102   
n= 6 for each sample  n.d.= non-detectable 
* basal serum concentration 
** basal serum concentration + 0.1 ng/ absolute injection 
*** basal serum concentration + 1 ng/ absolute injection 
**** basal serum concentration + 10 ng/ absolute injection 
(1)
 n= 4 
 
 
3.2.7. Quality assurance 
For quality assurance in analysis, the intraday and interday CVs were evaluated 
(shown in table 10-13; see section 3.2.5.). 
Spiked samples and solutions in isopropanol of the substances of interest (e.g. QM3, 
QM4, Cal.5, Cal.8) were used to monitor the performance of the bioanalytical method 
for vitamin K determination and to assess the integrity and validity of the results of 
the unknown samples analyzed in an individual batch.  
A batch run was accepted and the data underwent further analysis when following 
conditions were met: 
 The relative error does not exceed 15 % (20 % for LLOQ) 
 2/3 of all quality assurance samples should meet this condition 
The relative error RE is calculated as follows: 
 
        
            
    
      
       = mean of actual concentration  
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      = nominal concentration 
 
3.2.8. Stability 
Stability testing of K vitamins (MK4, K1) was performed on both in serum and stock 
solution. For stability in serum, QMs were analyzed in triplicate for determination of 
freeze and thaw stability; short-term stability; long-term stability and post-preparative 
stability. The substances of interest were considered stable if more than 85 % were 
retained at the end of the study period; for the lowest and highest quantifiable 
concentration 80 - 120 % recovery were accepted. CV values of lower than 20 % 
were required. 
 
3.2.8.1. Freeze and thaw stability 
The freeze-thaw stability was determined after 3 refreeze and thaw cycles. Three 
aliquots of the low (solution LQ, QM1) and high (cal. solution 10, QM4) concentration 
were stored at -80 °C for 24 h and thawed unassisted at room temperature. When 
completely thawed, the samples were refrozen for 24 hours under the same 
conditions. The freeze-thaw cycles were repeated twice and then analyzed 
immediately on the third cycle. The results are summarized in table 15. 
 
Table 15 Freeze and thaw stability 
Sample Nominal 
value 
[ng/ abs.inj.] 
Actual value 
Mean 
[ng/ abs.inj.] 
Standard 
deviation 
SD 
Variation 
coefficient 
CV % 
Recovery 
% 
 MK4 K1 MK4 K1 MK4 K1 MK4 K1 MK4 K1 
Solution LQ 0.1 0.1 0.081 0.091 0.001 0.001 1.4 0.9 80.9 91.4 
Cal.point 10 20 20 22.175 23.395 2.281 2.438 10.3 10.4 110.9 117.0 
QM1 n.d. * n.d. 0.120  0.006  4.7   
QM4 10 **** 9.004 8.826 1.125 0.852 14.1 9.7 90.0 87.1 
n= 3 for each sample  n.d.= non-detectable 
* basal serum concentration 
**** basal serum concentration + 10 ng/ absolute injection 
 
3.2.8.2. Short-term stability 
Three aliquots of each of the low (solution LQ, QM1) and high concentrations (cal. 
solution 10, QM4) were thawed at room temperature, kept at this temperature for five 
hours (based on the expected duration that samples will be maintained at room 
100 
 
temperature in the intended study) and analyzed. Results are summarized in table 
16. 
 
Table 16 Short-term stability 
Sample Nominal 
value 
[ng/ abs.inj.] 
Actual value 
Mean 
[ng/ abs.inj.] 
Standard 
deviation 
SD 
Variation 
coefficient 
CV % 
Recovery 
% 
 MK4 K1 MK4 K1 MK4 K1 MK4 K1 MK4 K1 
Solution LQ 0.1 0.1 0.083 0.092 0.010 0.005 7.9 5.3 83.2 92.0 
Cal.point 10 20 20 22.486 22.405 2.455 1.948 10.9 8.7 112.4 112.0 
QM1 n.d. *  0.155  0.043  7.7   
QM4 10 **** 9.627 9.058 1.291 0.543 13.4 6.0 96.3 89.1 
n= 3 for each sample  n.d.= non-detectable 
* basal serum concentration 
**** basal serum concentration + 10 ng/absolute injection 
 
3.2.8.3. Long-term stability 
The long-term stability in frozen human serum (-80 °C) was determined by storing 
three aliquots of each of the low (solution LQ, QM1) and high concentrations (cal. 
solution 10, QM4) under the same conditions as the study samples (at -80 °C) and 
periodic analysis over six months. Prior to their analysis, samples were brought to 
room temperature and vortex-mixed well. The following batches of serum samples 
were prepared: 
 
Batch I → analysis immediately 
Batch II → analysis after 1 month storage at -80 °C 
Batch III → analysis after 3 months storage at -80 °C 
Batch IV → analysis after 6 months storage at -80 °C 
Table 17 and 18 present the results for the long-term stability of K1 and MK4 
respectively. The corresponding CV and recovery values were within the acceptable 
range (CV< 20 %, Recovery 80-120 %) during performed periodic analysis over six 
months. 
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Table 17 Long-term stability of K1 
 
Sample Nominal 
value 
[ng/ inj.] 
Actual value 
Mean 
[ng/ inj.] 
Variation 
coefficient 
CV % 
Recovery 
% 
Batch  I II  III IV I II  III IV I II  III IV 
Solution LQ 0.1 0.09 0.09 0.10 0.08 0.9 5.2 2.9 2.1 91 92 103 84 
Cal.point 10 20 23.4 19.1 21.4 17.5 10.4 3.5 1.7 3.5 117 96 107 88 
QM1 * 0.12 0.12 0.13 0.18 4.7 8.5 7.5 3.5     
QM4 **** 8.83 9.72 8.16 10.1 9.7 3.4 4.7 16.1 87 96 81 99 
n= 3 for each sample and batch    
* basal serum concentration 
**** basal serum concentration + 10 ng/ absolute injection 
 
Table 18 Long-term stability of MK4 
Sample Nominal 
value 
[ng/ inj.] 
Actual value 
Mean 
[ng/ inj.] 
Variation 
coefficient 
CV % 
Recovery 
% 
Batch  I II  III IV I II  III IV I II  III IV 
Solution LQ 0.1 0.08 0.08 0.08 0.08 1.4 6.5 5.5 2.6 81 85 82 81 
Cal.point 10 20 22.2 19.2 20.6 17.0 10.3 5.1 1.3 7.6 111 96 103 85 
QM1 n.d. n.d. n.d. n.d. n.d.         
QM4 10 8.01 9.8 8.56 10.7 14.1 3.4 2.4 12.8 80 98 86 107 
n= 3 for each sample and batch  n.d.= non-detectable 
 
 
3.2.8.4. Stock solution stability 
The stability of stock solutions of the substances of interest and the internal standard 
were evaluated by storing the solutions 1-10 under defined conditions for a 
designated period of time. Thereafter, analysis of the samples was carried out and 
vitamin K concentration was calculated. 
 
Batch I → at room temperature + daylight for 6 h  → analysis 
Batch II → at room temperature + in the dark for 6 h → analysis 
Batch III → frozen at -20 °C for 6 h, 
thawed at room temperature for 1 h  → analysis 
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Table 19 Stock solution stability for K1 
Sample Nominal 
value 
[ng/ inj.] 
Actual value 
Mean 
[ng/ inj.] 
I,II,III 
Mean 
[ng/ inj.] 
SD CV 
% 
Recovery 
% 
Batch  I*
 
II * III* 
   
 
Cal.point 1 0.0625 0.056 0.055 0.058 0.056 0.002 2.9 90.2 
Cal.point 2 0.125 0.116 0.119 0.113 0.116 0.003 2.4 92.7 
Cal.point 3 0.25 0.251 0.291 0.255 0.266 0.022 8.2 106.3 
Cal.point 4 0.5 0.456 0.498 0.510 0.488 0.029 5.9 97.6 
Cal.point 5 1 0.971 1.054 1.088 1.038 0.060 5.8 103.8 
Cal.point 6 2 2.043 2.429 2.062 2.178 0.218 10.0 108.9 
Cal.point 7 5 4.849 5.082 5.199 5.044 0.178 3.5 100.9 
Cal.point 8 10 9.455 10.609 9.203 9.755 0.750 7.7 97.6 
Cal.point 9 15 16.595 14.973 13.899 15.156 1.357 9.0 101.0 
Cal.point 10 20 18.520 22.122 23.341 21.328 2.507 11.8 106.6 
n= 3 for each sample   
I* batch I (room temperature + daylight for 6 h before analysis) 
II* batch II (room temperature + in the dark for 6 h before analysis) 
III* batch III (frozen at -20°C for 6 h, thawed at room temperature for 1 h before analysis) 
 
 
Table 20 Stock solution stability for MK4 
Sample Nominal 
value 
[ng/ inj.] 
Actual value 
Mean 
[ng/ inj.] 
I,II,III 
Mean 
[ng/ inj.] 
SD CV 
% 
Recovery 
% 
Batch  I*
 
II * III* 
   
 
Cal.point 1 0.0625 0.044 0.052 0.054 0.050 0.005 10.8 79.9 
Cal.point 2 0.125 0.106 0.116 0.118 0.113 0.007 5.9 90.5 
Cal.point 3 0.25 0.263 0.254 0.243 0.244 0.009 3.7 97.7 
Cal.point 4 0.5 0.439 0.496 0.495 0.477 0.033 6.9 95.3 
Cal.point 5 1 0.949 1.083 1.076 1.036 0.076 7.3 103.6 
Cal.point 6 2 2.328 2.410 1.972 2.237 0.232 10.4 111.8 
Cal.point 7 5 4.478 4.808 4.857 4.715 0.206 4.4 94.3 
Cal.point 8 10 9.063 10.157 8.844 9.355 0.704 7.5 93.5 
Cal.point 9 15 15.600 14.101 13.618 14.440 1.034 7.2 96.3 
Cal.point 10 20 17.726 21.082 22.068 20.292 2.276 11.2 101.5 
n= 3 for each sample   
I* batch I (room temperature + daylight for 6 h before analysis) 
II* batch II (room temperature + in the dark for 6 h before analysis) 
III* batch III (frozen at -20°C for 6 h, thawed at room temperature for 1 h before analysis) 
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3.2.8.5. Post-preparative stability 
The stability of the substance of interest and the internal standard were assessed 
over a period of 24 h run time for the batch size in validation samples by determining 
concentrations on the basis of original calibration standards. 
Processed serum samples and stock solutions containing MK4 and K1 were found to 
be stable at 10° C for 24 h in the autosampler. CV and recovery values were within 
the acceptable range as stated above. 
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3.3. Vitamin K levels in mouse tissue 
Organ phylloquinone and MK4 were assayed as previously described in 3.6. The 
following mice tissues were dissected and prepared for analysis: 
lung, bone, pancreas, kidney, tongue, muscle, heart, brain, liver, ovary, uterus, testis, 
salivary gland 
The calculated concentrations of vitamin K1 and MK4 varied per tissue and are 
shown in table 21. Values are represented as means in pmol per g dry weight tissue 
as well as medians for both genders separately. Additionally, K1 to MK4 ratio was 
calculated for each tissue. 
Phylloquinone (K1) was recovered in all tissues with highest levels found in liver, 
ovary and tongue. Menaquinone-4 (MK4) was also present in all tissues. Remarkably 
high tissue concentrations of MK4 exceeding significantly the K1 levels were found in 
pancreas, brain, heart, kidney and testis. K1 status nearly equalled MK4 levels in 
lung and uterus. Relatively high tissue concentrations of K1 and MK4 were measured 
in bone, muscle and salivary gland. Thereby, the MK4 values exceeded the 
corresponding K1 levels. 
 
Table 21 Tissue distribution of vitamin K in mice [ pmol/ g dry tissue ] 
Organ Vit. K Mean ± S.E. Median 
  Male ♂ Female ♀ Male Female 
Lung K1 
MK4 
200.5 ± 60.5  
n=6 
290.2 ± 53.9  
n=8 
361.3 ± 137.6  
n=7 
398.0 ± 69.5  
n=9 
198.6 
262.7 
342.5 
288.8 
  
     0.69 0.91 0.76 1.19 
Bone K1 
MK4 
156.8 ± 88.5  
n=7 
304.3 ± 44.1  
n=9 
314.7 ± 127.7  
n=7 
591.6 ± 183.8  
n=9 
29.9 
305.4 
237.2 
550.5 
  
     0.52 0.53 0.10 0.43 
Pancreas K1 
MK4 
191.5 ± 92.7  
n=7 
3609.1 ± 389.0  
n=9 
319.8 ± 130.7  
n=6 
3746.6 ± 444.3  
n=9 
93.3 
4140.2 
190.2 
4110.3 
  
     0.05 0.09 0.02 0.05 
Kidney K1 
MK4 
171.0 ± 78.4  
n=7 
1270.8 ± 216.7  
n=8 
373.9 ± 245.8  
n=5 
2605.5 ± 665.4  
n=8 
56.5 
1210.9 
180.6 
2030.9 
  
     0.13 0.14 0.05 0.09 
Tongue K1 
MK4 
889.9 ± 531.2  
n=7 
572.3 ± 62.1  
n=9 
1747.7 ± 760.3  
n=7 
1120.0 ± 86.6  
n=9 
191.5 
624.2 
903.2 
1105.6 
  
     1.55 1.56 0.31 0.82 
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Organ Vit. K Mean ± S.E. Median 
Muscle K1 
MK4 
72.8 ± 28.0  
n=7 
439.7 ± 93.1  
n=9 
153.0 ± 54.3  
n=8 
589.4 ± 18.9  
n=9 
35.9 
380.9 
111.3 
589.8 
  
     0.17 0.26 0.09 0.19 
Heart K1 
MK4 
148.1 ± 53.6  
n=7 
979.0 ± 104.5  
n=9 
175.9 ± 59.8  
n=7 
1576.0 ± 135.4  
n=9 
86.6 
1151.4 
186.2 
1499.6 
  
     0.15 0.11 0.08 0.12 
Brain K1 
MK4 
161.8 ± 87.0  
n=6 
2328.8 ± 307.7  
n=9 
483.8 ± 296.5  
n=5 
3559.9 ± 148.8  
n=8 
99.9 
2352.7 
225.2 
3521.1 
  
     0.07 0.14 0.04 0.06 
Liver K1 
MK4 
210.4 ± 134.3  
n=8 
94.9 ± 14.9  
n=9 
1054.5 ± 839.8  
n=8 
232.0 ± 29.3  
n=9 
25.9 
102.5 
105.2 
199.7 
  
     2.22 4.55 0.25 0.53 
Ovary K1  
MK4 
      
 
 2384.0 ± 1465.4  
n=8 
912.2 ± 97.7  
n=9 
 699.5 
 819.5 
  
      2.61  0.85 
Uterus K1        
MK4     
 890.1 ± 547.9  
n=8 
892.6 ± 83.1  
n=9 
 376.5 
891.5 
  
      1.00  0.42 
Testis  K1
 
        
MK4    
 
 
259.9 ± 119.3  
n=8 
2983.8 ± 360.7  
n=9 
 79.5 
3278.5 
 
  
     0.09  0.02  
Salivary 
gland 
K1
 
        
MK4    
 
 
348.6 ± 231.0  
n=4 
514.3 ± 77.3  
n=4 
 154.2 
480.9 
 
  
     0.68  0.32  
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3.4. Vitamin K1 determination assay and pharmacokinetic analysis 
- preliminary studies in human volunteers  
Some preliminary experiments were performed over a two-year period and served as 
first relevant application of the vitamin K determination assay from human serum. 
Four human volunteers A, B, C and D were investigated (experiment 1) starting with 
a single oral administration of 2 mg Konakion® MM (p.o.). A wash-out period of 7 
days was followed by a single intravenous administration (i.v.) of the same dosage, 
except for volunteer C and D where a period of more than two weeks reclined 
between both experiments. Blood samples were collected within 24 h following each 
Konakion® MM intake.  
The experiment was repeated two years later with two of the volunteers (A and B) 
(experiment 2). In addition the same experiment , however, without any Konakion® 
MM intake (experiment 3) was performed to gain the so-called “zero” kinetics when 
only the endogenous amount of vitamin K1 was present and measured.  
After centrifugation collected blood samples were kept frozen until analysis. The 
samples from each experiment were analyzed directly after the investigation was 
performed (A1, B1, A2, B2, C1, D1) and a determined period of time later (two years for 
A1R, B1R, and one year for C1R, D1R). 
 A B C D 
p.o.  
experiment 1 
A1,p.o. 
▪ A1,p.o. 
▪ A1R,p.o. 
B1,p.o. 
▪ B1,p.o. 
▪ B1R,p.o. 
C1,p.o. 
▪ C1,p.o. 
▪ C1R,p.o. 
D1,p.o. 
▪ D1,p.o. 
▪ D1R,p.o. 
i.v.  
experiment 1 
A1,i.v. 
▪ A1,i.v. 
▪ A1R,i.v. 
B1,i.v. 
▪ B1,i.v. 
▪ B1R,i.v. 
C1,i.v. 
▪ C1,i.v. 
▪ C1R,i.v. 
D1,i.v. 
▪ D1,i.v. 
▪ D1R,i.v. 
p.o.  
experiment 2 
A2,p.o. 
▪ A2,p.o. 
B2,p.o. 
▪ B2,p.o. 
  
i.v.  
experiment 2 
A2,i.v. 
▪ A2,i.v. 
B2,i.v. 
▪ B2,i.v. 
  
0 kinetics 
experiment 3 
A3 B3   
 
107 
 
Furthermore, the VKORC1 promoter polymorphism c.-1639 G>A of the four 
volunteers was analyzed. A and B are homozygous AA carriers, C is heterozygous 
(AG) and D is a carrier of GG genotype (wild-type). 
In addition, serum bile acids levels and the serum concentrations of cholesterol and 
the immediate cholesterol metabolite and bile acid precursor 7-hydroxycholesterol 
were determined from the kinetic samples of volunteers A and B. 
 
3.4.1. Raw concentration – time data after/ without administration 
of Konakion® MM 2 mg 
The following tables present mean values of minimum two measurements of vitamin 
K1 serum concentrations for each volunteer (A, B, C, D). Additionally, the mean 
values are plotted in figures/ graphs against the time points of blood collection after 
vitamin K1 administration. 
 
A1,p.o., A1R,p.o., A2,p.o. 
Tables 22 and 23 present mean values of vitamin K1 serum concentrations in ng/ mL 
after 2 mg Konakion® MM were administered orally to volunteer A. 
A1,p.o. refers to the experiment which was carried out in 2008, while A2,p.o. relates to 
the investigation repeated two years later. A1R,p.o. column shows the vitamin K1 
values of the same blood samples collected in 2008 but measured two years later. 
There was a notable decrease of detectable vitamin K1 by 39.5 % in the mean 
between the measurements directly after blood collection and two years later.  
The mean vitamin K1 serum values obtained from both experiments (experiment 1 in 
2008 and experiment 2 in 2010, respectively) are plotted against the time in figure 26 
and 27. 
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Table 22   Serum concentration of K1                 Table 23   Serum concentration of K1   
 A1,p.o. A1R,p.o.   A2,p.o. 
Point 
[min] 
K1 
[ng/ mL] 
K1 
[ng/ mL] 
Point 
[min] 
K1 
[ng/ mL] 
-15 0.850 0.186 -15 0.548 
20 0.582 0.024 46 0.721 
63 1.068 0.449 106 42.211 
120 54.302 40.591 135 46.711 
149 44.503 29.369 165 28.625 
183 32.086 20.503 197 19.086 
210 22.052 14.793 231 18.267 
250 23.915 14.881 253 18.496 
270 23.607 9.904 289 34.964 
302 17.792 11.980 316 18.098 
340 17.661 12.851 345 15.793 
362 14.183 9.642 375 10.151 
393 10.804 8.007 406 9.863 
420 10.244 6.359 439 9.767 
480 12.479 8.542 470 9.316 
538 11.271 9.549 498 7.463 
600 8.841 6.885 555 5.180 
1455 2.258 1.580 1436 3.404 
 
           
Fig. 26   Vitamin K1 vs time- A1,p.o.   Fig. 27   Vitamin K1 vs time- A2,p.o. 
 
A1,i.v., A1R,i.v., A2,i.v. 
Tables 24 and 25 show mean values of vitamin K1 serum concentrations in ng/ mL 
after 2 mg Konakion® MM were administered intravenously to volunteer A. 
A1,i.v. refers to the experiment which was performed in 2008 while A2,i.v. to the two 
years later repeated investigation. A1R,i.v. column shows the vitamin K1 values of the 
same blood samples collected in 2008 but measured two years later. There was a 
considerable decrease of detectable vitamin K1 by 12.3 % in the mean between the 
measurements directly after blood samples were collected and two years later.  
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The mean vitamin K1 serum values obtained from both experiments (experiment 1 in 
2008 and experiment 2 in 2010, respectively) are plotted against the time in figure 28 
and 29. 
Table 24   Serum concentration of K1                 Table 25   Serum concentration of K1   
 A1,i.v. A1R,i.v.    A2,i.v. 
Point 
[min] 
K1 
[ng/ mL] 
K1 
 [ng/ mL] 
Point 
[min] 
K1 
[ng/ mL] 
-15 1.219 0.670 -15 0.918 
3 662.504 453.300 3 430.192 
6 485.355 331.060 5 365.483 
10 456.886 289.700 10 274.372 
21 202.571 139.120 23 137.205 
29 148.213 129.063 32 85.652 
40 121.644 96.684 42 69.141 
50 103.964 89.375 55 58.044 
60 90.133 87.488 62 52.046 
80 75.969 77.369 80 42.623 
100 69.491 71.150 97 40.123 
124 56.857 54.703 129 35.032 
139 42.185 43.752 143 27.635 
160 41.850 32.281 157 27.001 
180 36.096 23.517 183 19.734 
210 27.265 22.366 209 17.768 
242 25.670 26.142 242 16.613 
270 21.526 16.200 270 13.580 
302 16.292 15.603 300 12.693 
331 13.693 13.472 365 7.324 
361 14.416 10.686 420 8.253 
422 7.478 10.428 482 5.241 
480 6.675 6.331 539 4.808 
540 5.993 6.701 600 3.356 
610 4.816 4.301 1442 1.184 
1455 1.375 1.343   
 
             
Fig. 28   Vitamin K1 vs time- A1,i.v.               Fig. 29   Vitamin K1 vs time- A2,i.v. 
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B1,p.o., B1R,p.o., B2,p.o.  
Tables 26 and 27 present mean values of vitamin K1 serum concentrations in ng/ mL 
after 2 mg Konakion® MM were administered orally to volunteer B. 
B1,p.o. refers to the experiment which was carried out in 2008, while B2,p.o. relates to 
the investigation repeated two years later. B1R,p.o. column shows the vitamin K1 
values of the same blood samples collected in 2008 but measured two years later. 
There was a notable decrease of detected vitamin K1 by 27.8 % in the mean 
between the measurements directly after blood collection and two years later. The 
mean vitamin K1 serum values obtained from both experiments (experiment 1 in 
2008 and experiment 2 in 2010, respectively) are plotted against the time in figure 30 
and 31. 
Table 26   Serum concentration of K1                 Table 27   Serum concentration of K1   
 B1,p.o. B1R,p.o.   B2,p.o. 
Point 
[min] 
K1 
[ng/ mL] 
K1 
[ng/ mL] 
Point 
[min] 
K1 
[ng/ mL] 
0 0.585 0.582 -15 0.325 
60 0.583 0.543 60 0.393 
120 13.527 8.900 119 7.386 
180 53.673 34.461 150 20.926 
210 59.931 44.065 179 19.829 
240 48.211 44.690 210 14.386 
270 42.221 31.226 242 12.231 
300 30.271 27.860 271 10.401 
330 33.002 22.408 300 16.728 
360 36.638 25.679 330 18.649 
390 39.998 21.105 360 14.425 
420 40.963 22.721 390 9.737 
450 41.676 24.427 423 7.960 
480 38.005 12.390 450 7.172 
520 27.689 23.426 482 6.768 
580 24.273 16.374 541 3.977 
1440 3.800 3.188 596 3.645 
   1440 0.956 
           
Fig. 30 Vitamin K1 vs time- B1,p.o.                Fig. 31   Vitamin K1 vs time- B2,p.o. 
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B1,i.v., B1R,i.v., B2,i.v.  
Tables 28 and 29 show mean values of vitamin K1 serum concentrations in ng/ mL 
after 2 mg Konakion® MM were administered intravenously to volunteer B. 
B1,i.v. refers to the experiment which was performed in 2008, while B2,i.v. relates to the 
two years later repeated investigation. B1R,i.v. column presents the vitamin K1 values 
of the same blood samples collected in 2008 but measured two years later. The 
decrease of detectable vitamin K1 averaged 28.0 % between the measurements 
directly after blood sampling and after two year storage.  
The mean vitamin K1 serum values obtained from both experiments (experiment 1 in 
2008 and experiment 2 in 2010, respectively) are plotted against the time in figure 32 
and 33. 
 
Table 28   Serum concentration of K1                 Table 29   Serum concentration of K1   
 B1,i.v. B1R,i.v.   B2,i.v. 
Point 
[min] 
K1 
[ng/ mL] 
K1 
[ng/ mL] 
Point 
[min] 
K1 
[ng/ mL] 
0 0.699 0.288 -8 0.593 
5 674.960 512.590 2 167.422 
10 352.920 233.620 5 348.069 
20 202.830 159.380 10 245.194 
30 115.467 87.645 20 155.593 
40 130.153 90.953 30 82.831 
50 97.485 54.473 40 61.731 
60 73.544 51.635 51 50.453 
80 76.022 45.661 65 39.170 
100 62.457 40.161 80 34.030 
120 53.321 32.075 100 27.605 
140 38.511 25.235 124 21.890 
160 35.262 26.846 142 17.736 
180 30.516 23.451 159 16.961 
210 25.766 18.725 185 11.782 
240 22.921 18.320 209 9.950 
270 17.772 16.269 239 6.913 
300 21.682 13.794 264 6.199 
330 18.838 12.045 298 5.248 
360 13.957 9.667 327 4.797 
420 9.682 8.005 359 4.109 
480 8.860 7.250 418 3.410 
540 6.504 5.754 473 2.390 
600 6.631 5.883 531 2.093 
1440 1.295 1.045 590 1.625 
   1498 0.665 
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Fig. 32 Vitamin K1 vs time- B1,i.v.   Fig. 33 Vitamin K1 vs time- B2,i.v. 
 
A3, B3 
Tables 30 and 31 present mean values, standard deviation and coefficient of 
variation of vitamin K1 serum concentrations without any Konakion® MM intake. A3 
shows mean baseline K1 serum concentrations for volunteer A, while B3 presents 
mean baseline K1 serum concentrations for volunteer B. 
Table 30   Endogenous vitamin K1            Table 31   Endogenous vitamin K1 
 A3     B3 
Point 
[min] 
K1 
[ng/ mL] 
Point 
[min] 
K1 
[ng/ mL] 
-16 0.431 -35 0.296 
7 0.484 4 0.284 
38 0.549 32 0.487 
58 0.490 60 0.450 
88 0.488 91 1.077 
121 0.518 122 0.309 
149 0.524 152 0.772 
179 0.538 182 0.675 
210 0.457 212 0.458 
240 0.589 246 0.233 
268 0.505 269 0.896 
300 0.333 300 0.837 
331 0.589 326 0.817 
394 0.355 357 0.646 
457 0.608 385 0.694 
1321 0.865 413 0.672 
mean 0.520 447 0.467 
sd 0.116 475 0.581 
cv 22.29 % 504 0.428 
 535 0.414 
1356 1.408 
mean 0.614 
sd 0.282 
cv 45.86 % 
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There is no significant difference between the individual vitamin K1 serum 
concentrations for volunteer A and B (p= 0,188; unpaired t-test), though the 
coefficient of variation within this time interval in volunteer B appears to be as twice 
as high in comparison to the variation in volunteer A. 
 
C1,p.o., C1R,p.o. 
Table 32 presents mean values of vitamin K1 serum concentrations in ng/ mL after 2 
mg Konakion® MM were administered orally to volunteer C. 
C1,p.o. refers to the experiment which was performed in 2009. C1R,p.o. column shows 
the vitamin K1 values of the same blood samples collected in 2009 but measured a 
year later. There was a notable decrease of detectable vitamin K1 by 30.6 % in the 
mean. The mean vitamin K1 serum values are plotted against the time in figure 34.  
 
Table 32   Serum concentration of K1 
 C1,p.o. C1R,p.o. 
Point 
[min] 
K1 
[ng/ mL] 
K1 
[ng/ mL] 
0 1.477 0.516 
60 1.401 0.787 
120 49.234 33.596 
180 44.561 30.711 
210 31.753 23.698 
240 20.095 16.210 
270 17.510 9.742 
300 19.507 13.357 
330 16.324 14.029 
360 13.025 12.821 
390 17.650 10.603 
420 13.724 9.671 
450 18.087 13.812 
480 24.014 19.819 
520 21.463 13.269 
580 18.562 14.156 
1440 2.396 1.464 
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Fig. 34   Vitamin K1 vs time- C1,p.o. 
 
 
 
C1,i.v., C1R,i.v. 
Table 33 presents mean values of vitamin K1 serum concentrations in ng/ mL after 2 
mg Konakion® MM were administered intravenously to volunteer C. 
C1,i.v. refers to the experiment which was performed in 2009. C1R,i.v. column shows 
the vitamin K1 values of the same blood samples collected in 2009 but measured a 
year later. There was a slight increase of detectable vitamin K1 by 1.1 % in the mean 
between the measurement directly after blood samples were collected and a year 
later. The mean vitamin K1 serum values are plotted against the time in figure 35. 
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Table 33   Serum concentration of K1 
 C1,i.v. C1R,i.v. 
Point 
[min] 
K1 
[ng/ mL] 
K1 
[ng/ mL] 
-15 0.804 0.960 
3.8 430.145 348.900 
5 354.580 352.800 
11 237.275 189.100 
21 134.510 123.800 
28 103.401 104.400 
40 77.413 69.775 
51 63.261 58.263 
65 54.724 49.763 
80 45.757 41.450 
101 35.145 34.325 
120 30.558 28.338 
142 26.541 25.635 
160 21.748 21.580 
182 17.589 18.950 
212 15.737 17.445 
243 12.124 13.400 
275 10.079 12.455 
301 8.585 10.993 
330 7.352 8.790 
361 6.800 5.805 
423 5.523 6.848 
480 4.574 4.365 
543 3.640 4.285 
600 3.149 4.410 
1460 0.463 1.253 
 
 
Fig. 35   Vitamin K1 vs time- C1,i.v.  
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D1,p.o., D1R,p.o. 
Table 34 presents mean values of vitamin K1 serum concentrations in ng/ mL after 2 
mg Konakion® MM were administered orally to volunteer D. 
D1,p.o. refers to the experiment which was performed in 2009. D1R,p.o. column shows 
the vitamin K1 values of the same blood samples collected in 2009 but measured a 
year later. The decrease of detectable vitamin K1 averaged 6.5 % between the 
measurements directly after blood sampling and a year later. The mean vitamin K1 
serum values are plotted against the time in figure 36. 
 
Table 34   Serum concentration of K1 
 D1,p.o. D1R,p.o. 
Point 
[min] 
K1 
[ng/ mL] 
K1 
[ng/ mL] 
0 0.520 0.796 
60 2.640 0.858 
120 4.409 3.184 
180 35.375 23.985 
210 21.253 18.295 
240 28.338 21.555 
270 25.638 21.101 
300 22.466 18.795 
330 17.355 14.947 
360 15.922 13.506 
390 12.773 10.606 
420 9.169 8.612 
450 6.353 6.842 
480 5.264 5.846 
520 4.835 5.527 
580 3.308 4.034 
1440 1.037 1.376 
 
 
Fig. 36   Vitamin K1 vs time- D1,p.o. 
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D1,i.v., D1R,i.v. 
Table 35 presents mean values of vitamin K1 serum concentrations in ng/ mL after 2 
mg Konakion® MM were administered intravenously to volunteer D. 
D1,i.v. refers to the experiment which was performed in 2009. D1R,i.v. column shows 
the vitamin K1 values of the same blood samples collected in 2009 but measured a 
year later. The decrease of detected vitamin K1 averaged 10.9 % between the 
measurements directly after blood collection and a year later. The mean vitamin K1 
serum values are plotted against the time in figure 37. 
 
Table 35   Serum concentration of K1 
 D1,i.v. D1R,i.v. 
Point 
[min] 
K1 
[ng/ mL] 
K1 
[ng/ mL] 
-15 0.140 0.628 
2 327.505 279.123 
5 309.950 273.200 
10 210.688 212.500 
20 130.853 101.700 
30 97.505 99.038 
40 74.609 78.563 
50 73.168 67.363 
30 60.180 56.563 
80 44.635 43.875 
100 34.039 33.150 
120 28.328 25.375 
140 27.666 24.050 
160 23.745 20.615 
180 21.363 14.230 
210 14.629 13.205 
240 12.645 11.770 
270 10.333 10.693 
300 8.737 7.605 
330 6.643 5.158 
360 5.500 5.675 
420 4.558 4.888 
480 3.455 3.308 
540 2.693 2.870 
600 2.100 1.873 
1440 0.292 1.323 
 
118 
 
 
Fig. 37   Vitamin K1 vs time- D1,i.v. 
 
3.4.2. Pharmacokinetic analysis 
Pharmacokinetic analysis after p.o. and i.v. administration of 2 mg Konakion® MM  
was performed for all participants A, B, C, and D. 
 
3.4.2.1. Graphic presentation of the data 
By using y-axis scaled logarithmically, vitamin K1 serum concentrations were plotted 
against time profiles in order to elucidate pharmacokinetic data more clearly. 
For each curve and each volunteer, the baseline serum concentration of vitamin K1 
(the vitamin K1 value in serum before any Konakion® MM administration) was 
subtracted from the vitamin K1 serum value at the corresponding time point. Hereby, 
negative values were equated with zero. In this way calculated values were further 
used to generate the appropriate graphs. 
 
3.4.2.1.1. Serum concentration vs time profiles of vitamin K1 
following p.o. administration of Konakion® MM 2 mg 
The following figures (38 – 43) show vitamin K1 serum concentration vs time profiles 
obtained from each volunteer (A, B, C, and D) after 2 mg Konakion® MM were 
administered orally. 
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  Fig. 38   LOG-Vitamin K1 vs time- A1,p.o.  Fig. 39   LOG-Vitamin K1 vs time- A2,p.o. 
 
  
Fig. 40   LOG-Vitamin K1 vs time- B1,p.o.  Fig. 41   LOG-Vitamin K1 vs time- B2,p.o. 
 
  
Fig. 42   LOG-Vitamin K1 vs time- C1,p.o.  Fig. 43   LOG-Vitamin K1 vs time- D1,p.o.
  
 
3.4.2.1.2. Serum concentration vs time profiles of vitamin K1 
following i.v. administration of Konakion® MM 2 mg 
The figures below (44 – 49) present vitamin K1 serum concentration vs time profiles 
obtained from each volunteer (A, B, C, and D) after 2 mg Konakion® MM were 
administered intravenously. 
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Fig. 44   LOG-Vitamin K1 vs time- A1,i.v.  Fig. 45   LOG-Vitamin K1 vs time- A2,i.v. 
 
   
Fig. 46   LOG-Vitamin K1 vs time- B1,i.v.  Fig. 47   LOG-Vitamin K1 vs time- B2,i.v. 
 
  
Fig. 48   LOG-Vitamin K1 vs time- C1,i.v.  Fig. 49  LOG-Vitamin K1 vs time- D1,i.v.
  
3.4.2.2. Pharmacokinetic parameters after p.o./ i.v. administration 
of Konakion® MM 2 mg 
The pharmacokinetic evaluation was carried out for all participants (A, B, C, and D). 
Following pharmacokinetic parameters were estimated on the basis of the data: 
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Symbol Unit Definition Calculation 
tmax min Time of maximum plasma 
concentration 
directly taken from analytical 
data 
Cmax ng mL
-1
 Maximum plasma concentration directly taken from analytical 
data 
Cmax_D L
-1
 Cmax  divided by dose         
C0 ng mL
-1
 Back extrapolated concentration at 
time = 0  
 
Tlast min Time of last observation where C is 
positive 
 
Clast ng mL
-1
 Concentration at Tlast  
AUClast ng h mL
-1
 Area under the curve from 0 to Tlast  
AUCall ng h mL
-1
 Area under the curve from 0 to time 
of last observation 
 
AUC0_600 ng h mL
-1
 Area under the curve from 0 to 600 
min 
 
F0_600  Bioavailability as calculated from IV 
and PO  AUC0-600 
 
                
                
 
 
AUCINF_obs ng h mL
-1
 Area under the curve from 0 to 
infinity, where the extrapolation is 
based on Clast 
      
 
 
 
 
Finf  Bioavailability as calculated from IV 
and PO AUCINF-obs 
 
                
                
 
 
AUCINF_D_obs min L
-1
 AUCINF-obs divided by dose                  
 
AUC%Extrap_obs  Percentage of total AUC which is 
extrapolated 
 
AUC%Back_Ext_obs  Percentage of total AUC which is 
back extrapolated from first 
observation to time 0 
 
Vss_obs L Volume of distribution at steady-
state, calculated from mean 
residence time and clearance 
 
Vz_obs L Volume of distribution based on the 
terminal phase 
→ i.v. administration 
              ) 
 
Vz_F_obs L Volume of distribution based on the 
terminal phase divided by 
bioavailability 
→ p.o. administration 
                 
Clobs L min
-1
 Clearance calculated from AUC 
INF_obs and Dose 
→ i.v. administration 
         
 
ClF_obs L min
-1
 Clearance calculated from AUCINF-
obs and Dose divided by 
bioavailability 
→ p.o. administration 
             
Rsq  Goodness of fit statistic for the 
terminal phase 
 
Rsq adjusted  Goodness of fit statistic for the 
terminal phase 
 
CorrXY  Correlation between time and log 
concentration for the observations 
used in ƛz (terminal slope) 
estimation 
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ƛz No_points 
 Number of observations used in 
computation of ƛz 
 
ƛz  
min
-1
 Terminal elimination slope  
ƛz lower 
 Lower limit of time time values for 
calculation of l ƛz  
 
ƛz upper 
 Upper limit of time time values for 
calculation of ƛz 
 
t½ ƛz 
min Terminal half life as calcualted from 
ƛz 
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3.4.2.2.1. Pharmacokinetic parameters of volunteer A 
 
Table 36 below presents pharmacokinetic parameters of volunteer A starting with 
data from the experiment performed in 2008. Thereby, data after intravenous 
administration of 2 mg Konakion® MM are listed followed by these after oral 
application of the drug. Subsequently, the parameters from the same experiment in 
2010 are shown in the same order – i.v. data first followed by p.o. values. 
The maximum concentration (Cmax) and the time point of Cmax (tmax) of the K1 serum 
concentration after oral and intravenous administration of Konakion® MM 2 mg were 
determined from the raw data. 
tmax was 6 and 5 minutes for A1,i.v. and A2,i.v., respectively, while tmax amounted to 120 
min for A1,p.o. and to 135 min for A2,p.o.. 
Cmax reached 484 and 365 ng mL
-1 for A1,i.v. and A2,i.v., respectively. Cmax obtained 
after p.o. administration showed 9.1 and 7.9-fold lower values for the experiment in 
2008 and 2010, respectively compared to the i.v. data and equaled 53 ng mL-1 for 
A1,p.o.  and 46 ng mL
-1 for A2,p.o.. 
The area under the curve AUC was calculated using the linear-logarithmic 
trapezoidal rule. 
AUCall was after i.v. administration of 2 mg Konakion
® MM in 2008 1.9-fold higher 
compared to AUCall after p.o. application of the same dosage. For the experiment in 
2010, AUCall was 1.4-fold higher after i.v. dose than the corresponding p.o. value. 
Bioavailability F0_600 as calculated from AUC0_600 i.v. and p.o. seemed to be 1.4-fold 
higher when the experiment was repeated two years later while Finf as calculated 
from AUCINF_obs i.v. and p.o. showed 1.5- fold higher value by comparing A2,p.o. and 
A1,p.o.. 
The observed volume of distribution at steady-state Vss was 10 and 17 L after i.v. 
dose in 2008 and 2010, respectively and therewith 1.7-fold lower for the first 
experiment.  
Clearance Clobs calculated from AUCINF_obs and Dose (mL min
-1) was 1.5-fold higher 
for A2,i.v. compared to A1,i.v. while ClF_obs with regard to biovailability was nearly equal 
for both p.o. experiments. 
Elimination half-lives t½ ƛz ranged from 175 to 386 min. Comparing both p.o. 
experiments in 2008 and 2010, t½ ƛz was 1.2-fold lower in the first test. Comparing 
both i.v. experiments in 2008 and 2010, t½ ƛz was also 1.2-fold lower in the first test.  
124 
 
Table 36 Pharmacokinetic parameters of volunteer A 
 
 A1,i.v. A1,p.o. A2,i.v. A2,p.o. Units 
tmax 6 120 5 135 min 
Cmax 484 53 365 46 ng mL
-1
 
Cmax_D 0.24 0.03 0.18 0.02 L
-1
 
C0 530  486  ng mL
-1
 
Tlast 1455 1455 1442 1436 min 
Clast 0.16 1.41 0.27 2.86 ng mL
-1
 
AUClast 438 226 293 208 ng h mL
-1
 
AUCall 438 226 293 208 ng h mL
-1
 
AUC0_600 421 172 279 157 ng h mL
-1
 
F0_600  41  56 % 
AUCINF_obs 438 237 294 234 ng h mL
-1
 
Finf  54  80 % 
AUCINF_D_obs 13.15 7.10 8.82 7.02 min L
-1
 
AUC%Extrap_obs 0.15 4.62 0.47 11.331  
AUC%Back_Ext_obs 11.57  11.97   
Vss_obs 10  17  L 
Vz_obs 19  35  L 
Vz_F_obs  66  79 L µg
-1
 
Clobs 76  113  mL min
-1
 
ClF_obs  141  142 mL min
-1
 
Rsq 0.983 0.948 0.968 0.674  
Rsq adjusted 0.980 0.941 0.962 0.647  
CorrXY -0.991 -0.973 -0.984 -0.821  
ƛz No_points 
9 10 8 14  
ƛz  
0.0040 0.0021 0.0032 0.0018  
ƛz lower 
270 270 270 165  
ƛz upper 
1455 1455 1442 1436  
t½ ƛz 
175 323 215 386 min 
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3.4.2.2.2. Pharmakocinetic parameters of volunteer B 
 
Table 37 below presents pharmacokinetic parameters of volunteer B starting with 
data from the intravenous experiment performed in 2008 and followed by these 
obtained after oral administration of 2 mg Konakion® MM. Subsequently, the 
parameters from the same experiment in 2010 are shown in the same order – i.v. 
data first followed by p.o. values. 
tmax was 5 minutes for B1,i.v. and B2,i.v. while tmax amounted to 210 min for B1,p.o. and 
to 150 min for B2,p.o.. 
Cmax reached 674 and 347 ng mL
-1 for B1,i.v. and B2,i.v., respectively. Cmax obtained 
after p.o. administration showed 11.4 and 16.9-fold lower values for the experiment in 
2008 and 2010, respectively compared to the i.v. data and equaled 59 ng mL-1 for 
B1,p.o. and 21 ng mL
-1  for B2,p.o.. 
AUCall was after i.v. administration of 2 mg Konakion
® MM in 2008 1.1-fold higher 
compared to AUCall after p.o. application of the same dosage. For the experiment in 
2010, AUCall was 2.0-fold higher after i.v. dose than the corresponding p.o. value. 
Bioavailability F0_600  as calculated from AUC0_600 i.v. and p.o. was 1.6-fold lower 
when the experiment was repeated two years later while Finf as calculated from 
AUCINF_obs i.v. and p.o. showed 1.8-fold higher value for the first experiment B1,p.o. 
compared to B2,p.o.. 
The observed volume of distribution at steady-state Vss was 12 and 15 L after i.v. 
dose in 2008 and 2010, respectively and 1.3-fold lower for the first experiment.  
Clearance Clobs calculated from AUCINF_obs and Dose (mL min
-1) was 2.2-fold higher 
for B2,i.v. compared to B1,i.v. while ClF_obs with regard to biovailability was nearly 4-fold 
higher for B2,p.o.. 
Elimination half-lives t½ ƛz ranged from 201 to 316 min. Comparing both p.o. 
experiments in 2008 and 2010, t½ ƛz was 1.2-fold higher in the first test. Comparing 
both i.v. experiments in 2008 and 2010, t½ ƛz was also 1.2-fold higher in the first test.  
  
126 
 
Table 37 Pharmacokinetic parameters of volunteer B 
 
 B1,i.v. B1,p.o. B2,i.v. B2,p.o. Units 
tmax 5 210 5 150 min 
Cmax 674 59 347 21 ng mL
-1
 
Cmax_D 0.34 0.03 0.17 0.01 L
-1
 
C0 1291  494  ng mL
-1
 
Tlast 1440 1440 1509 1440 min 
Clast 0.60 3.22 0.07 0.63 ng mL
-1
 
AUClast 476 439 219 112 ng h mL
-1
 
AUCall 476 439 219 112 ng h mL
-1
 
AUC0_600 443 300 214 90 ng h mL
-1
 
F0_600  68  42 % 
AUCINF_obs 479 464 220 116 ng h mL
-1
 
Finf  97  53 % 
AUCINF_D_obs 14.37 13.91 6.59 3.49 min L
-1
 
AUC%Extrap_obs 0.69 5.27 0.16 3.34  
AUC%Back_Ext_obs 16.52  15.79   
Vss_obs 12  15  L 
Vz_obs 23  44  L 
Vz_F_obs  33  106 L µg
-1
 
Clobs 70  152  mL min
-1
 
ClF_obs  72  287 mL min
-1
 
Rsq 0.969 0.935 0.978 0.887  
Rsq adjusted 0.965 0.930 0.975 0.876  
CorrXY -0.984 -0.967 -0.989 -0.942  
ƛz No_points 
10 14 9 13  
ƛz  
0.0030 0.0022 0.0035 0.0027  
ƛz lower 
240 180 264 185  
ƛz upper 
1440 1440 1509 1509  
t½ ƛz 
231 316 201 255 min 
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3.4.2.2.3. Pharmakocinetic parameters of volunteer C 
 
Table 38 presents pharmacokinetic parameters of volunteer C. Calculated values 
from the intravenous experiment are listed first followed by these obtained after oral 
administration of 2 mg Konakion® MM. 
tmax was 5 min for C1,i.v. while tmax amounted to 120 min for C1,p.o.. 
Cmax reached 354 and 48 ng mL
-1 after intravenous and oral administration, 
respectively. Therewith, Cmax obtained after p.o. intake showed 7.4-fold lower value 
compared to the i.v. value. 
AUCall after i.v. and p.o. administration of 2 mg Konakion
® MM was nearly equal. 
Clearance Clobs as calculated from AUCINF_obs and Dose was 126 mL min
-1 while 
ClF_obs with regard to biovailability was 119 mL min
-1. 
Elimination half-lives t½ ƛz 129 min was calculated for the i.v. experiment and 280 
min for p.o. experiment. 
Finally, it should be noted that bioavailability could not be calculated for volunteer C 
due to the fact that there was a period of more than two weeks between the p.o. and 
i.v. experiment. 
 
  
128 
 
Table 38 Pharmacokinetic parameters of volunteer C 
 C1,i.v. C1,p.o. Units 
tmax 5 120 min 
Cmax 354 48 ng mL
-1
 
Cmax_D 0.18 0.02 L
-1
 
C0 495  ng mL
-1
 
Tlast 600 1440 min 
Clast 2.35 0.92 ng mL
-1
 
AUClast 258 274 ng h mL
-1
 
AUCall 275 274 ng h mL
-1
 
AUCINF_obs 265 280 ng h mL
-1
 
AUCINF_D_obs 7.96 8.41 min L
-1
 
AUC%Extrap_obs 2.732 2.21  
AUC%Back_Ext_obs 13.20   
Vz_obs 23  L 
Vz_F_obs  48 L µg
-1
 
Clobs 126  mL min
-1
 
ClF_obs  119 mL min
-1
 
ƛz No_points 
15 13  
ƛz  
0.0054 0.0025  
ƛz lower 
101 210  
ƛz upper 
600 1440  
t½ ƛz 
129 280 min 
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3.4.2.2.4. Pharmakocinetic parameters of volunteer D 
 
Table 39 presents pharmacokinetic parameters of volunteer D. Calculated values 
from the intravenous experiment are listed at first followed by these obtained after 
p.o. intake of 2 mg Konakion® MM. 
tmax was 5 minutes for D1,i.v. while tmax amounted to 180 min for D1,p.o.. 
Cmax reached 310 and 35 ng mL
-1 after intravenous and oral administration, 
respectively. Therewith, Cmax obtained after p.o. intake showed 8.9-fold lower value 
compared to the i.v. value. 
AUCall was after i.v. administration of 2 mg Konakion
® MM 1.9-fold higher compared 
to AUCall after p.o. application of the same dosage.  
Clearance Clobs as calculated from AUCINF_obs and Dose was 128 mL min
-1 while 
ClF_obs with regard to biovailability was 239 mL min
-1. 
Elimination half-lives t½ ƛz 200 min was calculated for the i.v. experiment and 301 
min for p.o. experiment. 
Finally, it should be noted that bioavailability could not be calculated for volunteer D 
due to the fact that there was a period of more than two weeks between the p.o. and 
i.v. experiment. 
 
  
130 
 
Table 39 Pharmacokinetic parameters of volunteer D 
 D1,i.v. D1,p.o. Units 
tmax 5 180 min 
Cmax 310 35 ng mL
-1
 
Cmax_D 0.16 0.02 L
-1
 
C0 456  ng mL
-1
 
Tlast 1440 1440 Min 
Clast 0.152 0.517 ng mL
-1
 
AUClast 260 136 ng h mL
-1
 
AUCall 260 136 ng h mL
-1
 
AUCINF_obs 260 140 ng h mL
-1
 
AUCINF_D_obs 7.81 4.19 min L
-1
 
AUC%Extrap_obs 0.28 2.68  
AUC%Back_Ext_obs 12.11   
Vz_obs 36.86  L 
Vz_F_obs  103.52 L µg
-1
 
Clobs 128  mL min
-1
 
ClF_obs  239 mL min
-1
 
ƛz No_points 
9 5  
ƛz  
0.035 0.0023  
ƛz lower 
270 450  
ƛz upper 
1440 1440  
t½ ƛz 
200 301 min 
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3.4.3. Bile acid, cholesterol and 7α-hydroxycholesterol 
concentrations 
 
Bile acid levels and the serum concentrations of cholesterol and the immediate 
cholesterol metabolite and bile acid precursor 7-hydroxycholesterol were 
determined from the kinetic samples of volunteers A and B, i.e. in specific: A2,p.o., 
A2,i.v., A3 and B2,p.o., B2,i.v., B3.  
The following tables present values of bile acids, cholesterol and 7-
hydroxycholesterol serum concentrations for volunteer A and B. The values for cholic 
acid (contained in each ampoule Konakion® MM 2 mg) and total bile acids as well are 
plotted in figures against the time points of blood collection after vitamin K1 
administration. 
  
3.4.3.1. Bile acid concentrations 
 
3.4.3.1.1. A2,p.o., A2,i.v., A3 
Tables 40 and 41 present values of bile acids serum concentration in µg/ mL after 2 
mg Konakion® MM were administered orally (A2,p.o.) and intravenously (A2,i.v.) 
respectively or without any vitamin K1 administration (A3) to volunteer A (table 42). 
The figures below (50 – 55) present cholic acid and total bile acid concentration 
plotted against time. 
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Table 40 Serum concentration of bile acids A2,p.o. 
Point 
[min] 
DCA 
[µg/ mL] 
CA 
[µg/ mL] 
LICA 
[µg/ mL] 
CDCA 
[µg/ mL] 
UDCA 
[µg/ mL] 
Total Bile Acids 
[µg/ mL] 
-15 0.202 0.108 0.031 0.143 0.003 0.487 
46 0.331 0.244 0.060 0.273 0.006 0.913 
106 0.369 0.286 0.090 0.327 0.004 1.078 
135 0.577 0.563 0.084 0.651 0.009 1.883 
165 0.541 0.418 0.085 0.566 0.006 1.615 
197 0.563 0.541 0.064 0.676 0.009 1.853 
231 0.579 0.436 0.065 0.702 0.008 1.790 
253 0.449 0.271 0.075 0.510 0.006 1.312 
289 0.861 1.091 0.058 1.281 0.011 3.302 
316 0.787 0.617 0.097 0.976 0.011 2.488 
345 0.705 0.418 0.087 0.871 0.011 2.091 
375 0.725 0.413 0.093 0.819 0.008 2.058 
406 0.510 0.198 0.053 0.477 0.004 1.242 
439 0.393 0.200 0.049 0.424 0.005 1.072 
470 0.650 0.418 0.058 0.733 0.007 1.866 
498 0.739 0.350 0.080 0.763 0.008 1.940 
555 0.341 0.127 0.034 0.332 0.003 0.837 
1436 1.660 1.124 0.101 1.789 0.011 4.685 
 
 
 
  
Fig. 50   Cholic acid vs time- A2,p.o.   Fig. 51   Total bile acids vs time- A2,p.o. 
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Table 41 Serum concentration of bile acids A2,i.v. 
Point 
[min] 
DCA 
[µg/ mL] 
CA 
[µg/ mL] 
LICA 
[µg/ mL] 
CDCA 
[µg/ mL] 
UDCA 
[µg/ mL] 
Total Bile Acids 
[µg/ mL] 
-15 0.312 0.118 0.084 0.260 0.006 0.780 
3 0.290 0.866 0.097 0.278 0.005 1.536 
5 0.320 0.552 0.096 0.263 0.005 1.236 
10 0.295 0.320 0.087 0.251 0.005 0.958 
23 0.374 0.153 0.071 0.252 0.006 0.856 
32 0.342 0.169 0.080 0.292 0.004 0.888 
42 0.375 0.138 0.077 0.270 0.009 0.869 
55 0.356 0.220 0.067 0.384 0.007 1.034 
62 0.559 0.280 0.065 0.444 0.008 1.356 
80 0.690 0.673 0.136 0.656 0.010 2.166 
97 0.442 0.219 0.157 0.374 0.007 1.199 
129 1.019 0.066 0.434 0.607 0.008 2.134 
143 0.452 0.142 0.151 0.341 0.006 1.092 
157 0.577 0.212 0.156 0.546 0.007 1.498 
183 0.514 0.189 0.144 0.475 0.009 1.331 
209 0.454 0.165 0.114 0.396 0.007 1.136 
242 0.629 0.323 0.132 0.635 0.009 1.729 
270 0.509 0.183 0.152 0.438 0.007 1.289 
300 0.561 0.172 0.142 0.459 0.007 1.341 
365 0.859 0.302 0.123 0.776 0.009 2.069 
420 0.951 0.458 0.171 0.930 0.012 2.522 
482 1.976 0.060 0.420 1.803 0.020 4.279 
539 0.587 0.164 0.104 0.500 0.010 1.365 
600 0.433 0.285 0.067 0.407 0.006 1.198 
1442 0.902 0.195 0.104 0.576 0.014 1.791 
 
  
Fig. 52   Cholic acid vs time- A2,i.v.   Fig. 53   Total bile acids vs time- A2,i.v. 
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Table 42 Serum concentration of bile acids A3 
Point 
[min] 
DCA 
[µg/ mL] 
CA 
[µg/ mL] 
LICA 
[µg/ mL] 
CDCA 
[µg/ mL] 
UDCA 
[µg/ mL] 
Total Bile Acids 
[µg/ mL] 
-16 0.433 0.101 0.150 0.305 0.005 0.993 
7 0.226 0.036 0.083 0.133 0.004 0.482 
38 0.511 0.195 0.110 0.432 0.008 1.255 
58 0.710 0.184 0.198 0.429 0.011 1.532 
88 0.449 0.081 0.133 0.258 0.006 0.926 
121 0.413 0.092 0.111 0.298 0.005 0.919 
149 0.314 0.050 0.120 0.188 0.005 0.677 
179 0.274 0.047 0.095 0.195 0.005 0.617 
210 0.217 0.027 0.081 0.124 0.003 0.452 
240 0.624 0.316 0.091 0.696 0.009 1.736 
268 0.547 0.245 0.116 0.491 0.009 1.409 
300 0.455 0.084 0.105 0.351 0.007 1.002 
331 0.432 0.085 0.089 0.296 0.005 0.907 
394 0.422 0.060 0.073 0.235 0.004 0.795 
457 0.270 0.037 0.055 0.167 0.004 0.534 
1321 0.812 0.130 0.115 0.461 0.009 1.527 
 
   
Fig. 54   Cholic acid vs time- A3   Fig. 55   Total bile acids vs time- A3 
 
 
3.4.3.1.2. B2,p.o., B2,i.v., B3 
Tables 43 and 44 present values of bile acids serum concentration in µg/ mL after 2 
mg Konakion® MM were administered orally (B2,p.o.) and intravenously (B2,i.v.) 
respectively or without any vitamin K1 administration (B3) to volunteer B (table 45). 
The figures below (56 – 61) present cholic acid and total bile acid concentration 
plotted against time.  
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Table 43 Serum concentration of bile acids B2,p.o. 
Point 
[min] 
DCA 
[µg/ mL] 
CA 
[µg/ mL] 
LICA 
[µg/ mL] 
CDCA 
[µg/ mL] 
UDCA 
[µg/ mL] 
Total Bile Acids 
[µg/ mL] 
-15 0.571 0.170 0.323 0.256 0.011 1.331 
60 0.358 0.121 0.223 0.183 0.006 0.890 
119 0.418 0.131 0.215 0.193 0.009 0.966 
150 0.564 0.371 0.252 0.349 0.008 1.544 
179 0.596 0.538 0.222 0.439 0.018 1.814 
210 0.730 0.740 0.311 0.562 0.014 2.357 
242 1.289 0.787 0.349 0.911 0.025 3.361 
271 1.214 1.173 0.284 1.104 0.030 3.805 
300 1.150 1.012 0.339 0.941 0.025 3.468 
330 1.133 0.991 0.298 0.975 0.020 3.418 
360 0.908 0.516 0.300 0.605 0.017 2.345 
390 0.800 0.697 0.241 0.573 0.017 2.328 
423 0.664 0.503 0.217 0.576 0.020 1.981 
450 1.157 0.969 0.269 0.985 0.026 3.406 
482 0.877 0.686 0.198 0.686 0.018 2.465 
541 1.183 0.873 0.277 0.996 0.021 3.350 
596 0.612 0.297 0.178 0.450 0.016 1.553 
1440 1.414 1.938 0.355 0.538 0.020 4.265 
 
   
Fig. 56   Cholic acid vs time- B2,p.o.   Fig. 57   Total bile acids vs time- B2,p.o. 
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Table 44 Serum concentration of bile acids B2,i.v.    
Point 
[min] 
DCA 
[µg/ mL] 
CA 
[µg/ mL] 
LICA 
[µg/ mL] 
CDCA 
[µg/ mL] 
UDCA 
[µg/ mL] 
Total Bile Acids 
[µg/ mL] 
-8 0.981 0.151 0.303 0.273 0.032 1.739 
2 0.555 0.989 0.183 0.136 0.017 1.880 
5 0.598 1.303 0.177 0.145 0.015 2.236 
10 0.791 0.885 0.261 0.255 0.026 2.219 
20 0.536 0.185 0.181 0.154 0.012 1.069 
30 0.814 0.182 0.183 0.185 0.027 1.391 
40 0.588 0.215 0.180 0.211 0.025 1.219 
51 0.989 0.274 0.222 0.256 0.036 1.778 
65 0.883 0.141 0.280 0.274 0.033 1.611 
80 0.866 0.100 0.283 0.240 0.024 1.513 
100 0.852 0.125 0.313 0.259 0.020 1.569 
124 0.845 0.161 0.338 0.306 0.020 1.671 
142 0.738 0.070 0.263 0.200 0.017 1.288 
159 0.712 0.044 0.264 0.216 0.020 1.256 
185 0.986 0.124 0.295 0.412 0.030 1.846 
209 0.671 0.102 0.302 0.287 0.021 1.383 
239 0.743 0.162 0.251 0.466 0.030 1.651 
264 0.997 0.169 0.286 0.349 0.025 1.827 
298 0.924 0.175 0.265 0.387 0.026 1.776 
327 1.208 0.375 0.266 0.692 0.040 2.581 
359 1.123 0.406 0.343 0.546 0.040 2.458 
418 0.999 0.205 0.332 0.432 0.030 1.997 
473 1.198 0.331 0.328 0.672 0.040 2.569 
531 1.076 0.189 0.300 0.620 0.026 2.210 
590 0.651 0.083 0.244 0.342 0.025 1.345 
1498 1.283 0.115 0.373 0.435 0.028 2.234 
  
   
Fig. 58   Cholic acid vs time- B2,i.v.   Fig. 59   Total bile acids vs time- B2,i.v. 
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Table 45 Serum concentration of bile acids B3 
Point 
[ min ] 
DCA 
[µg/ mL] 
CA 
[µg/ mL] 
LICA 
[µg/ mL] 
CDCA 
[µg/ mL] 
UDCA 
[µg/ mL] 
Total Bile Acids 
[µg/ mL] 
-35 0.197 0.023 0.100 0.095 0.004 0.418 
4 0.123 0.013 0.070 0.041 0.003 0.250 
32 0.216 0.181 0.094 0.157 0.008 0.656 
60 0.286 0.112 0.124 0.159 0.009 0.691 
91 0.243 0.037 0.107 0.111 0.008 0.507 
122 0.647 0.423 0.231 0.425 0.015 1.741 
152 0.824 0.347 0.261 0.660 0.018 2.110 
182 0.305 0.065 0.114 0.175 0.014 0.673 
212 0.538 0.170 0.164 0.356 0.015 1.243 
246 0.664 0.456 0.159 0.503 0.027 1.808 
269 1.220 1.240 0.237 0.843 0.026 3.566 
300 1.071 0.879 0.232 0.746 0.017 2.945 
326 0.468 0.128 0.186 0.264 0.019 1.065 
357 0.469 0.167 0.154 0.302 0.018 1.111 
385 0.435 0.104 0.155 0.265 0.013 0.973 
413 0.486 0.152 0.169 0.306 0.014 1.127 
447 0.944 0.315 0.326 0.685 0.020 2.290 
475 0.806 0.201 0.282 0.476 0.013 1.779 
504 0.456 0.179 0.124 0.338 0.017 1.114 
535 0.922 0.544 0.244 0.571 0.015 2.295 
1356 1.861 0.724 0.355 0.971 0.032 3.942 
 
    
Fig. 60   Cholic acid vs time- B3   Fig. 61   Total bile acids vs time- B3 
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3.4.3.2. Cholesterol and 7α-hydroxycholesterol concentrations 
 
3.4.3.2.1. A2,p.o., A2,i.v., A3 
Table 46 presents values of 7α-hydroxycholesterol (7αOH) and cholesterol (Ch) 
serum concentrations in ng/ mL and mg/ dL respectively as well as the ratio 7αOH to 
Ch in ng/ mg after 2 mg Konakion® MM were administered orally (A2,p.o.) to volunteer 
A. 
 
Table 46   Serum concentration of 7α-hydroxycholesterol and cholesterol A2,p.o. 
Point 
[min] 
7αOH 
[ng/ mL] 
Cholesterol 
[mg/ dL] 
7αOH / Ch 
[ng/ mg] 
-15 54.8 214.3 25.6 
46 53.9 232.3 23.2 
106 51.0 219.8 23.2 
135 56.3 225.4 25.0 
165 48.1 225.5 21.3 
197 50.8 219.8 23.1 
231 51.9 230.4 22.5 
253 48.8 226.5 21.5 
289 49.5 233.8 21.2 
316 51.5 227.6 22.6 
345 52.0 220.9 23.5 
375 48.0 218.7 22.0 
406 46.2 218.0 21.2 
439 45.7 223.4 20.5 
470 42.1 226.5 18.6 
498 44.5 226.5 19.8 
555 42.9 213.7 20.1 
1436 41.6 229.8 18.1 
mean 48.9 224.0 21.8 
sd 4.4 5.8 2.0 
cv 8.9 % 2.6 % 9.2 % 
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Table 47 presents values of 7αOH and Ch serum concentrations in ng/ mL and mg/ 
dL respectively as well as the ratio 7αOH to Ch in ng/ mg after 2 mg Konakion® MM 
were administered intravenously (A2,i.v.) to volunteer A. 
 
Table 47   Serum concentration of 7α-hydroxycholesterol and cholesterol A2,i.v. 
Point 
[min] 
7αOH 
[ng/ mL] 
Cholesterol 
[mg/ dL] 
7αOH / Ch 
[ng/ mg] 
-15 42.9 170.5 25.2 
3 35.6 186.9 19.1 
5 83.7 134.4 62.3 
10 33.7 182.8 18.4 
23 32.1 178.1 18.0 
32 27.9 179.9 15.5 
42 36.4 175.0 20.8 
55 33.2 173.5 19.2 
62 32.5 181.9 17.9 
80 32.7 180.1 18.1 
97 37.3 174.3 21.4 
129 35.8 181.3 19.7 
143 30.5 181.6 16.8 
157 30.6 181.1 16.9 
183 35.1 179.7 19.5 
209 31.6 181.7 17.4 
242 33.9 181.5 18.7 
270 30.3 176.8 17.1 
300 32.4 184.6 17.6 
365 30.4 179.2 17.0 
420 29.7 181.9 16.3 
482 35.2 166.9 21.1 
539 26.4 171.4 15.4 
600 33.4 176.2 19.0 
1442 30.8 184.1 16.7 
mean 33.2 177.0 18.9 
sd 3.5 10.1 3.0 
cv 10.6 % 5.7 % 15.7 % 
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Table 48 presents values of 7αOH and Ch serum concentrations in ng/ mL and mg/ 
dL respectively as well as the ratio 7αOH to Ch in ng/ mg without any vitamin K1 
administration (A3) to volunteer A. 
 
Table 48   Serum concentration of 7α-hydroxycholesterol and cholesterol A3 
 
Point 
[min] 
7αOH 
[ng/ mL] 
Cholesterol 
[mg/ dL] 
7αOH / Ch 
[ng/ mg] 
-16 41.2 191.1 21.5 
7 42.0 202.6 20.7 
38 30.6 189.2 16.2 
58 36.0 193.2 18.6 
88 37.2 185.7 20.1 
121 42.9 176.0 24.4 
149 29.8 191.0 15.6 
179 34.7 179.0 19.4 
210 32.9 185.6 17.7 
240 39.5 191.7 20.6 
268 31.5 187.2 16.8 
300 34.1 187.6 18.2 
331 35.3 184.5 19.1 
394 30.5 196.7 15.5 
457 37.9 184.0 20.6 
1321 34.2 193.2 17.7 
mean 35.6 188.6 18.9 
sd 4.2 6.5 2.4 
cv 11.7 % 3.4 % 12.6 % 
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3.4.3.2.2. B2,p.o., B2,i.v., B3 
Table 49 presents values of 7αOH and Ch serum concentrations in ng/ mL and mg/ 
dL respectively as well as the ratio 7αOH to Ch in ng/ mg after 2 mg Konakion® MM 
were administered orally (B2,p.o.) to volunteer B. 
 
Table 49   Serum concentration of 7α-hydroxycholesterol and cholesterol B2,p.o. 
Point 
[min] 
7αOH 
[ng/ mL] 
Cholesterol 
[mg/ dL] 
7αOH / Ch 
[ng/ mg] 
-15 26.0 131.6 19.8 
60 25.5 127.2 20.0 
119 23.3 130.8 17.8 
150 31.8 125.8 25.3 
179 25.7 127.8 20.1 
210 25.6 122.0 21.0 
242 31.2 125.8 24.8 
271 29.7 125.6 23.7 
300 26.2 127.8 20.5 
330 28.7 127.4 22.6 
360 25.1 126.7 19.8 
390 25.8 127.7 20.2 
423 33.5 111.3 30.1 
450 26.2 129.3 20.3 
482 25.4 131.4 19.3 
541 24.7 123.3 20.0 
596 25.8 126.4 20.4 
1440 28.5 131.8 21.6 
mean 27.1 126.6 21.5 
sd 2.8 4.7 2.9 
cv 10.2 % 3.7 % 13.4 % 
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Table 50 presents values of 7αOH and Ch serum concentrations in ng/ mL and mg/ 
dL respectively as well as the ratio 7αOH to Ch in ng/ mg after 2 mg Konakion® MM 
were administered intravenously (B2,i.v.) to volunteer B. 
 
Table 50    Serum concentration of 7α-hydroxycholesterol and cholesterol B2,i.v. 
Point 
[min] 
7αOH 
[ng /mL] 
Cholesterol 
[mg/ dL] 
7αOH / Ch 
[ng/ mg] 
-8 21.0 120.5 17.4 
2 19.9 117.5 16.9 
5 22.1 117.5 18.8 
10 25.5 114.5 22.3 
20 21.0 124.9 16.8 
30 24.8 119.4 20.8 
40 19.4 114.9 16.9 
51 20.3 121.0 16.8 
65 20.0 121.2 16.5 
80 22.3 121.3 18.4 
100 23.1 121.7 19.0 
124 24.3 122.0 19.9 
142 20.9 117.9 17.7 
159 20.7 123.1 16.8 
185 23.3 114.7 20.3 
209 21.4 121.7 17.6 
239 21.0 117.6 17.9 
264 21.7 119.8 18.2 
298 19.5 116.2 16.7 
327 18.0 121.0 14.9 
359 21.3 116.9 18.2 
418 17.9 121.5 14.7 
473 20.6 120.9 17.1 
531 18.9 123.9 15.3 
590 17.9 126.3 14.2 
1498 19.1 120.7 15.8 
mean 21.0 119.9 17.5 
sd 2.0 3.1 1.9 
cv 9.6 % 2.6 % 10.8 % 
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Table 51 presents values of 7αOH and Ch serum concentrations in ng/ mL and mg/ 
dL respectively as well as the ratio 7αOH to Ch in ng/ mg without any vitamin K1 
administration (B3) to volunteer B. 
 
Table 51   Serum concentration of 7α-hydroxycholesterol and cholesterol B3 
Point 
[min] 
7αOH 
[ng/ mL] 
Cholesterol 
[mg/ dL] 
7αOH / Ch 
[ng/ mg] 
-35 20.0 118.6 16.9 
4 18.5 122.0 15.2 
32 18.3 114.5 16.0 
60 19.0 117.4 16.2 
91 17.2 113.5 15.2 
122 18.6 118.2 15.7 
152 18.8 116.1 16.2 
182 18.9 118.7 15.9 
212 21.1 123.8 17.1 
246 20.7 122.7 16.8 
269 19.4 119.1 16.3 
300 19.2 121.1 15.9 
326 20.6 122.5 16.8 
357 18.9 122.0 15.5 
385 20.3 118.7 17.1 
413 19.6 121.1 16.2 
447 21.0 124.6 16.8 
475 21.4 118.8 18.0 
504 19.3 122.4 15.8 
535 18.4 115.9 15.9 
1356 18.1 118.00 15.3 
mean 19.4 119.5 16.2 
sd 1.1 3.0 0.7 
cv 5.7 % 2.5 % 4.5 % 
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3.5. Phase I clinical study – 
3.5.1. “Influence of VKORC1 promoter polymorphism c.-1639 G>A 
on the vitamin K1 pharmacokinetics” 
 
The study was conducted in accordance with Good Clinical Practice (GCP), the 
current requirements of EMEA (European Medicines Agency) 94 and the Helsinki 
Declaration.  Extensive pharmacokinetic evaluation was carried out for all 
participants in the clinical trial. Pharmacokinetic parameters were determined using 
non-compartmental analysis since a large number of data points were collected and 
were estimated on the basis of the data for each route of administration of 2 mg 
Konakion® MM (oral and intravenous). These data are presented in Table I – XII 
(appendix). 
Thirty healthy volunteers were included in the clinical study on the pharmacokinetics 
of vitamin K1. Demographic data of these consecutive subjects are presented in 
Table 52. Baseline characteristics were generally balanced across VKORC1 
genotype groups except for triglycerides significantly differing between GG and AG 
carriers and GG and AA group (p = 0.008) but not between AG and AA carriers. 
However, all triglycerides levels were in the acceptable range (< 200 mg/ dL). 
 
Table 52 Demographics of the study subjects 
 
 
Parameter 
Genotype group VKORC1:c.-1639 G>A P-value 
uANOVA GG AG AA 
Age 
[years] 
28.3 ± 4.6
a
 
(22 – 39) 
29.1 ± 8.7 
(20 – 46) 
28.4 ± 6.1 
(22 – 42) 
 
n.s. 
Body mass index 
[kg/m
2
] 
22.8 ± 2.2 
(20 – 28) 
22.9 ± 2.8 
(19 – 28) 
22.4 ± 2.7 
(19 – 27) 
 
n.s. 
Triglycerides 
[mg/ dL] 
58.8 ± 13.4* 
(36 – 74) 
99.1 ± 30.2 
(67 – 151) 
86.9 ± 32.0 
(44 – 133) 
 
0.008 
LDL-Cholesterol 
[mg/ dL] 
101.1 ± 26.4 
(74 – 150) 
99.2 ± 30.7 
(37 – 137) 
102.6 ± 26.2 
(65 – 134) 
 
n.s. 
HDL-Cholesterol 
[mg/ dL] 
62.5 ± 8.5 
(49 – 77) 
56.4 ± 17.1 
(37 – 93) 
60.6 ± 16.4 
(40 – 87) 
 
n.s. 
Creatinine 
[mg/ dL] 
0.9 ± 0.2 
(0.6 – 1.2) 
0.9 ± 0.1 
(0.8 – 1.2) 
1.0 ± 0.2 
(0.8 – 1.3) 
 
n.s. 
a   mean values ± standard deviation with range in parenthesis; n = 10 in each group 
*   p= 0.007; significantly different from AG; Post-hoc with Turkey 
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The plasma-concentration-time profiles of vitamin K1 were obtained by HPLC-RP18 
with fluorescence detection. All evaluated pharmacokinetic parameters using non-
compartmental analysis were normally distributed. Pharmacokinetic data for each 
genotype GG, AG and AA VKORC1:c.-1639 G>A are summarized in following Table 
53. 
 
Table 53 Differences in vitamin K1 pharmacokinetic parameters between 
VKORC1:c.-1639 G>A groups (uANOVA with regard to gender) 
 
 
 
Pharmacokinetic 
parameter 
 
Genotype       VKORC1:c.-1639 G>A 
 
 
P-value 
 
uANOVA 
 
GG 
 
AG 
 
AA 
p.o. 
tmax                     [min] 181 ± 67
a
 
(120 – 362) 
210 ± 119 
(119 – 481) 
217 ± 132 
(122 – 542) 
n.s. 
Cmax              [ng mL
-1
] 29 ± 11 
(15 – 55) 
30 ± 10 
(14 – 44) 
27 ± 12 
(6 – 46) 
n.s. 
AUC          [ng h mL-1] 145 ± 68 
(94 – 278) 
206 ± 79*
,§
 
(92 – 364) 
132 ± 50 
(45 – 211) 
0.015 
Fp.o.                        [%] 51 ± 20 
(23 – 90) 
73 ± 33
§
 
(38 – 150) 
43 ± 13 
(27 – 70) 
0.011 
CL
b 
            [mL min-1] 253 ± 80 
(116 – 331) 
165 ± 76 
(72 – 338) 
286 ± 160 
(154 – 679) 
n.s. 
t1/2                      [min] 311 ± 54 
(250 – 394) 
457 ± 141
$,§
 
(313 – 787) 
332 ± 48 
(261 – 429) 
0.003 
i.v. 
AUC          [ng h mL-1] 298 ± 97 
(204 – 510) 
318 ± 48 
(238 – 390) 
319 ± 78 
(177 – 453) 
n.s. 
Vss                            [L] 23 ± 8 
(11 – 35) 
25 ± 13 
(10 – 58) 
19 ± 5 
(12 – 27) 
n.s. 
CL               [mL min-1] 118 ± 32 
(64 – 164) 
104 ± 19 
(70 – 136) 
109 ± 33 
(71 – 187) 
n.s. 
t1/2                      [min] 436 ± 186 
(133 – 727) 
492 ± 385 
(194 – 1543) 
383 ± 114 
(158 – 548) 
n.s. 
a
Mean values ± standard deviation with range in parenthesis; n= 10 in each group 
b
Clearance following oral (p.o.) administration CL/F 
*p < 0.05; significantly different from GG (Post-hoc with Tukey) 
§
p < 0.05; significantly different from AA (Post-hoc with Tukey) 
$
p < 0.01; significantly different from GG (Post-hoc with Tukey) 
 
Some of the main parameters such as Cmax and tmax were taken directly from the 
data. Phylloquinone concentration-time curves varied between the volunteers as well 
as when p.o. and i.v. experiments were compared although the general curve shape 
following each route of administration remained similar. The i.v. plasma 
concentration-time curves showed a biexponential decline, suggesting a short initial 
distribution phase followed by an elimination phase. The curves obtained after p.o. 
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route of administration showed an initial absorption phase with a roughly 
monoexponential decay after Cmax was reached. However, there was also a second 
and a third distinct maximum following Cmax which is typical for substances 
undergoing enterohepatic circulation. 
Following oral vitamin K1 administration, pharmacokinetic parameters such as AUC, 
Fp.o. and t1/2 showed statistically significant differences between the VKORC1 
genotype groups (uANOVA model; correspondent p-values are listed in table 53). AG 
subjects exhibited 30 % (p=0.042) and 36 % (p=0.021) higher mean AUC compared 
to GG and AA individuals, respectively. The mean bioavailability for AG carriers was 
41 % higher (p=0.01; Fig.62) than for homozygous AA individuals. Statistically 
significant differences in terminal half-life between groups were also observed. AG 
genotype carriers showed 32 % and 27 % longer t1/2 to GG (p=0.004) and AA 
(p=0.015) genotype carriers, respectively.  
Interestingly, statistically significant differences in bioavailability (Fig.62) and terminal 
half-life (Fig.63) were also found when the results from both groups of homozygous 
individuals (GG + AA) were pooled and compared to those of heterozygous subjects 
(AG). In addition, homozygote carriers of the A-allele showed lower Fp.o. mean value 
compared to GG + AG genotype carriers (Fig.62), whereas homozygous carriers of 
the G-allele exhibited shorter t1/2 compared to the carriers of at least one A allele (AG 
+ AA) (Fig.63). 
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Figure 62 Significant differences (uANOVA with regard to gender) in 
Bioavailability between VKORC1 groups (AG to AA; AG to GG+AA; 
AA to GG+AG) following vitamin K1 p.o. administration 
 
 
 
 
Figure 63 Significant differences (uANOVA with regard to gender) in 
Elimination half-time between VKORC1 groups (AG+AA to GG; 
GG+AA to AG) 
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Following intravenous vitamin K1 administration, statistically significant differences 
between VKORC1 genotype groups were not observed for pharmacokinetic 
parameters AUC, Vss, CL and t1/2 by application of uANOVA analysis (mean values 
shown in Table 53). 
To investigate the role of polymorphisms of other genes such as CYP4F2 and 
ABCC6 on vitamin K pharmacokinetics, differences in main pharmacokinetic 
parameters were assessed in relationship to vitamin K metabolizing enzyme 
genotypes (Table 54). 
 
Table 54 Differences in vitamin K1 pharmacokinetic parameters between 
CYP4F2 (V433M polymorphism; haplotype CYP4F2*3) and ABCC6 
(promoter polymorphism c.-127C>T) group CC and group CT+TT 
 
 
Pharmacokinetic 
parameter 
 
CYP4F2 
 
ABCC6 
CC 
(n = 20) 
CT + TT 
(n = 10) 
CC 
(n = 21) 
CT + TT 
(n = 9) 
p.o. 
tmax                   [min] 209 ± 111
a
 
(119 – 542) 
190 ± 104 
(122 – 481) 
211 ± 120 
(119 – 542) 
184 ± 69 
(122 – 360) 
Cmax            [ng mL
-
1
] 
29 ± 13 
(6 – 55) 
29 ± 8 
(14 – 38) 
29 ± 13 
(6 – 55) 
28 ± 6 
(20 – 38) 
AUC        [ng h mL-1] 160 ± 82 
(45 – 364) 
163 ± 51 
(96 – 262) 
154 ± 81 
(45 – 364) 
176 ± 49 
(106 – 262) 
Fp.o.                      [%] 56 ± 30 
(23 – 150) 
54 ± 17 
(32 – 90) 
52 ± 28 
(23 – 150) 
63 ± 19 
(32 – 92) 
CL
b
           [mL min-1] 248 ± 138 
(72 – 679) 
208 ± 69 
(116 – 331) 
255 ± 133 
(72 – 679) 
187 ± 66 
(116 – 307) 
t1/2                    [min] 366 ± 126 
(250 – 787) 
367 ± 74 
(285 – 524) 
349 ± 76 
(250 – 592) 
409 ± 164 
(259 - 787) 
i.v. 
AUC        [ng h mL-1] 310 ± 81 
(177 – 510) 
322 ± 63 
(219 – 390) 
315 ± 78 
(177 – 510) 
303 ± 71 
(204 – 390) 
Vss                         [L] 20 ± 6* 
(10 – 35) 
27 ± 13 
(12 – 58) 
20 ± 6* 
(11 – 33) 
28 ± 13 
(10 – 58) 
CL            [mL min-1] 112 ± 30 
(64 – 187) 
106 ± 25 
(70 – 148) 
110 ± 28 
(64 – 187) 
112 ± 31 
(70 – 164) 
t1/2                    [min] 386 ± 135 
(133 – 707) 
539 ± 383 
(158 – 1,543) 
402 ± 120 
(194 – 707) 
519 ± 425 
(133 – 1,543) 
 
a
Mean values ± standard deviation with range in parenthesis 
b
Clearance following oral (p.o.) administration CL/F     
*p < 0.05; significantly different from CT+TT ABCC6; uANOVA (with regard to gender) 
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For both, CYP4F2 and ABCC6, two groups were selected: one group of homozygous 
wild-type carriers CC and one group of individuals of at least one T allele (CT + TT). 
For the V433M polymorphism in CYP4F2 gene, mean Vss values differed significantly 
between both groups (uANOVA; p=0.036) and were lower for the wild-type 
individuals. Between ABCC6 genotypes considerable differences in i.v. Vss mean 
values were also observed (uANOVA; p=0.031), in that Vss values were lower for the 
wild-type group (CC-genotype). 
Correlation analysis between vitamin K1 pharmacokinetic parameters and fasting 
plasma triglycerides was performed without stratification for VKORC1 genotypes. For 
each route of phylloquinone administration (p.o. and i.v), triglycerides levels inversely 
correlated significantly with CL (p<0.05), showing Pearson product-moment 
correlation coefficients of about -0.4 (data not shown).   
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4. DISCUSSION 
 
4.1. Enzymological characterization of the VKORC1 
 
To gain insight into the enzymatic characteristics of the VKORC1 with regard to its 
apparent kinetic constants Km and Vmax, various in vitro experiments were performed 
reproducing the step of quinone formation by the VKORC1 using the corresponding 
epoxide as substrate. The enzyme activity was characterized after chromatographic 
separation and quantification of the substrates, vitamin K1 and K2 epoxide, and of 
the corresponding quinone products. 
After calculation of the enzymatic kinetic constants Km and Vmax, the reaction velocity 
as well as the affinity of the substrate for the VKORC1 enzyme could be assessed to 
a certain extent. The study of enzyme kinetics is important for two basic reasons. 
Firstly, it helps to explain how enzymes work, and secondly, it helps to predict how 
enzymes behave in living organisms. The kinetic constants, Km and Vmax, are critical 
to attempts to understand how enzymes work together to control metabolism 84. 
Comparing both substrates and their constants, the Km value i.e. the substrate 
concentration that yields a half-maximal velocity was 1.5 fold higher for K1 than for 
K2. Therefore, the binding affinity of vitamin K2 epoxide to the VKORC1 appears to 
be higher while vitamin K1 epoxide seems to bind in a weaker manner to the 
enzyme. However, Km is not a binding constant that measures the strength of binding 
between the enzyme and substrate.  Its value takes into account the affinity of 
substrate for enzyme, and also the rate at which the substrate bound to the enzyme 
is converted to product. 
With regard to the enzyme velocity extrapolated to very high concentrations of 
substrate, the 1.4 fold higher Vmax value for K2 indicated faster generation of K2 
quinone by the VKORC1 compared with the formation of vitamin K1. 
At this point, it is important to make a note of the gradually reduced VKORC1 activity 
during the process of quinone generation due to product inhibition. Therefore, the 
estimated enzyme constants have some to these experiments bounded validity 98.  
Our measurements showed the higher binding affinity to the VKORC1 for vitamin K1 
whereas vitamin K2 conversion occurs faster. However, a prediction of being a 
“better” and preferred substrate for the enzyme cannot be stated at this point neither 
for K1 nor for K2. To enable evaluation of the real catalytic efficacy, the use of 
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defined enzyme amount is required. Additionally, the generated quinone should be 
removed from the reaction in order to avoid possible product inhibition and masking 
of the estimated enzymatic constants. Until now, no group could either purify the 
VKORC1 or hold off the substrate to enable the estimation of the specific activity.  
To gain deeper insight into the enzymatic characteristics of the VKOR, the VKORC1 
and VKORC1L1, paralog enzymes coexpressed in all tissues at relatively uniform 
levels, and their apparent enzymatic parameters were compared. Both enzymes 
possess both vitamin K 2,3-epoxide reductase (VKOR) and vitamin K quinone 
reductase (VKR) activities, although VKORC1 appears to be specialized to perform 
the VKOR reaction at high turnover rates relative to VKR activity, while our group 
recently proposed that VKORC1L1 is specialized to carry out the VKR reaction at 
high turnover rates relative to measured VKORC1L1-specific VKOR activity 99. 
Consistent with this view, we measured lower apparent Km and Vmax values for VKOR 
activity of VKORC1 compared to the values measured for VKORC1L1 (Table 55). 
VKORC1 showed Km value which was 1.4 fold higher for K1 than for K2 while Km 
value of VKORC1L1 was 5.2 fold lower for K1 compared to K2. This difference in 
determined Km values indicated opposite binding affinity of the isoenzymes to both 
substrates. Considering the enzyme velocity, VKORC1L1 showed 2.1 and 8 fold 
higher turnover for K1 and K2 respectively in comparison to VKORC1. 
 
Table 55 VKOR enzymatic parameters in vitro 
 
Enzyme Substrate Km 
[µM] 
Vmax 
[nmol.mg
-1
.h
-1
] 
VKORC1 K1O 2.34 1.20 
VKORC1 K2O 1.56 1.69 
VKORC1L1 K1O 4.15* 2.57* 
VKORC1L1 K2O 11.24* 13.46* 
* original data from Westhofen et al. 
 
At this point, it could be referred to the assumption of different functions of both 
isoenzymes. VKORC1L1 was reported not to be able to support adequate VKOR 
activity to substitute for the function of VKORC1 in VKORC1-/- mice 100. We 
hypothesize that VKOR enzymatic activity is the primary physiological enzymatic 
function of VKORC1L1 which is consistent with our findings that VKORC1L1 
supports vitamin K-mediated intracellular antioxidative mechanisms 99. 
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4.2. Bioanalytical method validation of vitamin K determination 
 
The modified HPLC method for vitamin K analysis in serum samples with 
fluorescence detection after post-column zinc reduction was validated according to 
the guidances for Bioanalytical Method Validation 92,93 of the International 
Conference of Harmonization for the intended purpose of use. The main purpose 
was to investigate the utility of the method to simultaneously define the kinetics of 
vitamin K1 and measure the extent to which oral doses are absorbed. 
Concerning the fundamental parameters to ensure the acceptability of the 
performance such as accuracy, precision, selectivity, sensitivity, reproducibility, and 
stability, the method was tested thoroughly and it showed good reproducible results 
within the acceptable ranges regarding each particular parameter. Finally, all the 
required criteria were met. 
To prove and warrant the practical applicability of the method for vitamin K 
determination in human serum, our laboratory participated in the vitamin K quality 
assurance scheme (KEQAS) representing robin-round tests and described as 
External Quality Assurance. The performance of these tests assisted in the 
development and harmonization of vitamin K analysis and tested the quality of 
vitamin K analysis. 
Within KEQAS, the performance of participating groups was assessed by 
comparison of each group´s percentage absolute difference from the ALTM, i.e. all 
laboratory trimmed mean representing the target concentration, in consideration of 
the fact that there is no particular reference laboratory stated and no gold standard 
method for vitamin K analysis defined. 
In the overall inter-laboratory assessment for low and high vitamin K serum 
concentrations, our group achieved Z score between 0.0 and 1.8. Our results, 
compared to the corresponding KEQAS consensus means, were indicative of good 
to very good performance. To what extent the other participating groups basically 
yield low- or high-leaning values, depended in the main on the used method for 
vitamin K analysis in human serum. 
There is a perceived need to harmonize serum K measurements by quantifying inter-
laboratory variation for vitamin K analysis in serum and developing an ongoing 
international scheme. Thereby, analytical performance can be gauged and 
participants encouraged to improve the accuracy of their analyses. 
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A number of HPLC assays using various detection systems have been reported. 
These include UV 101,102, electrochemical 101,103, electrofluorimetric 101, and 
postcolumn chemical reduction with fluorescence detection 86,87,104. The latter 
technique has been shown to be inherently more selective, sensitive, and 
reproducible86,87. Postcolumn chemical reduction of K vitamins is usually achieved by 
using a zinc reducer system- metallic/ ionic zinc 86,87,104. This system suffers from an 
impediment upon exhaustion of the supply of zinc in the reducer column. The 
shrinking zinc particles pass through the reducer column frits that limits the useful life 
of the reducer column and releases damaging particles into the HPLC system, 
leading to baseline shifts. In our experience, the zinc reducer column had to be 
replaced after every batch run of 40 samples to maintain optimal reduction and 
chromatographic performance which was proved to be sufficient for our purpose of 
use regarding pharmacokinetics of vitamin K1 within 24 hours after single-dose 
administration. The method allows analysis of up to 40 serum samples during a day 
and shows additionally the versatility by working with human serum or plasma as well 
as with organic tissues. The reported methods for the extraction of vitamin K from 
plasma or serum are labor intensive, all requiring multiple extraction procedures to 
remove lipophilic interferences. The single solid-phase extraction procedure for 
sample cleanup and concentration of vitamin K compounds, including the internal 
standard K1(25), showed good effectiveness with no interference from impurities and 
endogenous compounds. The internal standard is a structural analog of 
phylloquinone 86,87 and not present in biological material. The phylloquinone and 
menaquinone-4 peaks and that of internal standard were well separated during 
chromatographic analysis from matrix signals both in serum or plasma. The identity 
of the analyte was confirmed by the tests mentioned above. Intra- and interday 
repeatability was adequate as well as recovery testing. For the serum, a limit of 
detection of 0.03 nmol/ L (0.015 ng/ mL) was found, which indicates an about 3 fold 
higher sensitivity compared to assays, previously reported 86,87,103-105.  
The method fulfilled all analytical standard criteria. It provided high specificity for K 
vitamins that could be directly detected without conversion to other derivatives. We 
examined recovery and accuracy using pool serum. Each peak of the vitamin K 
analogues was clearly resolved as a single peak within a separation time of 20 
minutes. These results proved the system to be reliable and reproducible for the 
measurement of serum vitamin K. The reliability of the HPLC method was evaluated 
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based on the variation in retention times. The relative standard deviation, calculated 
from retention times obtained from over 40 injections, proved to be less than 1% for 
all compounds, indicating good chromatographic stability. The assay provides a rapid 
and relatively easy-to-use approach to the quantification of vitamin K analogues in 
human serum without compromising assay sensitivity and shows good reproducible 
results within the acceptable ranges regarding each particular validation parameter. 
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4.3. Vitamin K levels in mouse tissue 
 
K vitamins were found in all mice tissues investigated, however their levels varied 
greatly (3.3., table 21). Both their absolute tissue concentrations and the ratio 
between K1 and MK4 were tissue-dependent. The tissues which were examined 
originated from mice fed a conventional laboratory chow diet. 
Basically, tissue-distribution patterns of K vitamins did not differ highly between male 
and female mice, although the levels of vitamin K1 (phylloquinone) and vitamin K2 
(menaquinone-4) were relatively higher in the females in comparison to those in the 
males. In general, tissue concentrations of MK4 exceed those of K1 in all tissues 
examined except for liver and ovary. Relatively high levels of phylloquinone were 
found in liver, testis and salivary gland (> 200 pmol/ g tissue), while very high levels 
were detected in ovary and uterus (> 800 pmol/ g tissue). Most other tissues 
contained less than 200 pmol/ g phylloquinone. In contrast, relatively high MK4 levels 
(> 200 pmol/ g tissue) were found in lung, bone, muscle and salivary gland, while 
very high MK4 concentrations (> 800 pmol/ g tissue) were measured in almost all the 
other tissues (pancreas, kidney, heart, brain, ovary, uterus and testis). The heart 
contained the lowest MK4 amount (< 200 pmol/ g tissue). There was no consistent 
correlation between the tissue levels of K1 and MK4. 
Interestingly, the gender specific differences in vitamin K levels seemed to be higher 
for K1 compared to MK4 within the tissue. Thus, the ratio K1 to MK4 was 1.5-fold 
higher on the average for females and all tissues except for heart. 
Okano et al. 49 described a similar tissue distribution of vitamin K in mice fed a 
normal diet. In general, higher K1 and MK4 levels were found in females compared 
to those in males. The absolute vitamin K values are not directly comparable with our 
results. This could be due to analytical differences such as varying preparation 
procedures of the tissues and different methods of detection. In contrast to our 
method, Okano et al. used LC-MS methodology and the vitamin K concentration was 
given in pmol per g wet weight tissue 49 while we indicate the levels in pmol per g dry 
weight tissue. However, it is possible to neglect these different ways of data 
demonstration and to draw comparative conclusions from the ratios K1 to MK4 in the 
mice tissues examined during the experiments. Interestingly, upon close inspection 
of the data from Okano it appears that the differences in vitamin K levels between 
males and females seemed to be lower for K1 compared to those for MK4 within the 
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tissue. It is therefore obvious that the ratio K1 to MK4 is 1.4-fold lower on the average 
for females and all tissues except for heart and pancreas. 
The K1 to MK4 ratios we found in muscle and heart in males are comparable with 
those described by Okano et al. All the other ratios except for heart in females 
demonstrated in this study were nearly 10-fold lower in comparison to our results 
which remains unexplained. This difference may derive from the difference in the 
amount of vitamin K in the diets used as well as from the varying working procedures 
and detection methods, i.e. from the analytical procedure. 
In view of the results from rats 106 and humans 48 regarding the tissue distribution of 
vitamin K, the presented K1 to MK4 ratio in the liver supported our measurement due 
to the fact that phylloquinone concentration in this tissue remarkably exceeded the 
level of MK4. In contrast, Okano et al. found lower K1 concentration in the liver 
compared to MK4. 
The study from Ronden et al. 106 demonstrated tissue-dependent ratios between K1 
and MK4 which are good comparable with our results except for heart. Consistent 
with this report, more K1 was found in heart in comparison to MK4 level. The 
significantly higher MK4 amount in diverse tissues may be explained by vitamin K 
accumulation in extrahepatic tissues and assuming that nutritional K1 had been 
converted into MK4. Tissue K1 and MK4 levels in the sum can be regarded as the 
accumulated vitamin K after a certain dietary regimen. Amounts of accumulated 
vitamin K differ widely from one tissue to another, thereby the liver is unique in its 
selective accumulation of K1. Other tissues (like pancreas and testis) seem to have a 
substantially higher preference for MK4 than for K1. 
Thijssen et al. 48 showed that in man there are tissue-specific, vitamin K distribution 
patterns comparable to our results and to those in the rat except for pancreas and 
heart. This observational study on vitamin K contents in human tissues demonstrated 
the specific accumulation of K1 and/ or MK4 in the different human organs. 
In conclusion, the comparison of our data with recently published vitamin K tissue 
levels in mice, rats and humans either using absolute values or the ratio of K1 to 
MK4 ranges from good agreement to poor accordance. These differences in storing 
of the samples, work-up procedures and detection methodologies could be balanced 
by harmonizing the procedures for analyses of vitamin K1 and MK4. A rational 
approach is the use of robin-round tests, spreading well defined samples containing 
K vitamins at a low and higher range. This should be done by reference laboratories, 
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which finally discuss the measured results from all the laboratories taking part in such 
a trial. 
Accumulation of K1 and MK4 was found in all tissues investigated. Thereby, both the 
absolute tissue concentration and the ratio between K1 and MK4 were tissue-
dependent. This may be linked to the fact that many of the vitamin K dependent 
(VKD) proteins (e.g., the transmembrane Gla proteins, matrix Gla protein and Gas6) 
show widespread tissue distribution, and virtually every tissue expresses vitamin K 
dependent carboxylase activity. This distribution and the diverse range of functions 
for VKD proteins in hemostasis, apoptosis, bone mineralization, calcium 
homeostasis, growth control, and signal transduction implicate a broad biological 
impact of K vitamins as reviewed by Berkner 107. 
Many studies and overviews demonstrate the essential role of vitamin K and VKD 
proteins in the different tissues and organs which is especially investigated for 
humans. The liver with high hepatic accumulation of K1 is the main site of hemostatic 
VKD protein synthesis. Vitamin K is absolutely necessary as a co-factor of γ-
carboxylase, an enzyme responsible for functional active blood coagulation factors. 
Due to hereditary conditions such as mutations in VKORC1 or γ-carboxylase (GGCX) 
or to acquired pathophysiological conditions like vitamin K deficiency due to 
malnutrition/malabsorption, coumarin poisoning, or autoimmune response to 
VKORC1/ GGCX, a severe bleeding phenotype is observed. In some cases, 
especially due to acquired pathophysiologies, high doses of vitamin K can reverse 
the bleeding phenotype.   
Furthermore, in recent years the vitamin K antitumor effects have been closely 
examined. The suppressive effects of vitamin K2 on tumor recurrence after curative 
treatment for hepatocellular carcinoma (HCC) were clinically investigated on the 
basis of reports of the antitumor effects of vitamin K on various cancers 108. 
Consistent with this report was showed that vitamin K2 administration significantly 
suppressed HCC recurrence by suppressing cyclin D1 expression through inhibition 
of NF-kappa B activation. 
Moreover as described by Arai et al. 109, vitamin K-dependent growth factor (Gas6) 
has a significant role in the pathogenesis of diabetic nephropathy. 
Bügel 110 reviews the role of K vitamins in bone health in adult humans with regard to 
osteocalcin, another VKD protein, and thereby in the prevention of osteoporosis. 
Several studies have demonstrated that vitamin K insufficiency is associated with low 
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bone mineral density (BMD) and increased fractures. Vitamin K supplementation, on 
the other hand, has been shown to improve the bone turnover profile. 
Matrix Gla protein (MGP), another VKD protein in calcium homoeostasis 111, 
regulates calcium metabolism predominantly in the extracellular matrix of soft tissue. 
MGP is expressed in almost all soft tissues with highest levels of expression found in 
vascular tissue, heart, lung, kidney and cartilage 112, where MGP serves as a central 
inhibitor of tissues  calcification . This can allude to the vitamin K presence in these 
tissues at high levels. 
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4.4. Pharmacokinetic analysis – preliminary studies in human 
volunteers 
 
First application of the HPLC method in a pharmacological study on the 
pharmacokinetics of vitamin K1 
 
As first application of the HPLC method for vitamin K serum determination served 
analysis of samples from an exploratory study on the pharmacokinetics of vitamin K1. 
There are only a few reports about direct measurements of serum concentrations of 
vitamin K after oral, intravenous or intramuscular single-dose administration 113-117. 
As soon as sensitive analytical methods for vitamin K determination were introduced 
86,101,102,104, information on the kinetics of phylloquinone became available. The 
methods showed sufficient sensitivity to enable detection of vitamin K1 in pg mL-1 
range and thus allowed profiling of phylloquinone levels for many hours to days after 
administration. 
Our study of the i.v. and p.o. pharmacokinetics of vitamin K1 as Konakion® MM 2 mg 
showed considerable differences between both repeated dosing occasions and 
between subjects. The pharmacokinetic results were indicative of intra- and inter-
subject variability. The general shape of  plasma concentration-time curves following 
p.o. and i.v (see section 3.4.2.1) administration remained similar during the two year 
interval although the systemic exposure in terms of Cmax and AUC showed changes. 
The i.v. plasma concentration-time curves showed a biexponential decline, 
suggesting a short intial distribution phase followed by an elimination phase. The 
curves obtained after p.o. route of administration showed an intial absorption phase 
with a roughly monoexponential decay after Cmax was reached. However, there was 
also a second distinct maximum following Cmax which is typical for substances 
undergoing enterohepatic circulation.  
The mean clearance rate of 95 and 111 mL min-1 for volunteer A and B, respectively, 
found in our experiments is within the range of those that were calculated from 
previous data of phylloquinone behavior upon injection which varied from 60 to 128 
mL min-1 113,118-120. The corresponding mean terminal half-lives of 3.5 h after i.v. 
administration and 5.4 h after p.o. intake were also well comparable with previously 
published data 113. Interestingly, phylloquinone serum half-lives in patients with 
severe acute liver disease were approximately two-fold longer than those found in 
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subjects with normal hepatic function 116. Furthermore, terminal half-lives of vitamin 
K1 in newborns were also considerably longer compared to adults 115. 
Oral administration of phylloquinone revealed  substantial inter- and intra-individual 
variations in the bioavailability of this compound. Comparing both experiments, a 
considerable increase from 54 % to 80 % for volunteer A and a decrease from 97 % 
to 53 % for volunteer B was noted during the two-year interval. The differences in 
volunteer B might have been caused by significant loss of body weight and change in 
life-style. Hence, observed differences may be explained by intra- and inter-individual 
variation in dietary intake, transport and uptake of vitamin K as well as in lipoprotein 
metabolism, especially regarding triglyceride-enriched lipoproteins (VLDL)9,41 and 
other determinants of vitamin K status. All these findings affirm the importance of 
standardizing trial procedures including co-medication when performing 
pharmacokinetic experiments. 
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4.5. Pharmacokinetic analysis – phase I clinical study 
 
Inter-individual variance in pharmacokinetics of intravenous and oral 
phylloquinone (vitamin K1) mixed micelles formulation 
 
The present exploratory phase I clinical study was designed to determine inter-
individual variance in pharmacokinetics of intravenous and oral phylloquinone 
(vitamin K1) mixed micelles formulation as well as to explore a possible effect of the 
VKORC1 promoter polymorphism c.-1639 G>A on the metabolism of phylloquinone, 
by means of correlating pharmacokinetic properties with the different genotypes in 
humans. There are only a few reports about the pharmacokinetics of vitamin K after 
oral, intravenous or intramuscular single-dose administration 113-117. The investigation 
was performed in a representative group of healthy volunteers. The trial showed 
statistically significant difference in bioavailability after oral administration of 
phylloquinone between VKORC1 genotype groups (particularly by comparison of AG 
individuals to AA carriers). Fp.o. values were in accordance with data from previous 
studies 121 and revealed substantial inter-individual variability. It is noteworthy that the 
highest bioavailability was found in heterozygotes, carriers of the AG-genotype; 
furthermore, it was higher for males than to to females (data not shown). Therefore, 
this finding cannot be physiologically allegeable and might be indicative of certain 
heterozygote advantage in terms of phylloquinone availability in the human body 
where vitamin K is mostly required for blood coagulation but is also involved in 
metabolic pathways in bone and other tissue. In view of the multifunctional role of this 
vitamin in the human body, an evolutionary enrichment in individuals with a potential 
of high vitamin K exposure in the population seems reasonable. However, the 
mechanism by which the VKORC1 AG genotype would yield the highest 
bioavailability compared to the other polymorphisms remains to be elucidated. 
Moreover, it must be noted that AA genotype carriers showed the lowest 
phylloquinone bioavailability. This fact could play a role, for instance, when vitamin K 
adjustment in unstable patients under warfarin therapy is required or vitamin K has to 
be supplemented orally to antagonize intoxications with rodenticides. 
Considering retrospectively other genes involved in vitamin K metabolism and tissue 
distribution, such as CYP4F2 and ABCC6 polymorphisms, considerable difference in 
intravenous Vss between phenotypes was shown, whereas other pharmacokinetic 
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parameters seemed not to be influenced. However, to obtain a deeper insight into 
such a relationship further investigations with more subjects are needed. 
The degree of considerable differences in terminal half-life, is also apparent from this 
study. Terminal half-lives following oral and intravenous phylloquinone administration 
were considerably longer for VKORC1 heterozygotes compared to the homozygous 
carriers. This observation remained also valid after pooling both homozygous groups, 
GG and AA genotypes, together and comparing them to the AG genotype carriers. 
The estimated mean terminal half-lives of 6.1 h after oral phylloquinone 
administration were comparable with previously published data 113 . In contrast, the 
mean terminal half-life of 7.3 h following intravenous administration was longer than 
previous data, but can be explained by one subject showing an extremely long value. 
It should be noted that all observed significant differences between groups remain 
valid even after excluding this individual from the analysis.  
The liver is the primary eliminating organ, as is evident from previously published 
studies in patients with severe acute liver disease, where phylloquinone serum half-
lives were approximately twice longer than those found in subjects with normal 
hepatic function 116. Moreover, terminal half-lives of vitamin K1 in newborns were 
also considerably longer compared to adults 115. Based on our findings, it can be 
suggested that the highest phylloquinone bioavailability in VKORC1 heterozygotes 
can be aligned with lower clearance and a potential of higher systemic exposure to 
vitamin K in these subjects.  Furthermore, provided that hepatic metabolism is the 
major route of elimination, lower clearance indicates lower hepatic uptake and/ or 
vitamin K metabolism in VKORC1 AG genotype carriers. Theoretically, differences in 
body composition (fatty tissue) and transporting triglyceride-enriched lipoproteins 
(VLDL)9,41 could affect tissue distribution and elimination rates for a lipid soluble 
compound such as vitamin K. However, in this study there were no significant 
differences in Vss between groups, and inclusion of plasma triglyceride levels as a 
potential influencing factor in uANOVA did not diminish the significance of differences 
in Fp.o. between groups.    
In conclusion, significant inter-individual pharmacokinetic variance of vitamin K fate in 
the human body could be indicated. Further, an influence of the VKORC1 promoter 
polymorphism c.-1639 G>A on the pharmacokinetic properties of phylloquinone in 
humans was shown. Significant differences in main pharmacokinetic parameters 
such as bioavailability and terminal half-life between groups suggest corresponding 
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differences in processing of vitamin K in the human body. The relevance of 
polymorphisms in CYP4F2 and ABCC6 in this regard must be further elucidated in an 
enlarged sampling. The clinical importance of potential genetic determinants of 
vitamin K status should be further investigated with respect to effects on absorption, 
distribution, metabolism and elimination of vitamin K. 
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5. SUMMARY 
The main objective of the present work by means of a phase I clinical study was to 
determine inter-individual variance in pharmacokinetics of intravenous and oral 
phylloquinone (vitamin K1) mixed micelles formulation in humans as well as to 
explore a possible effect of the VKORC1 promoter polymorphism c.-1639 G>A on the 
metabolism of phylloquinone. The pharmacokinetics of phylloquinone mixed micelles 
formulation (Konakion® MM 2 mg) were evaluated, in healthy human adult volunteers 
(n=30; 15 m, 15 f) using an open phase I design protocol upon oral and intravenous 
administration. The probands were subjected equally distributed (n=10; 5 m, 5 f) to 
three genotype-specific groups regarding VKORC1 promoter polymorphism c.-1639 
G>A (GG, AG and AA) to explore their relationship to specific pharmacokinetic 
parameters. Phylloquinone serum levels were determined by reversed phase HPLC 
with fluorometric detection after post-column zinc reduction. The method proved to 
be highly accurate, robust and reliable and showed a limit of detection and 
quantification of 0.015 ng mL-1 and 0.15 ng mL-1, respectively. Measured 
phylloquinone serum concentrations were subjected to pharmacokinetic evaluation 
using a non-compartment analysis. Pharmacokinetic analysis of serum phylloquinone 
concentration versus time profiles revealed significant differences in main 
pharmacokinetic parameters. Significant inter-individual pharmacokinetic variance of 
vitamin K fate in the human body could be indicated. Further, an influence of the 
VKORC1 promoter polymorphism c.-1639 G>A on the pharmacokinetic properties of 
phylloquinone in humans was shown. Significant differences in main pharmacokinetic 
parameters such as bioavailability and terminal half-life between groups suggest 
corresponding differences in processing of vitamin K in the human body. The 
relevance of polymorphisms in CYP4F2 and ABCC6 in this regard must be further 
elucidated in an enlarged sampling. The clinical importance of potential genetic 
determinants of vitamin K status should be further investigated with respect to effects 
on absorption, distribution, metabolism and elimination of vitamin K. 
Furthermore, the enzymatic characteristics of the VKORC1 were examined by 
studying its enzyme kinetics. Comparing vitamin K1 and K2 as substrates and their 
apparent kinetic constants Km and Vmax, the binding affinity of vitamin K2 epoxide to 
the VKORC1 appears to be higher while vitamin K1 epoxide seems to bind in a 
weaker manner to the enzyme. 
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6. Appendix                    Table I Pharmacokinetic parameters of group GG, female, p.o. 
 
 
 GG_01_F_po GG_02_F_po 
 
GG_03_F_po GG_04_F_po GG_05_F_po Mean ± S.E.M. 
tmax                    [min] 150 362 183 151 120 193 ± 43 
Cmax          [ng mL
-1
] 27 28 30 26 42 31 ± 3 
Cmax_D                 [L
-1
] 0.01 0.01 0.01 0.01 0.02 0.02 ± 0.001 
Tlast                    [min] 1445 1443 1447 1432 1440 1441 ± 3 
Clast             [ng mL
-1
] 0.61 0.54 2.60 0.87 0.47 1.02 ± 0.40 
AUCall      [ng h mL
-1
] 96 103 262 111 127 140 ± 31 
AUC0_600  [ng h mL
-1
] 76 82 156 77 104 99 ± 15 
F0_600                    [%] 31 26 56 16 43 34 ± 7 
AUCINFobs [ng h mL
-1
] 101 107 287 118 130 148 ± 35 
Finf                                    [%] 40 32 90 23 50 47 ± 12 
Vz_F_obs           [L µg
-1
] 136 136 65 143 100 116 ± 15 
ClF_obs       [mL min
-1
] 331 311 116 282 257 259 ± 38 
Rsq 0.855 0.997 0.790 0.836 0.900 0.875 ± 0.035 
CorrXY -0.925 -0.998 -0.889 -0.914 -0.949 -0.935 ± 0.019 
ƛz No_points 
14 5 12 13 14 12 ± 1.7 
ƛz  
0.0024 0.0023 0.0018 0.0020 0.0026 0.0022 ± 0.0001 
ƛz lower 
180 461 212 213 180 249 ± 53 
ƛz upper 
1445 1443 1447 1432 1440 1441 ± 3 
t½ƛz                   [min] 
285 303 389 352 270 320 ± 22  
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Table II Pharmacokinetic parameters of group AG, female, p.o. 
 
 AG_01_F_po AG_02_F_po 
 
AG_03_F_po AG_04_F_po AG_05_F_po Mean ± S.E.M. 
tmax                    [min] 122 119 151 120 360 174 ± 47 
Cmax          [ng mL
-1
] 20 30 37 42 20 30 ± 4 
Cmax_D                 [L
-1
] 0.01 0.02 0.02 0.02 0.01 0.02 ± 0.002 
Tlast                    [min] 1440 1441 1453 1442 1435 1442 ± 3 
Clast             [ng mL
-1
] 0.77 1.12 2.68 1.87 1.88 1.66 ± 0.33 
AUCall      [ng h mL
-1
] 92 132 219 239 176 172 ± 27 
AUC0_600  [ng h mL
-1
] 68 96 143 171 108 117 ± 18 
F0_600                    [%] 27 34 41 51 31 37 ± 4 
AUCINFobs [ng h mL
-1
] 99 143 253 256 193 189 ± 31 
Finf                                    [%] 38 46 53 68 55 52 ± 5 
Vz_F_obs           [L µg
-1
] 178 141 100 72 93 117 ± 19 
ClF_obs       [mL min
-1
] 338 233 132 130 173 201 ± 39 
Rsq 0.884 0.917 0.849 0.767 0.761 0.836 ± 0.031 
CorrXY -0.940 -0.958 -0.921 -0.876 -0.873 -0.914 ± 0.017 
ƛz No_points 
13 11 12 14 9 12 ± 0.9 
ƛz 
0.0019 0.0017 0.0013 0.0018 0.0019 0.0017 ± 0.0001 
ƛz lower 
212 284 242 183 330 250 ± 26 
ƛz upper 
1440 1441 1453 1442 1435 1442 ± 3 
t½ƛz                   [min] 
364 419 524 382 373 412 ± 29 
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Table III Pharmacokinetic parameters of group AA, female, p.o. 
 
 
 AA_01_F_po AA_02_F_po 
 
AA_03_F_po AA_04_F_po AA_05_F_po Mean ± S.E.M. 
tmax                    [min] 122 359 542 150 150 265 ± 81 
Cmax          [ng mL
-1
] 27 24 10 37 26 25 ± 4 
Cmax_D                 [L
-1
] 0.01 0.01 0.01 0.02 0.01 0.01 ± 0.002 
Tlast                    [min] 1428 1433 1428 1440 1440 1434 ± 3 
Clast             [ng mL
-1
] 0.82 1.34 1.31 0.95 0.37 0.96 ± 0.18 
AUCall      [ng h mL
-1
] 117 140 102 149 75 116 ± 13 
AUC0_600  [ng h mL
-1
] 87 87 57 108 60 80 ± 9 
F0_600                    [%] 27 28 20 30 23 26 ± 2 
AUCINFobs [ng h mL
-1
] 124 150 113 156 77 124 ± 14 
Finf                                    [%] 33 46 35 41 28 37 ± 3 
Vz_F_obs           [L µg
-1
] 133 96 153 103 183 134 ± 16 
ClF_obs       [mL min
-1
] 269 223 295 213 4322 286 ± 39 
Rsq 0.907 0.994 1.000 0.836 0.934 0.934 ± 0.030 
CorrXY -0.953 -0.997 -1.000 -0.914 -0.967 -0.966 ± 0.016 
ƛz No_points 
13 3 2 14 9 8 ± 2.5 
ƛz  
0.0020 0.0023 0.0019 0.0021 0.0024 0.0021 ± 0.0001 
ƛz lower 
219 540 600 180 326 373 ± 84 
ƛz upper 
1428 1433 1428 1440 1440 1434 ± 3 
t½ƛz                   [min] 
342 298 360 336 294 326 ± 13 
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Table IV Pharmacokinetic parameters of group GG, male, p.o. 
 
 GG_01_M_po GG_02_M_po 
 
GG_03_M_po GG_04_M_po GG_05_M_po Mean ± S.E.M. 
tmax                    [min] 180 150 180 182 150 168 ± 8 
Cmax          [ng mL
-1
] 55 23 23 15 22 28 ± 7 
Cmax_D                 [L
-1
] 0.03 0.01 0.01 0.01 0.01 0.01 ± 0.004 
Tlast                    [min] 1438 1439 1433 1447 1462 1444 ± 5 
Clast             [ng mL
-1
] 0.81 0.91 0.44 0.87 0.62 0.73 ± 0.09 
AUCall      [ng h mL
-1
] 278 120 106 94 148 149 ± 34 
AUC0_600  [ng h mL
-1
] 207 81 76 64 104 106 ± 26 
F0_600                    [%] 54 40 38 24 53 42 ± 5 
AUCINFobs [ng h mL
-1
] 283 127 109 102 152 155 ± 33 
Finf                                    [%] 68 56 53 34 68 56 ± 6 
Vz_F_obs           [L µg
-1
] 42 129 116 186 82 140 ± 52 
ClF_obs       [mL min
-1
] 118 262 307 327 219 247 ± 37 
Rsq 0.835 0.849 0.860 0.805 0.920 0.858 ± 0.018 
CorrXY -0.924 -0.922 -0.927 -0.897 -0.959 -0.926 ± 0.010 
ƛz No_points 
13 13 12 13 12 13 ± 0.2 
ƛz  
0.028 0.0020 0.0026 0.0018 0.0027 0.0024 ± 0.0002 
ƛz lower 
211 209 238 213 240 222 ± 7 
ƛz upper 
1438 1439 1433 1447 1462 1444 ± 5 
t½ƛz                   [min] 
250 341 262 394 259 301 ± 28 
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Table V Pharmacokinetic parameters of group AG, male, p.o. 
 
 
 AG_01_M_po AG_02_M_po 
 
AG_03_M_po AG_04_M_po AG_05_M_po Mean ± S.E.M. 
tmax                    [min] 210 180 149 481 210 246 ± 60 
Cmax          [ng mL
-1
] 44 25 30 14 39 31 ± 5 
Cmax_D                 [L
-1
] 0.02 0.01 0.02 0.01 0.02 0.02 ± 0.003 
Tlast                    [min] 1441 1481 1440 1422 1440 1445 ± 10 
Clast             [ng mL
-1
] 6.85 3.99 1.15 2.99 3.57 3.71 ± 0.92 
AUCall      [ng h mL
-1
] 364 193 169 177 296 240 ± 39 
AUC0_600  [ng h mL
-1
] 218 101 122 92 189 144 ± 25 
F0_600                    [%] 75 39 55 31 60 52 ± 8 
AUCINFobs [ng h mL
-1
] 462 269 177 208 330 289 ± 51 
Finf                                    [%] 150 92 72 60 97 94 ± 15 
Vz_F_obs           [L µg
-1
] 61 141 85 98 58 89 ± 15 
ClF_obs       [mL min
-1
] 72 124 188 161 101 129 ± 21 
Rsq 0.712 0.692 0.907 1.000 0.953 0.853 ± 0.063 
CorrXY -0.844 -0.832 -0.952 -1.000 -0.976 -0.921 ± 0.035 
ƛz No_points 
10 11 13 4 12 10 ± 1.6 
ƛz 
0.0012 0.0009 0.0022 0.0016 0.0017 0.0015 ± 0.0002 
ƛz lower 
299 274 211 481 240 301 ± 47 
ƛz upper 
1441 1481 1440 1422 1440 1445 ± 10 
t½ƛz                   [min] 
592 787 313 423 397 502 ± 84 
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Table VI Pharmacokinetic parameters of group AA, male, p.o. 
 
 AA_01_M_po AA_02_M_po 
 
AA_03_M_po AA_04_M_po AA_05_M_po Mean ± S.E.M. 
tmax                    [min] 150 185 180 150 182 169 ± 8 
Cmax          [ng mL
-1
] 46 6 38 27 24 28 ± 7 
Cmax_D                 [L
-1
] 0.02 0.01 0.02 0.01 0.01 0.01 ± 0.003 
Tlast                    [min] 1435 1438 1440 1440 1432 1437 ± 2 
Clast             [ng mL
-1
] 0.87 0.47 2.02 1.98 0.84 1.23 ± 0.32 
AUCall      [ng h mL
-1
] 211 45 190 163 128 147 ± 29 
AUC0_600  [ng h mL
-1
] 163 32 127 93 101 103 ± 22 
F0_600                    [%] 40 19 39 38 36 34 ± 4 
AUCINFobs [ng h mL
-1
] 216 49 210 180 134 158 ± 31 
Finf                                    [%] 46 28 55 71 45 49 ± 7 
Vz_F_obs           [L µg
-1
] 58 344 98 95 105 140 ± 52 
ClF_obs       [mL min
-1
] 154 679 158 186 248 285 ± 100 
Rsq 0.950 0.870 0.888 1.000 0.950 0.932 ± 0.023 
CorrXY -0.975 -0.933 -0.943 -1.000 -0.974 -0.965 ± 0.012 
ƛz No_points 
13 11 8 2 11 9 ± 1.9 
ƛz  
0.0027 0.0020 0.0016 0.0019 0.0024 0.0021 ± 0.0002 
ƛz lower 
210 274 363 600 270 343 ± 69 
ƛz upper 
1435 1438 1440 1440 1432 1437 ± 2 
t½ƛz                   [min] 
261 351 429 357 294 338 ± 29 
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Table VII Pharmacokinetic parameters of group GG, female, i.v. 
 
 GG_01_F_iv GG_02_F_iv 
 
GG_03_F_iv GG_04_F_iv GG_05_F_iv Mean ± S.E.M. 
tmax                    [min] 7 5 5 5 5 5 ± 0.4 
Cmax          [ng mL
-1
] 356 414 384 597 319 414 ± 48 
Cmax_D                 [L
-1
] 0.18 0.21 0.19 0.30 0.16 0.21 ± 0.2 
C0                [ng mL
-1
] 565 554 486 862 442 582 ± 73 
Tlast                    [min] 1440 1454 1443 1444 1458 1448 ± 3 
Clast             [ng mL
-1
] 0.38 0.78 1.01 0.87 0.25 0.66 ± 0.15 
AUCall      [ng h mL
-1
] 250 329 301 510 257 330 ± 47 
AUC0_600  [ng h mL
-1
] 241 312 279 484 242 312 ± 45 
AUCINFobs [ng h mL
-1
] 255 338 319 519 259 338 ± 48 
Vss_obs                [L] 18 19 29 11 18 19 ± 3 
Vz_obs                     [L] 89 73 110 39 41 70 ± 14 
Clobs          [mL min
-1
] 131 99 105 64 129 105 ± 12 
Rsq 0.953 0.878 1.000 0.981 1.000 0.962 ± 0.023 
CorrXY -0.976 -0.937 -1.000 -0.990 -1.000 -0.981 ± 0.012 
ƛz No_points 
4 4 3 4 2 3 ± 0.4 
ƛz  
0.0015 0.0014 0.0010 0.0016 0.0031 0.0017 ± 0.0004 
ƛz lower 
482 480 540 479 783 553 ± 59 
ƛz upper 
1440 1454 1443 1444 1458 1448 ± 3 
t½ƛz                   [min] 
469 511 727 423 222 470 ± 81 
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Table VIII Pharmacokinetic parameters of group AG, female, i.v. 
 
 AG_01_F_iv AG_02_F_iv 
 
AG_03_F_iv AG_04_F_iv AG_05_F_iv Mean ± S.E.M. 
tmax                    [min] 5 6 5 5 5 5 ± 0.2 
Cmax          [ng mL
-1
] 320 301 430 425 485 392 ± 35 
Cmax_D                 [L
-1
] 0.16 0.15 0.21 0.21 0.24 0.20 ± 0.02 
C0                [ng mL
-1
] 447 333 505 566 600 490 ± 47 
Tlast                    [min] 1454 1436 1459 1448 1435 1446 ± 5 
Clast             [ng mL
-1
] 0.21 0.82 2.38 0.94 0.26 0.92 ± 0.39 
AUCall      [ng h mL
-1
] 261 301 390 365 353 334 ± 23 
AUC0_600  [ng h mL
-1
] 251 281 353 337 343 313 ± 20 
AUCINFobs [ng h mL
-1
] 263 311 478 376 355 356 ± 36 
Vss_obs                [L] 16 23 58 20 10 25 ± 8 
Vz_obs                     [L] 55 78 155 61 44 79 ± 20 
Clobs          [mL min
-1
] 127 107 70 89 94 97 ± 10 
Rsq 1.000 0.980 0.594 0.969 0.993 0.907 ± 0.079 
CorrXY -1.000 -0.990 -0.771 -0.985 -0.997 -0.948 ± 0.045 
ƛz No_points 
3 3 3 4 4 3 ± 0.2 
ƛz  
0.0023 0.0014 0.004 0.0014 0.0021 0.0015 ± 0.0003 
ƛz lower 
538 541 540 485 480 517 ± 14 
ƛz upper 
1454 1436 1459 1448 1435 1446 ± 5 
t½ƛz                   [min] 
298 505 1543 479 326 630 ± 232 
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Table IX Pharmacokinetic parameters of group AA, female, i.v. 
 
 AA_01_F_iv AA_02_F_iv 
 
AA_03_F_iv AA_04_F_iv AA_05_F_iv Mean ± S.E.M. 
tmax                    [min] 5 5 6 5 5 5 ± 0.2 
Cmax          [ng mL
-1
] 369 423 431 489 392 421 ± 20 
Cmax_D                 [L
-1
] 0.18 0.21 0.22 0.24 0.20 0.21 ± 0.01 
C0                [ng mL
-1
] 536 523 868 730 542 640 ± 69 
Tlast                    [min] 1463 1437 1450 1454 1440 1449 ± 5 
Clast             [ng mL
-1
] 1.31 0.47 1.15 0.40 0.35 0.74 ± 0.20 
AUCall      [ng h mL
-1
] 366 321 308 380 269 329 ± 20 
AUC0_600  [ng h mL
-1
] 330 304 280 365 259 308 ± 19 
AUCINFobs [ng h mL
-1
] 382 324 323 383 272 337 ± 21 
Vss_obs                [L] 24 15 27 12 16  19 ± 3 
Vz_obs                     [L] 61 49 82 44 76 62 ± 7 
Clobs          [mL min
-1
] 87 103 103 87 122 101 ± 7 
Rsq 0.998 0.984 0.999 1.000 0.996 0.996 ± 0.003 
CorrXY -0.999 -0.992 -1.000 -1.000 -0.998 -0.998 ± 0.001 
ƛz No_points 
3 4 4 3 4 4 ± 0.2 
ƛz  
0.0014 0.0021 0.0013 0.0020 0.0016 0.0017 ± 0.0002 
ƛz lower 
543 479 474 553 480 506 ± 17 
ƛz upper 
1463 1437 1450 1454 1440 1449 ± 5 
t½ƛz                   [min] 
480 328 548 354 433 428 ± 40 
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Table X Pharmacokinetic parameters of group GG, male, i.v. 
 
 
 GG_01_M_iv GG_02_M_iv 
 
GG_03_M_iv GG_04_M_iv GG_05_M_iv Mean ± S.E.M. 
tmax                    [min] 5 5 7 5 5 5 ± 0.4 
Cmax          [ng mL
-1
] 369 262 231 336 230 286 ± 28 
Cmax_D                 [L
-1
] 0.18 0.13 0.12 0.17 0.12 0.14 ± 0.01 
C0                [ng mL
-1
] 470 334 384 426 313 385 ± 29 
Tlast                    [min] 1433 1440 1433 1453 1431 1438 ± 4 
Clast             [ng mL
-1
] 1.02 0.62 0.02 0.95 0.66 0.65 ± 0.18 
AUCall      [ng h mL
-1
] 410 219 204 283 257 267 ± 38 
AUC0_600  [ng h mL
-1
] 381 201 199 263 197 248 ± 35 
AUCINFobs [ng h mL
-1
] 419 225 205 299 224 274 ± 40 
Vss_obs                [L] 17 33 17 30 35 26 ± 4 
Vz_obs                     [L] 42 92 31 114 78 72 ± 15 
Clobs          [mL min
-1
] 80 148 164 111 149 130 ± 15 
Rsq 0.972 0.998 0.994 0.947 0.998 0.982 ± 0.010 
CorrXY -0.986 -0.999 -0.997 -0.973 -0.999 -0.991 ± 0.005 
ƛz No_points 
4 4 4 3 3 4 ± 0.2 
ƛz  
0.0019 0.0016 0.0052 0.0010 0.0019 0.0023 ± 0.0007 
ƛz lower 
479 482 477 538 540 503 ± 15 
ƛz upper 
1433 1440 1433 1453 1431 1438 ± 4 
t½ƛz                   [min] 
369 432 133 707 365 401 ± 92 
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Table XI Pharmacokinetic parameters of group AG, male, i.v. 
 
 AG_01_M_iv AG_02_M_iv 
 
AG_03_M_iv AG_04_M_iv AG_05_M_iv Mean ± S.E.M. 
tmax                    [min] 6 5 5 5 5 5 ± 0.2 
Cmax          [ng mL
-1
] 296 296 258 244 385 296 ± 25 
Cmax_D                 [L
-1
] 0.15 0.15 0.13 0.12 0.19 0.15 ± 0.01 
C0                [ng mL
-1
] 459 371 324 367 608 426 ± 51 
Tlast                    [min] 1438 1470 1448 1528 1445 1466 ± 16 
Clast             [ng mL
-1
] 0.19 0.74 0.64 0.99 0.50 0.61 ± 0.13 
AUCall      [ng h mL
-1
] 307 284 238 340 338 301 ± 19 
AUC0_600  [ng h mL
-1
] 291 259 223 294 316 277 ± 16 
AUCINFobs [ng h mL
-1
] 308 291 246 348 342 307 ± 18 
Vss_obs                [L] 17 26 30 28 18 24 ± 3 
Vz_obs                     [L] 30 66 106 48 41 58 ± 13 
Clobs          [mL min
-1
] 108 115 136 96 98 110 ± 7 
Rsq 0.999 0.999 0.963 0.999 1.000 0.992 ± 0.007 
CorrXY -1.000 -0.999 -0.982 -0.999 -1.000 -0.996 ± 0.004 
ƛz No_points 
3 3 3 4 3 3 ± 0.2 
ƛz  
0.0036 0.0017 0.0013 0.0020 0.0024 0.0022 ± 0.0004 
ƛz lower 
542 540 543 483 544 530 ± 12 
ƛz upper 
1438 1470 1448 1528 1445 1466 ± 16 
t½ƛz                   [min] 
194 401 542 345 288 354 ± 58 
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Table XII Pharmacokinetic parameters of group AA, male, i.v. 
 
 
 AA_01_M_iv AA_02_M_iv 
 
AA_03_M_iv AA_04_M_iv AA_05_M_iv Mean ± S.E.M. 
tmax                    [min] 5 5 5 6 6 5 ± 0.2 
Cmax          [ng mL
-1
] 414 217 386 362 294 335 ± 35 
Cmax_D                 [L
-1
] 0.21 0.11 0.19 0.18 0.15 0.17 ± 0.02 
C0                [ng mL
-1
] 629 267 485 490 436 461 ± 58 
Tlast                    [min] 1436 1440 1440 1438 1435 1438 ± 1 
Clast             [ng mL
-1
] 1.57 0.18 3.11 0.26 0.46 1.12 ± 0.56 
AUCall      [ng h mL
-1
] 453 177 369 252 295 309 ± 47 
AUC0_600  [ng h mL
-1
] 412 169 329 244 278 287 ± 41 
AUCINFobs [ng h mL
-1
] 472 179 381 255 299 317 ± 51 
Vss_obs                [L] 19 25 22 15 19 20 ± 2 
Vz_obs                     [L] 51 79 20 73 55 56 ± 10 
Clobs          [mL min
-1
] 71 187 87 131 112 117 ± 20 
Rsq 0.999 0.997 0.977 0.995 0.999 0.993 ± 0.004 
CorrXY -0.999 -0.998 -0.988 -0.998 -0.999 0.997 ± 0.002 
ƛz No_points 
3 4 5 4 4 4 ± 0.3 
ƛz  
0.0014 0.0024 0.0044 0.0018 0.0020 0.0024 ± 0.0005 
ƛz lower 
541 482 364 484 488 472 ± 29 
ƛz upper 
1436 1440 600 1438 1435 1270 ± 167 
t½ƛz                   [min] 
503 293 158 388 343 337 ± 57 
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